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Summary 
 
Both mouse double minute (MDM2) and prostate-specific membrane antigen 
(PSMA) are known to be associated with the progressive properties of cancer.  
Moreover, overexpression of both molecules has been implicated in an increase in 
the proliferation, migration and invasion of tumour cells.  
MDM2 is a negative regulator of tumour suppressor of p53 but also is known to 
play multiple p53-independent roles in many cancer types.  PSMA was originally 
thought to be solely expressed in prostate tissues and overexpression prostatic 
cancers; however, recently its expression was reported in various other solid 
tumours, including those of the breast.   
Our work showed a possible link between these proteins following knockdown of 
each molecule in breast cancer cell lines, ZR-75.1 and MDA-MB-231, with targeted 
siRNA molecules.  A decrease of MDM2 and PSMA led to a decrease in the 
proliferative, adhesive, migratory and invasive capacities of the cell lines.   
Additionally, knockdown of MDM2 and PSMA led to similar changes in secretion of 
matrix metalloproteinases (MMPs), with decreases in MMP2 and MMP8 being 
seen from both breast cell lines investigated.  
It was then seen that a link between the two protein could be mediated through the 
phosphorylation status of serine 473 on protein kinase B (AKT).  PSMA knockdown 
in both breast cancer cell lines led to a decrease of AKT phosphorylation and thus 
a decrease in MDM2 serine 188.  Additionally, it was found that MDM2 siRNA 
leads to an increase in c-JUN serine 63 phosphorylation, and that PSMA siRNA 
can lead to an increase at the same site, depending on the cell line.  
These results indicate that MDM2, AKT and PSMA may represent a new pathway 
which could be targeted for therapy for breast tumours and perhaps other types of 
cancer.   
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1.1 The breast 
 
i. Development of the breast 
 
Before the onset of puberty, the human breast develops in a similar 
way in both males and females.  However, during puberty in females, 
the amount of luteinising and follicle-stimulating hormone increase, 
which causes the ovaries to begin producing oestrogens.  The 
female breasts then begin to develop under the influence of 
oestrogens and progesterone.  Following this, the duct system 
matures and there is deposition of fat.  The onset of ovulation and 
formation of the corpus luteum then lead to increased levels of 
oestrogens and progesterone, which results in the further 
development of the mammary glands and an establishment of the 
overall breast anatomy.   
During each menstrual cycle experienced, the female breasts 
undergo a proliferative phase, although they do not become fully 
developed until a pregnancy occurs.  During pregnancy, the breast 
tissue experiences acute proliferative and secretory alterations, with 
the gradual replacement of the connective and adipose tissue by 
large, densely packed lobules.  During lactation, the alveoli become 
distended with milk and after pregnancy, when lactation is 
discontinued, the mammary glands regain their original appearance 
(Javed and Lteif, 2013, Gusterson and Stein, 2012). 
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ii. Breast anatomy 
 
The female breast contains adipose tissue embedded with between 
15 and 25 lobes.  These lobes are radially distributed around the 
nipple and are interspersed with fibrous septa.  The lobes are 
subdivided into lobules, which are smaller compartments containing 
alveolar ducts (Figure 1.1a and b).  During pregnancy, these ducts 
develop into a large number of bunches of milk-secreting glands 
known as alveoli.  These alveoli are surrounded by myoepithelial 
cells and oxytocin-stimulated contractions of these cells aids the 
transportation of milk towards the nipple (Jesinger, 2014) (Figure 
1.1a).   
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Figure 1.1. The anatomy of the breast.  a) Anatomy of the breast, 
taken from www.aboutcancer.com/breast_anatomy.htm b) Diagram 
of a normal breast duct and the components of the local 
microenvironment, taken from Offiah et al., 2011.  
 
 
 
 
 
a 
b 
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1.2 .  Breast cancer 
 
As the second most common cancer worldwide, breast cancer is the 
leading cause of cancer-related death in women.  Breast cancer 
exceeds all other cancers in terms of its global burden and has a 
rising incidence which is extremely high in Northern Europe (Ferlay 
et al., 2012, Jemal et al., 2011).  However, the mortality rates are 
falling due to earlier diagnosis, as well as improved treatment for 
those affected by this disease (Figure 1.2).  Despite these 
encouraging improvements, metastasised breast cancer is incurable 
in many patients (Guth et al., 2009) and is not well understood in 
terms of molecular drivers and the underlying biological processes 
(Kimbung et al., 2015).   
The complex and heterogeneous nature of breast cancer makes it a 
fascinating and challenging research field for diagnosis and 
treatment, with breast cancers representing an array of different 
disease with both intratumoral and intertumoral genetic and 
epigenetic mutations (Swanton et al., 2011, Navin et al., 2010). 
Alcohol intake (Ellison et al., 2001, Zhang et al., 1999), body mass 
index (BMI) (Tretli, 1989), hormone replacement therapy (HRT) 
(Weiss et al., 2002, Nelson et al., 2002), exposure to radiation (Boice 
et al., 1991, Clemons et al., 2000), early menstruation (Brinton et al., 
1988), late menopause (Brinton et al., 1983, Trichopoulos et al., 
1972), age of first child birth (Brinton et al., 1983, White, 1987),  
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Figure 1.2. Incidence and mortality of breast cancer from 1993 
to 2012. Graph is a summarisation of data from Cancer Research 
UK (www.cancerresearchuk.org), showing the number of incidenc-
es and mortalities due to breast cancer over the years 1983-2012.   
 
1. General Introduction 
 
7 
 
past history of breast cancer (Page et al., 1982), breast biopsy 
(Dupont et al., 1993), family history (Pharoah et al., 1997) and 
germline mutations (Easton et al., 1993), are all known risk factors 
for the development of breast cancer in females (Singletary, 2003). 
i. Pathology and prognostic indicators 
 
Adenocarcinomas are the major type of breast cancer and these 
originate from the glandular epithelium of the terminal duct lobular 
unit.  Adenocarcinomas are classed as invasive or non-invasive. The 
term non-invasive refers to cancers which have not penetrated the 
basement membrane and they are classified as ductal carcinoma in 
situ, lobular carcinoma in situ or intraductal papillary carcinoma, with 
ductal being the most common type.  Invasive carcinomas are also 
designated ductal or lobular, depending on the cell type they 
resemble. Invasive ductal carcinoma is undeniably the most common 
form of breast cancer, comprising over three-quarters of cases 
(Cowell et al., 2013).  Besides these common variants, there are 
more rare or less common breast cancer types; including medullary, 
mucinous, tubular and metaplastic carcinomas (Yerushalmi et al., 
2009).  
In order to reach a prognosis, breast cancers are categorised by 
various classification systems.  The most widely applied method is 
the TNM classification system (Wittekind et al., 2002), which 
evaluates primary tumour size (T; graded from 1 to 4), the presence 
of metastasis to the lymph nodes (N; graded from 0 to 3) and distant 
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metastases occurrence (M; graded as 0 or 1). Another common 
classification system in use, which is based on histological grade and 
involves examination of sections using a microscope (Elston and 
Ellis, 1991). This microscopic analysis involves assessment of mitotic 
index, nuclear polymorphism and tubule formation.  Evaluation of 
these variables identifies the tumour as being well-differentiated, 
moderately differentiated or poorly differentiated.  The more well-
differentiated the cells are the better prognosis for the patient.  
Finally, Nottingham prognostic index (NPI) can be used to determine 
the clinical outcome of the patients and whether a patient will benefit 
from adjuvant therapy.  This assessment involves the appraisal of 
tumour size, lymph node status and histological grade (Albergaria et 
al., 2011, Hearne et al., 2015).  
As well as the use of stage and grade of the breast tumour, 
expression of oestrogen receptor (ER), progesterone receptor (PR) 
and human epidermal growth factor receptor (HER2) in the primary 
tumour is evaluated in order to elect a preferred treatment strategy 
(Joensuu et al., 2013, Parise and Caggiano, 2014a, Parise and 
Caggiano, 2014b).   
ii. Hereditary breast cancer 
 
Most breast cancers arise sporadically, meaning that patients do not 
hold a genetic disposition for the disease.  However, around 10% of 
all cases are associated with a family trait (Easton, 2002, Yarden and 
Papa, 2006).  Multiple genetic mutations have been identified to be 
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responsible for familial breast cancer. The first of these to be 
detected, and those which are most strongly related to hereditary 
breast malignancies, were breast cancer susceptibility genes 1 and 2 
(BRCA1 and BRCA 2), which give rise to proteins involved in the 
repair of DNA damage. More recently, more mutations of genes 
underlying cancer have been found, including p53 and phosphatase 
and tensin homolog (pTEN) (Easton, 1999a, Easton, 1999b).   
iii. Molecular subtypes 
 
Breast cancer is commonly classified into intrinsic molecular 
subtypes (Table 1.1).    
Luminal A 
Most breast cancers are luminal tumours and these cells look the 
most like cells of breast cancers which start in the inner (luminal) 
cells lining the mammary ducts.  Luminal A tumours tend to be ER- 
and /or PR-positive, HER2-negative and have a tumour grade of 1 or 
2.  Of the four subtypes of breast cancer, these tumours tend to have 
the best prognosis, with a high survival rate (Kennecke et al., 2010, 
Voduc et al., 2010, Falato et al., 2016, Metzger-Filho et al., 2013b).  
However, recent longer term studies suggest that luminal A breast 
cancers are more likely to relapse later compared to the other 
subtypes (Ribelles et al., 2013; Ciriello et al., 2013).  
Luminal B 
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Luminal B tumours are another type of luminal tumour.  They tend to 
be ER- and/or PR-positive and highly positive for Ki67, and/or HER2-
positive. Patients with luminal B tumours are often diagnosed at a 
younger age than those with luminal A (Metzger-Filho et al., 2013b, 
Lund et al., 2010). In comparison to luminal A tumours, luminal B 
tend to have factors leading to a poorer prognosis: higher tumour 
grade, larger tumour size and lymph node metastases (Kennecke et 
al., 2010, Voduc et al., 2010, Metzger-Filho et al., 2013b).  However, 
patients with luminal B tumours have reasonably high survival rates, 
compared to other subtypes other than luminal A (Falato et al., 2016, 
Metzger-Filho et al., 2013b). 
Triple-negative(TNBC)/basal-like  
Triple-negative/basal-like breast cancers  are ER-, PR- and HER2-
negative.  There are several subsets of TNBC.  One of these subsets 
is referred to as basal-like because the tumours have cells with 
features similar to those of the outer (basal) cells surrounding the 
mammary ducts.  Most basal-like tumours contain p53 gene 
mutations (Toft and Cryns, 2011).  
Most triple-negative breast tumours are basal-like and most basal-
like tumours are triple-negative; however, this is not always the case.  
Around 15-20% of breast cancers are solely triple-negative or basal-
like (Fan et al., 2006, Kennecke et al., 2010, Voduc et al., 2010, 
Falato et al., 2016, Howlader et al., 2014).     
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Triple-negative/basal-like tumours are often highly aggressive with a 
poor prognosis compared to the ER-positive subtypes (luminal A and 
B) (Voduc et al., 2010).   
Luminal B tumours are another type of luminal tumour.  They tend to 
be ER- and/or PR-positive and highly positive for Ki67, and/or HER2-
positive. Patients with luminal B tumours are often diagnosed at a  
HER2 type 
These tumours tend to be ER- and PR- negative, lymph node-
positive and have a higher tumour grade (Kennecke et al., 2010, 
Voduc et al., 2010, Falato et al., 2016, Metzger-Filho et al., 2013a). 
Around 15% of breast tumours are HER2 type and around 75% of 
these contain the p53 gene mutation (Falato et al., 2016, Howlader et 
al., 2014).  The prognosis for HER2 type patients has recently been 
improved due to the advent of anti-HER2 drugs such as Herceptin 
(Voduc et al., 2010, Yang et al., 2011).  
iv. Treatment 
 
If cancer is limited to the primary breast site upon detection, the 
primary treatment option is removal of the tumour through surgery.  
Along with this, a lymph node biopsy, most likely to be the sentinel 
node, is undertaken in order to determine if the cancer has spread to 
the lymph ducts or nodes.  In cases where metastasis to the lymph 
node is detected, treatment options are different and can include a 
wider mastectomy and axilla clearance in order to remove both 
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primary tumour and lymph nodes likely visited by cancer cells.  
Rapidly proliferating cells, like those ones seen in malignancies, are 
more sensitive to irradiation than non-malignant cells, so surgery is 
usually combined with radiotherapy of the adjacent breast tissue to 
eliminate residual tumour cells and so minimise the recurrence risk.  
Furthermore, adjuvant therapy is usually undertaken in order to 
target possible micrometastases (Barker, 2015). 
Approximately 70% of breast tumours express hormone receptors 
such as ER and PR (Lim et al., 2012), and those patients in this 
category are given anti-hormone therapy five years post-surgery.  
This approach has been shown to decrease the likelihood of disease 
recurrence (Konecny et al., 2003, Thurlimann and Senn, 2005).    
Chemotherapy, in contrast to radiation, is a systemic treatment 
option and is used for more aggressive breast cancers or those with 
distant metastases.  The most common chemotherapy types block 
cell division through varying mechanisms.  Alkylating agents cause 
DNA damage and tumour cell apoptosis; antimetabolites inhibit DNA 
nucleotide synthesis; anthracyclins interfere with enzymes involved in 
DNA replication; mitotic inhibitors hinder chromosome segregating 
proteins. The past few decades have witnessed the increase in the 
number of available agents for this purpose. Usually, a combination 
of two or three of these agents is used (Chabner and Murphy, 2005, 
Chabner and Roberts, 2005). 
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1.3 . Progressive properties of solid tumours 
 
Tumours are more than insular masses of proliferating cells; instead, 
they are complex tissues comprised of many distinct cell types which 
partake in heterotypic interactions with one another.  Normal cells are 
thought to be recruited to form tumour-associated stroma and play an 
active role in tumourigenesis; as such, these stromal cells contribute 
to the development and expression of certain hallmark capabilities 
(Hanahan and Weinberg, 2011).   
It has been proposed that there are six hallmarks of cancer which, 
together, constitute an organising principle which provides a logical 
framework for understanding the remarkable diversity of neoplastic 
diseases (Hanahan and Weinberg, 2011).  These hallmarks hold 
distinctive and complementary capabilities which enable tumour 
growth and metastatic dissemination of cells (Figure 1.3).  
i.   Sustaining proliferative signalling 
 
This is, arguably, the most central and essential trait of cancer cells, 
allowing them to sustain chronic proliferation.  The production and 
release of growth-promoting signals, which direct entry into and 
advancement through the cell cycle, by normal tissues.  Cancer cells 
are able to deregulate these signals, with the ability to produce 
growth factor ligands themselves and then release growth factors, 
resulting in autocrine proliferative stimulation.   
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Figure 1.3. Progressive properties of cancer (taken from Hanahan & 
Weinberg, 2000).  There are six properties which a cell has to gain in 
order to be considered malignant: limitless replicative potential, 
insensitivity to anti-growth signals, evasion of apoptosis, sustaining 
angiogenesis, self-sufficiency in growth signals and tissue invasion and 
metastasis.  
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Various tumour suppressors which operate to limit cell growth and 
proliferation have been found due to their inactivation in cancers.  
The two prototypic tumour suppressors encode the RB 
(retinoblastoma-associated) and TP53 proteins which function as 
central nodes within two key complementary cellular regulatory 
circuits which govern the decisions of cells to proliferate or stimulate 
normal cells in the tumour-associated stroma to release growth 
factors (Cheng et al., 2008, Bhowmick et al., 2004). Receptor 
signalling can also be deregulated by the elevation of receptor 
protein levels displayed at the cancer cell surface, rendering the cells 
hyperresponsive to the otherwise limiting amounts of growth factor 
ligand; the same response can be seen from structural changes in 
the receptor molecules which allow for ligand-independent firing.  
Ligand independence can also occur from constitutively active 
components of signalling pathways operating downstream of these 
receptors, discounting any growth factor stimulatory need of the 
receptors (Hanahan and Weinberg, 2000, Hanahan and Weinberg, 
2011). 
ii. Evading growth suppressors  
 
As well as possessing the ability to proliferate uncontrollably, cancer 
cells need to be able to circumvent the negative regulatory signals 
which control cell proliferation. Antigrowth signals block cell 
proliferation through two distinct mechanisms. Cells can be forced 
out of the active proliferation cycle into a quiescent (G0) state from 
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which they can re-emerge on some future occasion when 
extracellular signals permit.  Alternatively, cells may be induced to 
permanently relinquish their proliferative potential by being induced 
to enter into a post-mitotic state, usually associated with the 
acquisition of specific differentiation-associated traits (Williams and 
Stoeber, 2012, Hanahan and Weinberg, 2011).  
Normal cells can activate senescence and apoptotic programs 
(Jones and Thompson, 2009).  Cancer cells often contain mutations 
in the growth suppressor genes, rendering them inactive, and thus 
they can lose responsiveness to suppression pathways by 
downregulating receptors or receptors may become mutant or 
dysfunctional (Fynan and Reiss, 1993, Markowitz et al., 1995) 
iii.  Evading apoptosis 
 
The ability of tumour cells to expand in population is determined not 
only by the rate of cell proliferation but also by the rate of attrition.  It 
has been shown that programmed cell death (apoptosis) is present in 
a latent form in virtually all cell types throughout the body.  When 
triggered through the sensing of a variety of physiological signals, 
this program progresses in a strictly structured series of steps 
(Hanahan and Weinberg, 2000).  
The apoptotic machinery can be generally divided into two classes of 
components – sensors and effectors.  Sensors are responsible for 
monitoring both the external and internal environments of the cells for 
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conditions to assess whether a cell should live or die.  These sensors 
regulate the second class of components, the effectors, which are 
the initiators of cell death (Norbury and Zhivotovsky, 2004).     
Resistance to apoptosis can be acquired by cancer cells through a 
variety of stages, with the most common loss of pro-apoptotic 
regulator being a mutated p53 tumour suppressor gene. The 
resulting functional inactivation of p53 protein occurs in over 50% of 
human cancers and results in the removal of a key element of the 
DNA damage sensor which can induce the apoptotic effector 
cascade (Harris, 1996a, Harris, 1996c, Harris, 1996b). Signals 
incited by other abnormalities, including hypoxia and oncogene 
hyper-expression, are also funnelled in part via p53 to the apoptotic 
machinery; and so these too are compromised when p53 function is 
lost (Levine, 1997).   
iv. Enabling replicative immortality 
 
It is now well-known that the Hayflick limit defines the finite number of 
divisions a cell can undertake before it becomes senescent (Hayflick, 
1997).  Interestingly, most types of tumour cells propagated in vivo 
appear to be immortalised, suggesting that this limitless replicative 
potential is an acquired phenotype during in vivo tumour progression 
and could be essential for the development of a malignant growth 
state (Hayflick, 1997, Hanahan and Weinberg, 2000).   
The ends of chromosomes, known as telomeres, have been shown 
to be the counting mechanism for cell generations. Throughout each 
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replication, 50-100 base pairs are lost from telomeres, due to the 
inability of DNA polymerases to completely replicate the 3’ end of 
chromosomal DNA during S-phase of the cell cycle.  Thus, the 
progressive erosion of the telomeres causes them to lose their ability 
to perform their function, which is to protect the ends of 
chromosomes (Counter et al., 1992).   Telomere maintenance is 
evident in virtually all types of malignant cells (Shay and Bacchetti, 
1997) and most of this is done through the upregulation of an 
enzyme, telomerase, which holds the ability to add hexanucleotide 
repeats to the ends of telomeric DNA and thus repair chromosomes 
(Bryan and Cech, 1999).  Immortalised cells which do not use this 
mechanism are able to activate a mechanism, termed alternative 
lengthening of telomeres (ALT), which appears to maintain telomeres 
through recombination-based interchromosomal exchanges of 
sequence information (Bryan et al., 1995).  Therefore, via one of 
these mechanisms, telomeres are maintained above a critical 
threshold and so unlimited multiplication of descendant cells can 
occur.   
v. Inducing angiogenesis 
 
The oxygen and nutrients supplied by the vasculature are crucial for 
cell function and survival, obligating virtually all cells in a tissue to 
reside within 100 μm of a capillary blood vessel.  There is extensive 
and compelling evidence towards the importance of induction and 
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sustenance of angiogenesis in tumours (Bouck, 1996, Folkman and 
Hanahan, 1991, Hanahan and Weinberg, 2011). 
Positive and negative signals which encourage or discourage 
angiogenesis must be counter-balanced in normal cells in order for 
angiogenesis to be regulated accordingly.   One side of this signalling 
is communicated through soluble factors and their receptors, the 
latter being displayed on the surface of endothelial cells. Integrins 
and adhesion molecules mediating cell-matrix and cell-cell 
association also play vital roles.  The angiogenesis initiating signals 
are exemplified by vascular endothelial growth factor (VEGF) and 
acidic and basic fibroblast growth factors (FGF1/2).  Each binds to 
transmembrane tyrosine kinase receptors displayed by endothelial 
cells (Veikkola and Alitalo, 1999). A prototypical angiogenesis 
inhibitor is thrombospondin-1(TSP-1), which is able to bind to CD36, 
a transmembrane receptor on endothelial cells, couple to intracellular 
Src-like tyrosine kinases (Bull et al., 1994). Currently, there are more 
than 25 angiogenic inducing factors known, and a similar number of 
inhibitors (Hanahan and Weinberg, 2000).   
Also contributing to this regulatory balance is integrin signalling.  
Quiescent vessels express a class of integrins, whereas sprouting 
capillaries express another.  Intervening signalling from the latter 
class of integrins can inhibit angiogenesis (Giancotti and Ruoslahti, 
1999), highlighting the importance of cell adhesion to angiogenesis 
(Hynes and Wagner, 1996). 
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It has emerged that tumours possess the ability to activate the 
angiogenic switch by altering the balance of inducers and inhibitors 
(Hanahan and Folkman, 1996, Hanahan and Weinberg, 2000).  A 
common strategy used by cancer cells to modify this balance 
involves an alteration to gene transcription.  Many tumours show 
increased expression of VEGF or FGFs compared to their normal 
tissue counterparts.  In others, expression of endogenous inhibitors 
such as TSP-1 or β-interferon are downregulated.  Moreover, both 
transitions may occur in some tumours (Volpert et al., 1997). The 
tumour cell’s ability to induce and sustain angiogenesis appears to 
be attained in one or more discrete steps during tumour 
development, via an ‘angiogenic switch’ from vascular quiescence.  
The mechanisms fundamental to this angiogenic switch remain, thus 
far, incompletely understood.  However, it is apparent that tumour 
angiogenesis offers a uniquely attractive therapeutic target, as the 
trait of acquiring a blood supply is common to all tumours (Hanahan 
and Weinberg, 2011, Hanahan and Weinberg, 2000).   
vi. Activating invasion and metastasis 
 
In actuality, the metastasis of a primary tumour to distant locations in 
the true cause of cancer-related deaths (Sporn, 1996, Hanahan and 
Weinberg, 2000).  Sooner or later, in the development of most cancer 
types, cancer cells break free from the primary tumour mass and 
invade adjacent tissues and then colonise distant sites.  The 
capability of cancer cells to invade and metastasise enables them to 
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escape the primary tumour mass and colonise new terrain in the 
body where nutrients and space are not limiting.     
Invasion and metastasis are highly complex processes and their 
genetic and biochemical determinants remain incompletely 
understood.  At the mechanistic level, these processes are closely 
allied; both use similar strategies of operation, involving the changing 
of the physical coupling of cells to their microenvironment and 
activation of extracellular proteases.   
Several classes of proteins are altered in those cells possessing 
invasive or metastatic capabilities.  Altered proteins include cell-cell 
adhesion molecules (CAMs) and integrins, which link cells to 
substrates of the extracellular matrix (Hanahan and Weinberg, 2000). 
In cancer, the most commonly observed alteration in cell-to-
environment interactions involves E-cadherin, a cell-to-cell interaction 
molecule which is ubiquitously expressed on epithelial cells.  
Coupling between adjacent cells by E-cadherin assimilates the 
results of anti-growth and other signals through cytoplasmic contact 
(Christofori and Semb, 1999).  E-cadherin is lost in a high proportion 
of epithelial cancers through mechanisms which may include its 
mutational inactivation, transcriptional repression or proteolysis of the 
extracellular region (Christofori and Semb, 1999, Hanahan and 
Weinberg, 2000) 
Another general parameter of invasive and metastatic capability 
involves extracellular proteases (Coussens and Werb, 1996, 
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Chambers and Matrisian, 1997).  In cancer cells, the genes encoding 
proteases are upregulated, their inhibitor genes are downregulated 
and inactive forms are converted to active forms.   
vii. Enabling characteristics 
 
Acquisition of these hallmark characteristics is made possible by two 
enabling characteristics. The first is the development of genomic 
instability in cancer cells. This leads to the generation of random 
mutations and rearrangement of chromosomes, amongst which are 
rare genetic changes which can enable cells to gain these hallmark 
capabilities.  Secondly, the inflammatory state of premalignant and 
malignant lesions, driven by the cells of the immune system, is 
Enabling progression (Hanahan and Weinberg, 2011).  
viii. Emerging hallmarks  
As well as the currently known hallmarks of the progressive 
properties of cancer, there are two more capabilities which are 
important for the development of cancer. The first involves 
reprogramming of the energy metabolism of cells in order to support 
the continuous growth and proliferation of cancer cells. The second 
involves evasion of immune cells by cancer cells in order to avoid 
attach and evasion (Hanahan and Weinberg, 2011).  
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1.4  Mouse double minute 2 (MDM2)  
 
i. Clinical relevance of MDM2 
 
MDM2 is an evolutionary conserved gene (Fakharzadeh et al., 1991).  
The murine double minute 2 (mdm2) was originally identified as one 
of three mdm genes whose expression is increased more than 50-
fold in the spontaneously transformed mouse BALB/c cell line (3T3-
DM).  These genes are located on small, acentromeric 
extrachromosomal nuclear bodies, called double minutes (Cahilly-
Snyder et al., 1987). The overexpression of the product of the mdm 
gene was later proved to be the reason for the transformation 
(Fakharzadeh et al., 1991).   
The reason for this conveyed transformation potential was shortly 
discovered, with MDM2 being revealed to bind to the tumour 
suppressor p53 and thus inhibit its transactivation through its E3 
ubiquitin ligase activity (Haupt et al., 1997, Honda et al., 1997, 
Momand et al., 1992).Since then, in vivo experiments have provided 
compelling evidence towards the importance of the MDM2/p53 
interaction (Jones et al., 1995, Mendrysa et al., 2003). 
The p53 gene generates a protein which is involved in the sensing of 
cell stress and DNA damage, resulting in regulation of the cell cycle 
and apoptosis (Brown et al., 1998). Mice which do not possess the 
mdm2 gene die before embryonic implantation, with a total 
phenotypic rescue being possible through simultaneous deletion of 
1. General Introduction 
 
25 
 
the p53 gene.  One study showed genetically modified mice which 
express just 30% of the normal levels of MDM2 caused decreased 
body weight and defects in haematopoiesis (Mendrysa et al., 2003). 
These phenotypes were p53-dependent, emphasising the 
importance of MDM2 regulation in many cell types.  Some tumours 
contain both high levels of MDM2 and mutations in the p53 gene.  
The reason for this is not completely known, although it points 
towards the involvement of MDM2 in other p53-independent growth-
promoting functions (Iwakuma and Lozano, 2003).   
The p53 protein transcriptionally activates many genes, including the 
mdm2 gene (Lahav, 2008).  Therefore, p53 is regulated at protein 
level by MDM2, but once active, p53 activates the transcription of the 
mdm2 gene, locking the proteins into a tight negative feedback loop, 
vital for cell survival. In conclusion, it is obvious that MDM2 is a 
critical regulator of p53 activity and its loss leads to an active p53 
which has disastrous consequences for the cell or embryo.  
The mdm2 gene consists of 12 exons, which can generate a number 
of different proteins through alternative splicing. The gene is 
governed by two promoters, each of which produce a different 
protein.  Alternative splicing of the mdm2 gene and the generation of 
short proteins occurs in many tumours.  Many short MDM2 proteins 
encoding just the carboxyl terminus of MDM2 have been identified, 
meaning that MDM2 does not contain the p53-binding domain (Bartel 
et al., 2002). The p53-interaction domain is situated at the amino 
terminus, which in turn binds to the amino transactivation domain of 
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p53.  The really interesting new gene (RING) motif, found at the 
carboxyl terminus, is known to convey the E3 ubiquitin ligase activity 
of MDM2, which is vital for the ubiquitination and subsequent 
degradation of p53 (Haupt et al., 1997, Honda et al., 1997). Other 
motifs within the MDM2 protein include the nuclear localisation and 
export signals.  The signals are used to move MDM2 to and from the 
nucleus, another way in which the cell tightly regulates p53 (Roth et 
al., 1998, Freedman et al., 1997) (Figure 1.4).  
MDM4, also known as MDMX, was identified as a critical regulator of 
p53 also (Riemenschneider et al., 1999, Riemenschneider et al., 
2003). Some studies have shown that MDM2 interacts with and 
stabilised MDM2 through each of their RING domains (Tanimura et 
al., 1999, Sharp et al., 1999, Jackson and Berberich, 2000, Stad et 
al., 2001) suggesting a cooperation in order to inhibit p53 function.  
However, other reports claim that MDM4 works to prevent MDM2 
degradation and translocation of p53 (Stad et al., 2001). 
Another interaction partner, which works upstream of MDM2 is the 
tumour suppressor p14ARF.  This protein binds to MDM2 and blocks 
its ubiquitination of p53, as well as export from the nucleus (Weber et 
al., 2000). Appropriate and accurate control of the ARF-MDM2-p53 
pathway is vital for tumour suppression, meaning that this pathway is 
often targeted for alteration in cancer (Bouska and Eischen, 2009). 
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Apart from its involvement in p53-dependent activities, it was recently 
discovered that MDM2 plays a role in p53-independent functions 
which contribute to tumourigenesis (Lubet et al., 2005).  A study of 
human sarcomas and bladder cancers found tumours which 
overexpressed MDM2 and mutant p53 and the patients possessing 
both of these abnormalities had a poorer prognosis than those with 
just one (Cordon-Cardo et al., 1994).  Other studies show that 
lymphomas arising in transgenic mice with deleted or mutated p53 
also overexpress MDM2 (Alt et al., 2003, Eischen et al., 1999).  It 
has also been indicated that the MDM2 variants which do not 
possess the p53-binding domain increase cell transformation and 
tumour development when expressed in mice (Sigalas et al., 1996). 
These reports suggest that tumours are conveyed an advantage 
when overexpressing MDM2, even in the absence of functional p53.   
It is now known that MDM2 binds and regulates many proteins 
independent of p53, including proteins involved in DNA repair, DNA 
replication, cell-cycle control and the apoptosis pathway.  These 
pathways work together to preserve the integrity of genetic 
information, it has been suggested that MDM2 may act as a central 
node in the regulation of genome stability and thus transformation 
(Bouska and Eischen, 2009). 
MDM2 is overexpressed due to amplification in around 10% of all 
human cancers, and overexpression via other mechanisms also 
occurs in many human malignancies (Rayburn et al., 2005).   This 
means that development of a therapy involving the inhibition of 
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MDM2 could be used to treat many different patients with various 
cancer types.  Therefore, MDM2 is a major target for drug companies 
in the development of therapies for cancer patients.  
ii. MDM2 in breast cancer 
 
MDM2 protein expression has been shown to be a negative 
prognostic marker in breast carcinoma (Turbin et al., 2006, Jiang et 
al., 1997).   Other investigators have found that MDM2 
overexpression correlates with favourable prognostic parameters i.e. 
ER overexpression (Hori et al., 2002).  Interestingly, amplification of 
MDM2 as assessed by fluorescence in situ hybridisation (FISH), is 
not associated with a worse prognosis (Al-Kuraya et al., 2004).  
Moreover, a study into a breast cell lines (Sheikh et al., 1993) did not 
show any evidence of aberrant MDM2 gene copy number.  Also, at 
mRNA level, two studies found increased MDM2 expression with no 
apparent alteration in MDM2 gene copy number (Bueso-Ramos et 
al., 1993, Sheikh et al., 1993), with a later study backing up these 
results (McCann et al., 1995).  
It is known that oestrogen receptor positive breast cancers often 
have high levels of MDM2 (Hori et al., 2002).  A study into oestrogen-
mediated activation of breast cancer cell proliferation showed that 
oestrogen-treatment of the MCF-7 cell line led to an upregulation of 
MDM2 protein levels with no effect on p53 protein.  MDM2 siRNA 
treatment also led to an upregulation of basal transcription of p53-
target genes, as well as decreased cell growth in 3D Matrigel and 
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decreased oestrogen-induced cell proliferation in 2D culture.  It was 
also seen that knockdown of p53 protein showed no effect on 
oestrogen-induced cell proliferation, which led to the conclusion that 
the activation of MDM2 by oestrogen is independent of p53 
(Brekman et al., 2011).  
iii. MDM2 as a therapeutic target 
 
The main focus of most therapeutics targeted at MDM2 is to 
decrease the level of MDM2 protein in cells and therefore allow the 
reactivation of p53. There are several approaches undertaken to 
accomplish this: reducing MDM2 levels in cancer cells, inhibiting the 
E3 ubiquitin ligase complex of MDM2, or the disrupting the 
interaction between p53 and MDM2 (Wade et al., 2013). 
 A basic strategy to decreasing MDM2 protein expression is to 
specifically target the gene using small interfering RNA (siRNA), 
short hairpin RNA (shRNA) or microRNA (miRNA) approaches.  The 
downregulation of MDM2 using antisense oligonucleotides has led to 
the stabilisation and activation of the p53 pathway in cancer cells 
growing in culture and in tumour xenograft mice. Interestingly, mutant 
p53 cells have responded equally as well as those harbouring wild-
type p53.  This result supports the notion that MDM2 has other p53-
independent activities involved in its contribution to tumour growth 
and progression (Zhang et al., 2004). 
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Another way to reactivate p53 activity is to inhibit the ubiquitin ligase 
activity of MDM2 (Brooks and Gu, 2003). Recently, small-molecule 
inhibitors have been discovered which specifically target the E3 
ligase activity of MDM2. Numerous compounds from this group of 
inhibitors have been shown to inhibit in vitro p53 ubiquitination (Yang 
et al., 2005). Studies using cancer cells reported that these 
molecules activate p53 signalling and thus induced apoptosis.  
However, these compounds have shown low potency and selectivity, 
with more optimisation being vital before assessment of the therapy’s 
potential (Yang et al., 2005, Vassilev, 2007).  
Small molecule inhibitors of the MDM2-p53 interaction have been 
identified, with the logic that disruption of binding will lead to a 
degradation of p53. In the past decade, much effort has been 
invested in this approach, with a recent yield of the first potent and 
selective pharmacological activators of wild-type p53.  A few of these 
small molecules do represent viable leads for the development of 
therapeutic agents.  The first of these MDM2 antagonists, the nutlins, 
were identified from a class of compounds named cis-imidazoles 
(Vassilev, 2007, Vu et al., 2013).  The nutlins displace p53 from 
MDM2 in vitro and crystal structures have shown that they bind to the 
p53 pocket of MDM2 in a way which remarkably mimics the 
molecular interactions between the two proteins.  Proliferating cancer 
cells have been shown to be effectively blocked in the G1 and G2 
phases and undergo apoptosis following treatment with these 
inhibitors (Vassilev, 2007).  The nutlins were the first molecules to 
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prove that activation of wild-type p53 using pharmacological 
inhibitors of the MDM2-p53 interaction was a feasible therapeutic 
concept.  As predicted by the molecular mechanism, it seems that 
only cells with wild-type p53 are sensitive to these compounds, so 
the p53 status of tumours would need to be determined before any 
therapeutic approach is undertaken.  In vitro and in vivo studies 
conducted using the nutlins have verified their anti-tumour effect 
(Tovar et al., 2006).  
Recently, there has been an influx of small molecule MDM2 inhibitors 
undergoing clinical trials, with seven currently in Phase 1, all of which 
target the interaction between MDM2 and p53 (Zhao et al., 2015). 
The first of these, AM 232 was discovered through studies into AM 
8553, a compound produced using de novo design strategy based on 
the structure of MDM2.  AM 232 targets a shallow cleft on the surface 
of MDM2; has been found to be potent and selective; and has shown 
notable anti-tumoural activity in vivo (Bernard et al., 2012, Sun et al., 
2014). Roche currently have two compounds in trials, R05045337 
(RG7112) and R05503781 (RG7388),   with R05045337 being based 
on the original Nutlin family of inhibitors (Vu et al., 2013).  
R05503781 is the second generation of R05045337, with superior 
potency and selectivity (Ding et al., 2013).  Novartis have developed 
a drug named CGM097 which has been optimised and moved to 
clinical trials, with analogs currently being developed and their 
efficacy assessed in vivo (Parks et al., 2005).  A fifth inhibitor, named 
DS-3032b was developed by Daiichi Sankyo following a miniaturised 
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thermal denaturation assay used to screen chemical libraries, leading 
to a unique series of benzodiazepinedione antagonists of the MDM2-
p53 interaction being discovered (Grasberger et al., 2005). 
SAR4058383 was developed by the University of Michigan and 
Sanofi, with promising early studies showing that a single optimised 
oral dose of the compounds leading to complete tumour regression in 
the SJSA-1 cell line model (Wang et al., 2014).  Finally, MK-8242 
was developed by Merck Sharp & Dohme Corp and a clinical trial of 
patients with solid tumours was recently completed (Zhao et al., 
2015). 
It is well known that, following DNA damage, p53 is activated and this 
leads to  arrest of the cell cycle and apoptosis in sensitive tissues 
(Gudkov and Komarova, 2003). Therefore, a main concern of using 
therapeutics to activate p53 is the effect of this act in normal tissues. 
Mice with MDM2 reduced to around 30% of its normal level show 
increased p53 in all tissues tested. Apart from slight disturbances in 
haematopoiesis and an increase in apoptosis in the small intestine, 
these mice developed normally (Mendrysa et al., 2003, Vassilev, 
2007). Further, nude mice can tolerate nutlin-3 for three weeks at 
doses that cause inhibition and regression of tumours (Tovar et al., 
2013). It seems that these studies suggest that perhaps activation of 
p53 through MDM2 inhibition may be a promising therapeutic option 
and can be well tolerated in vivo (Vassilev, 2007).  
Although use of these inhibitors can be extremely useful for cancer 
therapeutic development, their effectiveness depends on multiple 
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factors.  Firstly, as already mentioned, the therapeutic effect of p53 
activation could be abolished through the potential cell cycle arrest or 
cell death caused by p53 activation.  Secondly, MDM2 is not the only 
regulator of p53 in cells, so other interactors may hinder the cellular 
response to MDM2 antagonists. For example, MDM4 another p53-
binding protein, cannot be displaced by nutlin-3, so the effectiveness 
of nutlins can be compromised in tumour cells which overexpress 
MDM4 (Vassilev, 2007). 
Therefore, although MDM2 represents a useful and potent target for 
inhibitors in the impedance of cancer progression, an ideal 
therapeutic has not yet been identified.  However, with our new 
understanding of the functions of p53-dependent and -independent 
MDM2 and accelerating speed of drug development, it is possible 
that an MDM2-targeted therapy could be effectively applied to halt 
tumour outgrowth in patients (clinical trials of MDM2-targeted 
therapeutics summarised in Table 1.2.).  
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Table 1.2. Clinical trials targeting MDM2 for cancer treatments.  
Table modified from Bradbury et al. (Bradbury et al., 2015).   
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vi. MDM2 involvement in tumour-associated angiogenesis 
 
VEGF is a potent angiogenic factor which plays an important role in 
regulating normal physiological and pathological angiogenesis.   
Correctly timed expression of VEGF at appropriate levels is crucial 
for normal development of vasculature and homeostasis, but also 
vital for solid tumour growth. VEGF is highly expressed in solid 
tumours and is required for the development and maintenance of 
blood vessels within the tumour, which is a prerequisite for 
successful tumour growth and metastasis. 
A co-expression study was undertaken to evaluate the correlated 
expression of MDM2 and VEGF, finding that, over eight different 
cancer cell lines, higher MDM2 expression meant higher VEGF 
mRNA, with the cell lines with lost p53 function showing highest 
VEGF levels (Narasimhan et al., 2007). They verified their findings 
further by inhibiting MDM2 using a specific MDM2-specific antisense 
oligonucleotide (HDMAS5) and saw a significant decrease in VEGF 
mRNA and protein levels. Finally, they proved that transfecting the 
MDM2 gene in the prostate cancer cell line, LNCaP, produced a cell 
line overexpressing MDM2 and VEGF.  The same group then 
identified MDM2 as a regulator of VEGF expression in cancer cells.  
Human umbilical vein endothelial cells (HUVECs) were treated with 
tumour-conditioned media (TCM) from HMAS5-treated cancer cells. 
They found that VEGF release from cells and VEGF-dependent 
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angiogenesis were significantly reduced in vitro (Narasimhan et al., 
2008).  
Hypoxia-inducible factor 1 (HIF-1) is a heterodimeric transcription 
factor which generates a response to oxygen deprivation due to 
hypoxic conditions. Active HIF-1 is comprised of two subunits:  HIF-
1β is constitutively expressed in the cell, however, under normoxic 
conditions HIF-1α is covalently modified by prolyl hydroxylases, 
allowing von Hippel-Lindau tumour suppressor (VHL) E3 ubiquitin 
ligase to polyubiquitinate and thus targets HIF-1α for degradation 
(Ivan et al., 2001, Jaakkola et al., 2001).  Factor inhibiting HIF-1 
(FIH-1) can also hydroxylate HIF-1α, preventing coactivator binding 
and so inhibiting transcription of target genes (Mahon et al., 2001).  
Following a decrease in cellular oxygen levels, the rates of 
hydroxylation are decreased, VHL does not bind, HIF-1α is stabilised 
and the HIF-1 the heterodimer can form (Joshi et al., 2014).  
Overexpression of HIF-1α has been linked to angiogenesis, tumour 
invasion and a poor prognosis in many types of cancer (Bos et al., 
2005, Nakanishi et al., 2005, Theodoropoulos et al., 2004, Zagzag et 
al., 2000).  The HIF-1 transcription factor binds to the 5’ flanking 
sequence of vegf and is essential for the transactivation of vegf 
during hypoxia.  
It has been known for some time that hypoxia is a physiological 
inducer of tumour suppressor p53, with p53 protein levels increasing 
under hypoxic conditions (Graeber et al., 1996).  Since MDM2 is the 
most important negative regulator of p53, many groups began to look 
1. General Introduction 
 
38 
 
into the precise mechanism of the interaction between hypoxia and 
p53, and whether MDM2 was involved (Nieminen et al., 2005, Lau et 
al., 2006, Secchiero et al., 2007, LaRusch et al., 2007, Binder, 2007, 
Lee et al., 2009, Mahon et al., 2001, Zhou et al., 2011, Muthumani et 
al., 2014, Xiong et al., 2014). 
In 2005, a study showed that MDM2 positively activates HIF-1α in 
hypoxic tumour cells. Co-immunoprecipitation showed that MDM2 
precipitates with HIF-1α, completely independently of p53 (Nieminen 
et al., 2005). Evidence towards the involvement of MDM2 in the 
regulation HIF-1α expression under hypoxic conditions came from 
Lau et al.(Lau et al., 2006), who found that inhibitory effects on HIF-
1α by the anti-cancer drug 3-(5’-hydroxymethyl-2’-furyl)-1-benzyl 
indazole (YC-1), was MDM2-dependent and that overexpression of 
MDM2 reversed its inhibitory effects.  A very recent study also 
suggested that, under hypoxic conditions, MDM2 is capable of 
ubiquitinating HIF-1α with its E3 ubiquitin ligase domain in a 
PTEN/phosphoinositide 3-kinase (PI3K)-dependent manner.  The 
group’s results suggested that the PI3K-protein kinase B (AKT) 
signalling axis is a requirement for the preservation of HIF-1α stability 
during hypoxia (Joshi et al., 2014). 
Another study showed that nutlin-3 conferred anti-angiogenic activity.  
It was found that nutlin-3 dose-dependently suppressed the total tube 
length and the number of capillary connections developed from 
HUVECs.  Also, the migration of endothelial cells was shown to be 
significantly inhibited by nutlin-3 in response to various 
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chemoattractants (Secchiero et al., 2007). In the same year, two 
more reports were published demonstrating the inhibition of HIF-1α 
by nutlin-3, leading to inhibited VEGF production and thus 
angiogenesis in tumours (LaRusch et al., 2007, Binder, 2007). Lee et 
al. (Lee et al., 2009) then suggested a mechanism through which this 
occurred after finding that nutlin-3 downregulated HIF-1α in p53-
positive cells but also functionally inactivated HIF-1α in p53-negative 
cells.  Of these two occurrences, they found that the second mainly 
contributed to VEGF suppression by nutlin-3.  It was reported that 
MDM2 competes with FIH which is a regulator of HIF-1α, by binding 
its C-terminal transactivation domain (CAD).  FIH hydroxylates 
Asn803 in the CAD domain under normoxic conditions.  However, 
when conditions are hypoxic, this hydroxylation is inhibited due to the 
limited oxygen and so HIF-1α becomes stable and active (Mahon et 
al., 2001, Lando et al., 2002). When MDM2 competes for binding of 
the CAD of HIF-1α, this hydroxylation is inhibited and so p300 is 
recruited.  They found that nutlin-3 reinforced the FIH-mediated 
inactivation of HIF-1α through inhibiting any interaction between CAD 
and MDM2 (Lee et al., 2009).This theory is in direct contrast to the 
report by LaRusch et al. (LaRusch et al., 2007), who reported that 
the N-terminal domain of HIF-1α was needed for binding of MDM2.  
This could imply that each domain of HIF-1α interacts individually in 
different ways with MDM2 or they cooperate to bind MDM2.  
Therefore, it is widely accepted that hypoxia induces VEGF 
transcription through induction of HIF-1α.  However, in 2011, a group 
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set out to investigate the posttranscriptional regulation occurring, in 
which HIF-1α does not seem to be important (Zhou et al., 2011). 
Their work followed on from a study which showed that in rat cardiac 
myocytes hypoxia can induce VEGF steady-state mRNA 25-fold, 
however the hypoxia-mediated transcription rate of VEGF increases 
just 3.1-fold (Levy et al., 1996).  Their results showed that the RING 
domain of MDM2 can bind to AU-rich elements of the VEGF 3’ 
untranslated region (UTR) and regulate VEGF mRNA stability and 
thus its translation.   Interestingly, they also demonstrated that during 
hypoxia, MDM2 was dephosphorylated and translocated to the 
cytoplasm from the nucleus, where it was able to induce high levels 
of VEGF in cancer cells (Zhou et al., 2011).  The same group then 
undertook a study to elucidate whether p53 played a role in the 
interaction between MDM2 and VEGF.  They did this through the use 
of two cell lines, MCF-7 which expresses wild-type p53 and MDA-
MB-468, which expresses mutant p53.  They studied the effect of 
nutlin-3 and anti-MDM2 antisense oligonucleotide (ASO), on these 
cell lines and saw that ASO significantly inhibited the VEGF transcript 
and protein levels in a dose- and time-dependent manner, whereas 
nutlin-3 had no effect.  The effect of hypoxia was also studied, and it 
was observed that ASO treatment significantly inhibited HIF-1α 
expression at 3, 6 and 12 hours of hypoxia in both cell lines.  An 
inhibitory effect on HIF-1α was also seen in the nutlin-3 treated MCF-
7 (wild-type p53) but not in MDA-MB-468 (mutant p53).  The group 
used siRNA targeted at HIF-1α as well as ASO treatment and found 
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that HIF-1α only seems to have a role in VEGF production in early 
hypoxia (at 6 hours, but not at 48 hours). HIF-1α siRNA did not 
reverse the inhibitory effect of ASO on VEGF production.  Therefore, 
the group surmised that ASO downregulates hypoxia-induced VEGF 
production via a HIF-1α-independent mechanism.  When the same 
experiment was undertaken using nutlin-3, it was seen that nutlin-3 
significantly inhibited the level of secreted VEGF from the MCF-7 
cells at early hypoxia. When the cells were transfected with HIF-1α 
siRNA, nutlin-3 failed to inhibit VEGF production.  This exhibits that 
the effect of nutlin-3 on VEGF regulation in early hypoxia is HIF-1α-
dependent.   ASO treatment of mice with tumours of each cell type 
showed a substantial decrease in serum VEGF levels, measured by 
ELISA.  On the other hand, nutlin-3 treatment produced little effect on 
VEGF production (Xiong et al., 2014). 
A very recent study investigated the precise mechanism supporting 
the induction of VEGF transcription by MDM2.  They used prostate 
cancer cell lines LNCaP and MDM2 transfected LNCaP (LNCaP-
MST).  As expected, they found that VEGF transcription was 
significantly higher in the LNCaP-MST cells compared to the non-
transfected LNCaP (Muthumani et al., 2014).  Activation of the PI3K-
mTOR pathway has previously been reported upon increase of 
VEGF expression in normoxic and hypoxic conditions (Narasimhan 
et al., 2008).  Since HIF-1α is required as a primary member of this 
pathway, it is generally assumed that activation of the pathway is 
more effective under hypoxic conditions, in terms of induction of 
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VEGF transcription.  Yet, this study showed that in the LNCaP-MST 
cells, the PI3K-mechanistic target of rapamycin (mTOR) pathway 
seems to be activated and the basal HIF-1α appear high.  They 
reported that MDM2 seemed to be triggering an elevated level of 
HIF-1α, in line with increasing expression of VEGF in normoxic cells, 
even when hypoxic conditions are lacking. The data presented also 
suggested that signal transducer and activator of transcription 3 
(STAT3) and nuclear factor κB (NF-κB) may play important roles in 
MDM2-mediated activation of VEGF transcription since their levels 
were increased in the LNCaP-MST cells compared to the non-
transfected LNCaP cells (Muthumani et al., 2014). 
It has also been suggested that p53 can negatively regulate VEGF 
expression.  In 2000, Ravi et al. (Ravi et al., 2000) claimed that 
homozygous deletion of p53 in human colon cancer cells promoted 
neovascularisation and growth of xenograft tumours in nude mice. 
They showed that upon loss of p53, HIF-1 protein levels are 
enhanced and so VEGF expression is augmented.  It was also 
demonstrated that forced HIF-1α expression in p53-expressing 
cancer cells promotes the expression of VEGF and this leads to 
neovascularisation of tumour xenografts.  Therefore, the group 
concluded that p53 acts as a molecular chaperone to HIF-1α, 
facilitating its recognition by MDM2 for ubiquitination.  This work was 
disputed by a later study (Nieminen et al., 2005) which suggests that 
the group’s results may be due to the use of hypoxia-mimicking 
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agents such as cobalt and thus the proteins in complex could 
change.  
In conclusion, despite the great amount of studies undertaken in 
order to elucidate the role of MDM2 in both angiogenesis and 
hypoxia, the precise mechanisms are yet to be exposed.  It is widely 
accepted that MDM2 and VEGF levels are coordinated in cancer and 
that HIF-1α increase can upregulate VEGF transcription during 
hypoxia.  It has been proved many times that MDM2 and HIF-1α 
interact during hypoxia, although whether this is a direct or indirect 
interaction, and whether it involves p53 tumour suppressor is under 
scrutiny.  It has also been suggested that a second layer of 
regulation occurs between MDM2 and VEGF, at post-transcriptional 
level, independent of HIF-1α.  Therefore, perhaps there are different 
points of regulation of VEGF levels by MDM2 during hypoxia and 
HIF-1α and p53 may play a role in some, but not others.  
v. Participation of MDM2 in tumour invasion and 
metastasis 
 
Due to the high expression of MDM2 in a number of cancer types, its 
roles in the invasion and subsequent metastasis of tumours have 
been studied.  Migration and invasion through the extracellular matrix 
are reliant on the matrix metalloproteinases (MMPs) which are zinc-
dependent remodelling endopeptidases implicated in many pivotal 
roles in tumour growth and the multistep processes of invasion and 
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metastasis.  Different members of the MMP family exert contradicting 
roles at various stages of cancer progression (Gialeli et al., 2011). 
The most obvious feature of MDM2 involvement in the progressive 
properties of cancer is its interaction with p53.  The ability of MDM2 
to block p53 activity is exploited by tumour cells. However, there are 
other ways in which MDM2 contributes to the progression of cancer.  
It was shown that in breast cancer cells MDM2 can decrease E-
cadherin protein level through ubiquitination and ectopic expression 
of MDM2 increases cell-cell dissociation, invasion and cell motility 
(Yang et al., 2006).  A study into patients with malignant melanoma 
showed that MDM2 expression level was directly associated with the 
thickness of a tumour and weakly with invasion level (Rajabi et al., 
2012).   
Immunohistochemical staining of invasive ductal breast carcinoma 
(IDC) showed a significant correlation between MDM2 and MMP9 
expression.  In vitro studies in MDA-MB-231 and MCF-7 breast 
cancer cell lines have shown that siRNA targeted at MDM2-targeted 
siRNA significantly decreased cell invasion, migration and 
proteolysis, with the opposite seen in cells overexpressing MDM2.  
MDM2 overexpression in these cells was seen to induce MMP9 
expression in a dose-dependent manner (Chen et al., 2013).  A 
slightly later study also linked the expression of MDM2 and MMP9 in 
the oncogenesis of lung cancer in rats (Zhang et al., 2014). 
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1.5  Prostate-specific membrane antigen (PSMA) 
 
i. Clinical relevance of PSMA  
 
PSMA is a type II membrane protein with a unique three-part 
structure: a 19 amino acid internal region, a 24 amino acid 
transmembrane region and a 707 amino acid external portion 
(Chang, 2004, Leek et al., 1995) (Figure 1.5). It has recently been 
demonstrated that PSMA has an internalisation signal which allows 
internalisation of the protein on the cell surface into an endosomal 
compartment (Rajasekaran et al., 2005).  The PSMA gene is located 
on the chromosome 11p in a region that is not currently deleted in 
prostate cancer (O'Keefe et al., 1998). 
PSMA has only a few sites of expression in normal tissues: the 
prostate epithelium, the kidney proximal tubules, the nervous system 
glial cells and the small bowel jejunal brush border (Mhawech-
Fauceglia et al., 2007, Sacha et al., 2007) .  At the jejunal brush 
border the protein is better known as FOLH1 and here it converts 
dietary folate (pteroylpolyglutamate) to monoglutamated folate 
(Halsted et al., 1998, Ristau et al., 2014). In the nervous system, 
however, PSMA carries out its N-Acetylated alpha-linked acidic 
dipeptidase (NAALADase) function and hydrolyses N-
Acetylaspartylglutamic acid (NAAG), the most abundant peptide 
neurotransmitter in the mammalian nervous system  
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(Neale et al., 2000, Ristau et al., 2014). The presence of PSMA in 
the prostate and proximal tubules of the kidneys is not yet under-
stood but it has been suggested that this could be due to the 
reuptake of folate in the kidneys and the release of monoglutamated 
folates into the seminal fluid (Ristau et al., 2014).   
The cell surface expression of PSMA has been shown to increase 
directly in cancers of higher-grade, metastases, prostate cancer 
which is castration-resistant and cancers giving an adverse clinical 
outcome (Ross et al., 2003, Perner et al., 2007). Furthermore, PSMA 
expression was observed to decrease in the prostate cancer cell line, 
LNCaP, when incubated with androgen dihydrotestosterone (DHT) 
and, conversely, cells grown in androgen-stripped media displayed 
increased PSMA expression (Liu et al., 2012b). It is clear that 
increased expression and enzymatic activity of PSMA in aggressive 
tumours are telling of a selective advantage bestowed by PSMA 
upon tumour cells and this contributes to prostate carcinogenesis.   
PSMA has also been reported to be expressed in the neovasculature 
of a considerable majority of malignant solid tumours (bladder, 
breast, kidney pancreas, lung and melanoma), but not in the 
corresponding normal vasculature (Chang and Heston, 2002). 
PSMA has been identified as an excellent target for imaging and 
therapy of cancer for several reasons.  The specificity of its 
expression is a key factor, with only a limited number of normal 
tissue types expressing the protein, along with PSMA’s large 
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extracellular region allowing therapeutics to be exclusively targeted 
to the tumour region and malignant cells.  The fact that PSMA is a 
transmembrane protein is also important, as its extracellular region 
can be easily targeted by therapeutics. Also, the presence of an 
internalisation sequence within the protein means that therapeutics 
targeted at PSMA could be internalised through binding. Finally, 
PSMA’s peptidase activities means that it could be involved in the 
processing of a pro-drug targeted at tumour cells (Rajasekaran et al., 
2005, Chang and Heston, 2002, Akhtar et al., 2012).  Therefore, 
there is a very strong case for the use of PSMA as a biomarker and 
therapeutic target in the fight against cancer.   
ii. PSMA in breast cancer 
 
PSMA was originally thought to be solely expressed in prostate 
cancer (Horoszewicz et al., 1987, Troyer et al., 1995, Pinto et al., 
1996); however, later it was shown to be highly expressed in both the 
cells and neovasculature of many other tumour types, including 
breast, gastric, colorectal, renal and bladder cancers (Chang et al., 
1999, Silver et al., 1997a, Silver et al., 1997b, Haffner et al., 2009). 
Recently, the expression of PSMA in breast cancer has been studied 
in the hope that targeting the molecule may give rise to a new 
therapy for this type of tumour.  One group investigated the 
expression of PSMA in breast neovasculature and found that 98% of 
the vasculature primary carcinoma shown PSMA positivity through 
immunohistochemical staining.  Further, it was seen that all breast 
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metastases which were secondary to invasive breast carcinoma 
showed PSMA expression. Interestingly, this group reported that 
when the metastasised and primary tumour staining scores from the 
same patient were compared, the same score was seen, which is 
opposing to other reports claiming that PSMA expression increases 
with metastasis (Ross et al., 2003, Perner et al., 2007).  They saw 
that patients with a higher PSMA staining score had a bigger median 
tumour size, a higher Ki-67 proliferation index, a higher nuclear grade 
and compared to those of a lower staining score (Wernicke et al., 
2014).  Another group showed that PSMA is expressed in the blood 
vessels of breast cancer brain metastases, as well as the primary 
tumours (Nomura et al., 2014).   Further, a recent report found that 
tumour-conditioned media (TCM) from metastatic, highly invasive cell 
lines MDA-MB-231 results in an increased expression of PSMA in 
HUVECs, compared to MCF-7 TCM or VEGF treatment (Liu et al., 
2012a). 
iii. PSMA as a biomarker for cancer 
 
Since prostate cancer tissues shows high PSMA expression and 
increased enzymatic activity of PSMA compared to normal and 
benign hyperplasia prostate (BHP) tissues (Lapidus et al., 2000, 
Burger et al., 2002) the use of PSMA as a biomarker for prostate 
cancer is under investigation.  A direct correlation has been identified 
in adenocarcinomas between the expression of PSMA and Gleason 
score, which is used to stage prostate cancer (Burger et al., 2002).  A 
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study by Ross et al. suggests that PSMA could act as a biomarker for 
prognosis as it shows a significant correlation with adverse 
prognostic factors such as tumour grade, aneuploidy, biochemical 
recurrence and pathological stage (Ross et al., 2003). 
The current standard for early detection of prostate cancer involves a 
digital rectal examination (DRE) and a serum test for prostate-
specific antigen (PSA).  Despite its use, there is no definite level of 
PSA which can actively distinguish between men with prostate 
cancer and those with a benign hyperplasia, leading to false positive 
results and overtreatment of men with limited disease (Perner et al., 
2007).  
PSA is different from PSMA in a number of ways: PSA is a secretory 
protein, whereas PSMA is an integral membrane protein. PSMA is a 
liquefaction in semen, whereas PSMA holds several enzymatic 
functions. PSA is decreased with androgen deprivation, whereas the 
inverse is true of PSMA (Chang, 2004).  
PSMA immunohistochemistry was seen to have a higher (84%) 
sensitivity than PSA (58%) in staining of tissues from metastatic 
sites. Strong, diffuse staining was seen in 17 of 19 cases of 
metastatic prostate cancers, compared to 13 from PSA staining. 
Positivity for either of the molecules was seen in 89% of metastatic 
prostate cancer and this combination immunohistochemistry was 
slightly more sensitive than that of PSMA alone, indicating that a 
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combination of PSMA and PSA immunohistochemistry could be a 
beneficial prognostic assessment for patients (Bernacki et al., 2014). 
Quantification of PSMA and PSA levels in peripheral blood showed 
significant differences among BPH, locally confined prostate cancer 
and metastasised prostate cancer in expression of PSA and PSMA.   
It was found that one cancer cell could be detected in 2 x 107 
mononuclear cells (Zhang et al., 2008).   
The first clinical agent targeting PSMA in prostate cancer was the 
monoclonal antibody 7E11/CYT-356, which was labelled with Indium-
111 and known as 111In-capromab or ProstaScint (Wynant et al., 
1991, Elsasser-Beile et al., 2009, Ristau et al., 2014).  The sensitivity 
and specificity of the antibody has differed in studies, with an 
average sensitivity of 60%, a specificity of 70%, a positive predictive 
value of 60% and a negative predictive value of 70% (Apolo et al., 
2008, Rosenthal et al., 2001). These poor results could be a 
consequence of 111In-capromab recognising an intracellular epitope, 
and therefore only binding molecules in cells with a damaged cell 
membrane (Ristau et al., 2014). 
This led to the development of second-generation antibodies which 
can bind to the extracellular region of PSMA and thus could be 
superior to the capromab pendetide.  One of these developed 
antibodies, J591, has shown potential in imaging primary prostate 
cancer, as well as bone metastases.  Clinical trials with 99mTc-
labelled J591 established detection of primary prostate cancer, as 
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well as prostate bed recurrence and distant metastases, again, 
including metastasis to bone (Ristau et al., 2014, Nargund et al., 
2005).  Several other developed monoclonal antibodies (3/A12, 3/E7 
and 3/F11) bind to different epitopes of PSMA (Ristau et al., 2014). A 
study using 64Cu-3/A12 for positron emission tomography (PET) 
imaging of prostate cancer xenograft showed a good tumour-to-
background ratio (Elsasser-Beile et al., 2009). A fourth monoclonal 
antibody targeting PSMA, 3C6, has been labelled with 111In for 
imaging in prostate cancer (Regino et al., 2009). 
Radiolabelled PSMA inhibitor N-[N-[-(S)-1,3-
dicarboxypropyl]carbamoyl]-S-[11C]methyl-l-cysteine (DCFBC) has 
been successfully used in PET imaging of xenografts expressing 
PSMA (Foss et al., 2005).The molecule was labelled with 18F, with 
studies into its biodistribution and imaging showing a high uptake of 
18F-DCFBC in PSMA-positive tumours but slight or no uptake in 
tumours negative for PSMA (Mease et al., 2008). Urea-based 
compounds have also been identified as possible targets for imaging 
of prostate cancer with PET and SPECT (Chen et al., 2009). MIP-
1095 and MIP-1072, which are small-molecule inhibitors targeting 
PSMA, have shown a high affinity for PSMA and their uptake when 
labelled with 123I has been successfully imaged by SPECT (Hillier et 
al., 2009, Osborne et al., 2013). 
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iv. PSMA as a therapeutic target 
 
PSMA has been exposed as an attractive therapeutic target due to 
its expression being 100- to 1000-fold less in normal cells in 
comparison to prostate carcinoma cells (Sokoloff et al., 2000). So far, 
antibody-based radiotherapy, antibody-drug conjugates (ADC), 
PSMA-targeted prodrug therapy and PSMA-based immunotherapy 
have been investigated (Ristau et al., 2014).   
The leading PSMA antibody-based radiotherapeutic is Lutetium-177 
J591, which showed acceptable toxicity and excellent metastatic site 
targeting in a phase I clinical trial (Bander et al., 2005).  A recent 
phase II clinical trial utilised Lutetium-177 J591 in patients with 
metastatic castration-resistant prostate cancer (Tagawa et al., 2013).  
Just less than 60% of patients showed a decrease in PSA levels with 
1/10 showing a reduction of more than half and the therapeutic 
showed accurate targeting of metastatic sites (Akhtar et al., 2012). 
The higher concentration used in the trials (70 mCi/m2) led to longer 
survival of patients (almost 22 months, compared to 12), but resulted 
in increased  grade 4 hematologic toxicity and platelet transfusions 
(Tagawa et al., 2013, Ristau et al., 2014) . 
J591 antibody has also been utilised in the production of ADC, which 
involves the linking of a drug or toxin to an antibody (Akhtar et al., 
2012).  MLN2704 is an antimicrotubule agent which has been 
conjugated to J591.  Phase 1 studies in over 20 patients showed 
>50% decrease in PSA levels dropped by more than half  in 2 
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patients, although grade 3 toxicities occurred in 3 patients3 of the 
patients (Galsky et al., 2008, Ristau et al., 2014).  A multicentre 
phase II/III clinical trial undertaken in 62 men with metastatic 
castration-resistant prostate cancer showed stabilisation or decline in 
PSA in a majority of patients; however, limitation of treatment 
occurred due to toxic effects of the compound (Ristau et al., 2014, 
Akhtar et al., 2012).   
Work has been undertaken in xenograft LNCaP mice, using an 
immunotoxin consisting of the anti-PSMA mAb E6 and 
deglycosylated ricin A, showing reduced tumour growth (Ristau et al., 
2014).  Another group coupled melitten-like peptide 101 to J591 and 
also saw a significant tumour growth inhibition in mice (Russell et al., 
2004, Akhtar et al., 2012).  Monomethylauristatin E (MMAE) has also 
been conjugated to a mAb which recognised the PSMA external 
domain (Ma et al., 2006). 
Recently, a group engineered a prodrug for tumour endothelial cells 
in prostate cancer therapy (Denmeade et al., 2012). Their work 
involved the coupling of a PSMA-specific peptide to thapsigargin 
(inhibitor) of the sarcoplasmic/endoplasmic reticulum calcium 
adenosine triphosphate (SERCA) pump.  SERCA is a vital cellular 
protein which is essential for the viability of all cell types.  Before 
cleavage of the PSMA-specific molecule, the conjugate is inactive.  
However, post-cleavage, local SERCA inhibition ensues (Ristau et 
al., 2014).  Preclinical xenograft models treated with thapsigargin 
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showed significant prostate cancer tumour regression at doses which 
were modestly toxic to the host (Denmeade et al., 2012). 
The use of immunotherapy in oncology has been long utilised, but 
only recently has work on PSMA as a target begun to be investigated 
(Akhtar et al., 2012).  This type of therapy is based on the concept 
that IL-2 stimulates natural killer cells, thus enhancing antibody-
dependent cellular cytotoxicity.  A phase II trial of the anti-PSMA 
monoclonal antibody J591 was undertaken in patients with recurrent 
prostate cancer for 8 weeks, with patients receiving continuous low-
dose subcutaneous interleukin-2 (IL-2) every day, with infusions of 
J591 weekly.  Of 176 patients, nine had stable PSA, with declines of 
up to 34%.  The therapy was well tolerated and the toxicity was low, 
with non-progressors showing a trend with significant natural killer 
(NK) cell expansion (Akhtar et al., 2012, Ristau et al., 2014).   
Thus, although PSMA-targeted therapy is yet to yield clinically 
important effects on the survival of patients without severe side 
effects ensuing, several fields are currently under study and as our 
molecular techniques and our understanding of tumour biology 
become more advanced, PSMA-therapeutics are likely to play an 
important role in the development of treatment for cancer patients 
(Ristau et al., 2014) (clinical trials of PSMA as a biomarker and 
therapeutic target summarised in Table 1.3.).  
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v. PSMA involvement in tumour-associated angiogenesis 
 
In terms of links of PSMA to VEGF, there are differing views.  A re-
port by Tsui et al. (Tsui et al., 2005) claimed that there was a correla-
tion between PSMA and VEGF expression in the tumours of xeno-
graft mice, when immunohistological analysis was undertaken.   
Forced PSMA expression in a prostate cancer cell line, RM-1, and 
quantification of secretion of VEGF by cells led to the conclusion that 
stable transfection of PSMA promoted VEGF release.   When these 
cells were injected into mice, immunohistochemistry was performed  
and VEGF levels were seen to be significantly higher in the mice 
injected with the cells expressing PSMA (Zhao et al., 2012).  
Since it is found in the neovasculature of many tumours, PSMA is 
thought to regulate angiogenesis. In 2006, a group demonstrated that 
PSMA is required for angiogenesis in vivo and invasion of endothelial 
cells in vitro, where it was exhibited  to be involved in laminin-specific 
signalling and regulation of the dynamics of the cytoskeleton through 
the Rho GTPase effector molecule p21-activated kinase 1 (PAK-1).  
The group hypothesised that PSMA partakes in an autoregulatory 
feedback loop where, in its active state, it increases integrin signal 
transduction, PAK activation, followed by endothelial cell adhesion 
and invasion.  This process leads to the dissociation the 
PSMA/filamin complex and a decrease in PSMA activity and 
therefore integrin-β1 activity is held in check (Conway et al., 2006). 
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Table 1.3. Clinical trials utilising PSMA for cancer imaging and 
treatment.  Table taken from (Bradbury et al., 2015). 
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In a subsequent study, the same group then went on to assess the 
role of PSMA in ocular neovascularisation.  To do this they used an 
oxygen induced retinopathy model (OIR) and it was observed that, 
after an initial decrease in retinal PSMA mRNA, transcript levels were 
progressively increased over the time of the relative hypoxia. Vessel 
formation was then assessed in the retina of PSMA null mice under 
these conditions of relative hypoxia.  Again, it was seen that the loss 
of PSMA in these mice did not affect the development of normal 
retinal vasculature.  However, mice undergoing OIR showed a 
remarkable difference between PSMA null and wild-type.  The 
capillaries in the mid-periphery formed a dense, honeycomb of close 
vessels.  In comparison, retinas from PSMA null animals after OIR 
showed a vascular pattern which closely resembled the normal 
structure, with less avascular area in the central region and more 
highly branched capillaries in the periphery.  It was also seen that, in 
comparison to the wild-type, PSMA null mice vessels were better 
perfused and more functional. Finally, the study evaluated the use of 
2-(phosphonomethyl)pentanedioic acid (2-PMPA) PSMA inhibitor in 
wild-type mice and obtained similar results. Therefore, the absence 
of PSMA seems to lead to a less pathogenic phenotype in the retina.  
The involvement of PSMA in angiogenesis through this mechanism 
was seen to be independent of VEGF (Grant et al., 2012). 
In 2011, a group undertook a study analysing the result of TCM from 
breast cancer cell lines, MDA-MB-231 (oestrogen receptor negative) 
and MCF-7 (oestrogen receptor positive), on human umbilical vein 
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endothelial cells (HUVECs).  They found that the aggressive MDA-
MB-231 breast cell line TCM induced tube formation of the HUVECs, 
however, TCM from MCF-7, PC3, LNCap, VEGF-containing 
Vasculife medium, or without Matrigel led to the HUVECs forming 
only incomplete, short tube-like structures.  In the tubules formed 
following treatment with TCM from MDA-MB-231, the high level of 
PSMA expression compared to HUVECs treated with the other TCM 
or VEGF-containing media, was demonstrated using both qRT-PCR 
and fluorescent inhibitor-affinity labelling.  Subsequently, to elucidate 
which factors in the TCM from MDA-MB-231 may cause the tubule 
formation and expression of PSMA, they fractioned the TCM and 
found that one factor above 30 kDa and another below 3 kDa were 
essential for formation.  This study needs to be extended and more 
ER+ and ER- cell line TCMs used, but if the results are confirmed in 
more cell lines, this model could be easily used to assess tumour-
vasculature targeting agents for imaging and therapeutic applications 
(Liu et al., 2011). 
It is certain that PSMA is involved in angiogenesis; however, the 
precise mechanism by which PSMA exerts its effect is unknown.  
PSMA has been linked to VEGF levels in some reports, with 
increased and decreased PSMA levels being reflected in VEGF 
expression.  However, a group who have released a number of 
related papers on the subject of PSMA in angiogenesis claim that the 
involvement of this protein is VEGF-independent.  This suggests that 
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PSMA may also play a number of roles in angiogenesis, some 
involving VEGF, others not.   
vi. PSMA involvement in tumour-associated invasion and 
metastasis 
 
A paper by Ghosh et al. (Ghosh et al., 2005) showed that, 
surprisingly, in prostate cancer cells, ectopic expression of PSMA in 
the PSMA-negative cell line PC-3 cells reduced their invasiveness.  
On the other hand, they found that knockdown of PSMA in the 
PSMA-positive cell line, LNCaP, increased their invasiveness five-
fold.  PSMA mutants lacking the carboxypeptidase activity of the 
protein were produced and showed that this reduced the impact of 
PSMA expression on invasiveness. Another study involving the 
injection of the mouse prostate cancer cell line RM-1 with stable 
expression of PSMA into mice showed the formation of lytic bone 
lesions and distinct MMP9 expression compared to the control (Zhao 
et al., 2012). 
It was found that the sequential digestion of laminin, a predominant 
component of the extracellular matrix (ECM), occurs through PSMA 
working downstream of MMP2, generating small peptides which 
enhance the invasive and adhesive abilities of HUVECs in vitro, 
providing evidence that these peptides activate adhesion through 
integrinα6β1 and focal adhesion kinase (FAK).  It was suggested that 
since PSMA is a glutamate-specific peptidase, cleavage of a laminin-
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derived peptide substrate could modify the overall charge of the 
peptide and so facilitate integrin binding (Conway et al., 2006). 
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1.6  The matrix metalloproteinases (MMPs)  
 
i. The extracellular matrix  
 
The extracellular matrix (ECM) is a structural support network, 
involved in the maintence of all cells (Hynes, 2009).  It is known that 
the ECM plays a role in many cellular processes including cell 
proliferation (Hynes, 2009), differentiation (Discher et al., 2005) and 
migration (Pelham and Wang, 1997). The ECM is the non-cellular 
element of tissues, sometimes likened to the ‘glue’ that links cells 
together, where it is a principal constituent of tissues (Rolfe and 
Grobbelaar, 2012).  The ECM is composed of proteins, such as 
collagens (Kim et al., 2011b), elastins (Eckes et al., 2010), fibronectin 
(Tanzer, 2006), laminins (Tanzer, 2006), tenascins (Eckes et al., 
2010), growth factors (Eckes et al., 2010, Kim et al., 2011b) and 
MMPs (Streuli, 1999, Page-McCaw, 2008).   
The multiple components of the ECM are organised into a 
distinguishable three-dimensional (3D) structure, which can be 
separated into two components, the basement membrane (BM) and 
interstitial matrix.    
The ECM is recognised as an active environment, constantly 
experiencing changes in composition and structure.  These changes 
occur in response to actions and signals from the surrounding cells.  
As a consequence, the communication between cells and the ECM is 
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vital to understanding how these two components of tissues respond 
and learn to adapt to one another (Kular et al., 2014).  
The basement membrane 
 
The main components of the BM include fibronectins, laminins and 
collagen type IV.  The latter provides the tissue with tensile strength.  
The BM is known to be more dense and ‘less porous’ than the 
interstitial matrix (Lu et al., 2012).  The BM is found in blood vessels, 
epithelial and endothelial tissues, forming an extremely orderly 
network, with the epithelial tissues being highly dependent on the BM 
in order to conduct its expected role (Kim et al., 2011b).  Integrin 
between the BM and the cells lying above convey messages 
regarding cell shape and motility (Tanzer, 2006). 
The interstitial matrix 
 
The interstitial matrix occurs in the same places as the BM; however, 
it is also found between connective tissue cells, such as those within 
the tendon.  The major elements which form this component of the 
ECM are collagens, elastin and fibronectin, creating a ‘3D 
amorphous ‘gel’.  Despite collagen composing the majority of the 
fibrous proteins within this matrix, it is fibronectin which dictates the 
organisation of the matrix structure.  Every tissue within the body 
exhibits its own characteristic ECM, fit for the purpose needed 
(Frantz et al., 2010). 
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ii. Role of the MMPs 
 
The MMPs are members of the large metzincin superfamily.  In a 
classical sense, MMPs work together to degrade all components of 
the ECM and the BM.   Recently, substrate identification studies have 
shown that MMPs can regulate the release or activation of antibiotics 
factors, chemokines, cytokines, growth factors and other bioactive 
molecules, and therefore are able to participate in physiological 
processes such as angiogenesis, bone remodelling, innate and 
adaptive immunity, inflammation and neurite growth (Loffek et al., 
2011).   
High sequence similarity in the MMP catalytic domains is found in 
almost all species tested.  At least 25 different vertebrate MMPs have 
been characterised up to now and 24 different MMPs are found in 
humans.  The diversity of the current mammalian MMP gene family is 
thought to be due to extensive gene tandem duplication and exon 
shuffling during evolution in the tetrapod lineages.  Taking this into 
account, some of the MMP members are most likely derivatives from 
a single gene resulting in an MMP gene cluster, whose organisation 
is preserved from amphibians to mammals.  The cluster in the human 
genome is located on chromosome 11q22 and contains MMP1, 
MMP3, MMP7, MMP8, MMP10, MMP12, MMP13, MMP20 and 
MMP27.  In contrast, most of the other human MMPs are located on 
other chromosomes, resulting in a total of 10 distinct chromosomal 
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locations for all 24 human MMP genes (Loffek et al., 2011, Fanjul-
Fernandez et al., 2010).     
Though MMP activity has been shown to be essential in many cell 
biological processes and various fundamental physiological events 
involving tissues remodelling, such as angiogenesis, wound healing, 
bone development and mammary involution (Page-McCaw et al., 
2007), the real interest in MMPs comes from their role in several 
pathological conditions, such as cancer and chronic inflammatory 
diseases (Lopez-Otin and Matrisian, 2007).   
Regulation of the MMPs 
Due to their wide substrate spectrum, MMPs are integrated as 
important regulators of tissue homeostasis and immunity in the 
networks of multidirectional communication within tissues and cells.  
Uncontrolled MMP activity can easily become destructive to cells and 
tissues and so their action must be tightly regulated. 
The catalytic activity of the MMPs is highly controlled at four different 
levels:  
1) Gene expression with transcriptional and post-transcriptional 
regulation 
2) Compartmentalisation of the MMPs 
3) Pro-enzyme activation by removal of the pro-domain 
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4) Inhibition by specific inhibitors e.g. tissue inhibitors of matrix 
metalloproteinases (TIMPs) and by non-specific proteinase 
inhibitors e.g. α2-macroglobulin.   
Once active, MMPs can modulate the global proteolytic potential 
in the extracellular milieu through zymogen (pro-form MMP) 
activator and inhibitor degradation (Overall and Lopez-Otin, 2002, 
Ra and Parks, 2007, Loffek et al., 2011).   
Control of MMPs at gene level 
Although MMP gene expression is chiefly regulated at 
transcriptional level, post-transcriptional control of mRNA stability 
also occurs, through the action of cytokines, nitric oxide or 
miRNA. 
Despite the low expression of most MMPs under quiescent 
conditions, their transcription is tightly controlled and individually 
regulated.  No solitary chemokine, cytokine, oncogene growth 
factor has been found which is solely responsible for the 
overexpression of MMPs in certain tumours, though tumour 
necrosis factor (TNF)-α and IL-1 are often implicated.  The signal 
transduction pathway which modulates MMP promoter activities 
are also diverse.  Several of the MMP promoters share multiple 
cis-elements in their promoters regions, consistent with 
observations that some MMPs are co-regulated by various 
inductive stimuli (Vincenti and Brinckerhoff, 2007).  
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Interestingly, it has been exhibited that promoters of functionally 
related MMPs such as MMP2/MMP9 (gelatinases) or 
MMP1/MMP8 (collagenases) are distinct, indicating different 
activation pathways.  Based on their cis-elements, MMP 
promoters are categorised into three groups (Yan and Boyd, 
2007).  The first represents the vast majority of MMP promoters 
and contains a TATA box and AP-1-binding site close to the 
transcription start site and is very often combined with an 
upstream PEA3-binding site, for the control of MMP transcription 
via several cytokines and growth factors, such as VEGF, 
keratinocyte growth factor or TNF-α The second group (promoters 
for MMP8, MMP11 and MMP21) also contain a TATA box but 
lack the proximal activator protein (AP-1) site.  The regulation of 
these promoters is fairly simple and distinct from the first type of 
promoter.  The final group of promoters (including MMP2, MMP14 
and MMP28) does not comprise a TATA box and, therefore, 
transcription from these promoters begins at multiple sites.  
Additionally, expression of MMPs in this group is mainly 
determined by the ubiquitous Sp-1 family of transcription factors 
which bind to a proximal GC box.  Expression of these MMPs is 
usually constitutive, which is only slightly sensitive to induction by 
growth factors of cytokines (Chakraborti et al., 2003).   
Transcriptional control of the MMPs is also most likely to be 
additionally influenced by epigenetic mechanisms such as DNA 
methylation and/or chromatin remodelling with histone 
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acetylation.  DNA methylation of cytosines within CpG islands in 
the promoter region represses chromatin state and thus inhibits 
gene expression.  Therefore, hypomethylation of MMP promoters 
can lead to increased enzyme expression in cancers (Loffek et 
al., 2011).   
Post-transcriptional gene regulation has also been shown to be 
important in the regulating the expression of MMPs, with MMP2, 
MMP9 and MMP13 also being shown to be regulated through 
mRNA stability (Yan and Boyd, 2007, Clark et al., 2008).   
Pro-MMP activation 
MMPs are initially produced as inactive pro-forms (zymogens) 
which are inactivated through removal of a pro-domain. The pro-
domains holds a conserved “cysteine switch” sequence motif 
which sits close to the catalytic domain, whose free cysteine 
residue interacts with the catalytic zinc ion to maintain enzyme 
latency and prevent binding and cleavage of the substrate (Van 
Wart & Birkedal-Hansen, 1990).  A conformational activation of 
the MMP zymogen in the pro-domain leads to a conformational 
activation, which removes the cysteine residue from the site, 
allowing water to interact with the zinc ion in the active site.  This 
event can be initiated by three mechanisms:  
1) Direct cleavage of another endopeptidase through removal of 
the pro-domain 
2) Allosteric reconformation of the pro-domain 
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3) Chemical modification of the free cysteine by reaction oxygen 
species or non-physiological agents 
Later events, allosteric control and reduction of the free cysteine 
also enables the enzyme to remove its own pro-domain by 
autoproteolysis (Ra and Parks, 2007).  
Eleven of the 24 MMPs in human, including all of the membrane-
bound MMPs, are activated through an intracellular process via 
pro-protein convertases or furins. Furins are transmembranous 
subtilisin-like serine proteinases in the trans-Golgi network which 
is responsible for sorting secretory pathway proteins to their final 
destination, including the cell surface and secretory granules.  
Consequentially, all these members of the MMP family can 
instantly begin their catalytic action either on the cell surface or 
when secreted into the pericellular environment.  
The remaining MMP members are expressed and secreted as 
inactive pro-forms, which must be activated.  The activation of 
pro-MMPs is thought to be a stepwise process which takes place 
in the immediate pericellular space.  The first step involves an 
initial conformational change within the pro-peptide, leading to a 
disruption of the cysteine switch-zinc interaction.  Successively, 
the pro-domain is removed by intra- or intermolecular processing 
of partially activate MMP intermediates or other active MMPs 
(Van Wart and Birkedal-Hansen, 1990).   
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An alternative method by which the zymogens are activated is 
probably initiated by the intrinsic allostery of the MMP molecule.   
Consequently, domain flexibility of the modular domain of the 
MMP can contribute through promotion of long-range 
conformational transitions induced by protein binding via exosites 
(Sela-Passwell et al., 2010).   
Tissue Inhibitors of MMPs (TIMPs) 
It is a recognised view that the balance between the production of 
active enzymes and their inhibition is critical to avoid the 
conditions of uncontrolled ECM turnover, inflammation and 
dysregulated cell growth and migration, which would result in 
disease (Loffek et al., 2011).   
The naturally occurring inhibitors of human MMP activity are the 
four TIMPs.  Each TIMP molecule consists of around 190 amino 
acids with two distinct domains: a large N-terminal and a smaller 
C-terminal domain, each one stabilised by three conserved 
disulphide bonds.  The N-terminal can fold independently and is 
fully functional to inhibit MMPs by chelated their catalytic zinc 
atom with a 1:1 molar ratio.  The function of the C-terminal is not 
fully understand but has been shown to bind tightly to the 
haemopexin domain of latent MMPs.  TIMP2, TIMP3 and TIMP4 
have been described to interact with MMP2 and TIMP1 and 
TIMP3 with MMP9 (Murphy and Nagase, 2008, Loffek et al., 
2011).  
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In general, all TIMPs are broad spectrum inhibitors of MMPs, but 
there are difference in their specificity.  For example, TIMP1 has 
been shown to have low inhibitory activity against MMP19 and 
MMP14 while it is more potent against MMP3 and MMP7 than the 
other TIMPs.  TIMP2 inhibits the activity of all of the MMPs and its 
expression of constitutive, in contrast to the other TIMP family 
members, which are inducible (Loffek et al., 2011).   
iii. MMPs and cancer 
 
The MMPs have been considered as a potential diagnostic and 
prognostic biomarker in many forms of cancer (Roy et al., 2009) and 
the notion of these enzymes being used as therapeutic targets was 
introduced many years ago due to their involvement in the metastatic 
potential of various cancer (Noel et al., 2008, Murphy and Nagase, 
2008).   
During the development to malignancy, tumour cells are involved in 
several interactions with the tumour microenvironment, involving the 
ECM, growth factors and cytokines, as well was surrounding cells 
such as macrophages, neutrophils, endothelial cells and fibroblasts 
(Kessenbrock et al., 2010, Murphy and Nagase, 2008).  Four of the 
hallmarks of progressive cancer (migration, invasion, angiogenesis 
and metastasis) are dependent on the surrounding environment.  
MMPs are critical to these processes as they degrade adhesion 
molecules and thus modulate cell-cell and cell-ECM interactions 
(Gialeli et al., 2011).   
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MMP and cancer cell invasion 
 
The ECM is a dynamic structure which can orchestrate cell behaviour 
by interacting with them.  MMP proteolytic activity is required for can-
cer cell degradation of the physical barriers during local expansion as 
well as intravasation at nearby blood vessels, extravasion and inva-
sion at a distant location.  During this invasive process, localisation of 
MMPs to specialised cell surface structures, called invadopodia, is 
requisite for their ability to promote cancer cell invasion. Invadopodia 
are where ECM degradation takes place and they utilise transmem-
brane invadopodia-related proteinases such as MMP14, as well as 
secreted and activated MMPs at the site, such as MMP2 and MMP9 
(Weaver et al., 2006, Gialeli et al., 2011).  
MMPs and cancer cell proliferation 
MMPs can modulate the bioavailability of growth factors and function 
of cell-surface receptors.  Moreover, several MMPs 
(MMP1,2,3,7,9,11 and 19) cleave insulin growth factor (IGF)-binding 
proteins which also regulate growth factor availability (Nakamura et 
al., 2005, Gialeli et al., 2011).     
MMPs and cancer cell apoptosis 
Enzymes which degrade matrices confer both apoptotic and anti-
apoptotic activities.  MMPs confers anti-apoptotic signals to cancer 
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cells by cleaving Fas ligand, a transmembrane stimulator of Fas 
death receptor, from the cell surface.  This activity inactivates this re-
ceptor and, in cancer cells, induces a resistance to apoptosis and 
chemoresistance.  It can also promote apoptosis in the neighbouring 
cells (Strand et al., 2004, Mitsiades et al., 2001, Kirkin et al., 2007). It 
is also thought that MMPs may show an anti-apoptotic effect through 
indirectly activating AKT (Gialeli et al., 2011, Kulik et al., 1997).  
However, MMPs are also known to promote apoptosis, usually 
through change of the ECM composition e.g. cleavage of laminin, 
which affects integrin signalling (Sympson et al., 1994, Gialeli et al., 
2011).   
MMPs and tumour angiogenesis and vasculogenesis 
The MMPs play a double role in the tumour vasculature as they can 
act to both positively and negatively regulate angiogenesis depend-
ing on the time points of expression during tumour angiogenesis and 
vasculogenesis, as well as the bioavailability of substrates.  Key 
players in tumour angiogenesis are MMP2, 9 and 19 (Rundhaug, 
2003, Gialeli et al., 2011).   
In order for new vessels to form, it is vital that ECM degradation oc-
curs and, subsequently, to generate pro-angiogenic factors.  MMP9 
participates in the angiogenic switch due to the increase in the avail-
ability of important factors in this process, such as VEGF (Xu et al., 
2001, Gialeli et al., 2011).     
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However, the angiogenic balance is highly regulated by MMPs since 
they can also downregulate the formation of new blood vessels 
through generation of degradation fragments which can inhibit angio-
genesis (Iozzo et al., 2009, Gialeli et al., 2011).  
MMPs and cell adhesion and migration 
Movement of cells is related to the proteolytic activity of MMPs, regu-
lating the dynamic ECM-cell and cell-cell interactions during migra-
tion.  In the beginning, degradation of the ECM leads to cryptic pep-
tide generation which promote the migration of cancer cells (Xu et al., 
2001, Koshikawa et al., 2000).  Several integrins also play a role in 
the regulation of cell migration as they can serve as MMP substrates 
(Baciu et al., 2003, Gialeli et al., 2011).  
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1.7 Protein kinase B (AKT) 
 
i. The role of the PI3K/AKT/mTOR pathway in the cell  
 
Various cytokines and growth factors can not only promote cell 
proliferation but also maintain the viability of cells.  The binding of 
these factors to receptors initiates a signalling cascade leading to the 
activation of the lipid kinase PI3K, and the generation of the second 
messengers phosphatidylinositol (3,4,5)-triphosphate PIP3 recruits 
protein kinases, including AKT (also known as protein kinase B) and 
its upstream activators pyruvate dehydrogenase kinases (PDK1 and 
PDK2) (Martini et al., 2014). 
AKT is a serine/threonine kinase which has emerged as a vital 
central node of signalling within all cells of higher eukaryotes and 
thus is one of the most important and versatile protein kinases at the 
core of human physiology and disease (Manning and Cantley, 2007).  
This pathway is a key component of growth factor-induced cell 
survival and has been implicated in the suppression of apoptosis in a 
number of cell types, through a variety of stimuli, including growth 
factor withdrawal, cell cycle discordance, loss of cell adhesion, DNA 
damage and treatment with anti-Fas antibody or transforming growth 
factor β (TGFβ) (Brunet et al., 2001, Feng et al., 2004a).The 
PI3K/AKT pathway is highly conserved and its activation is tightly 
controlled through a multistep process (Hemmings and Restuccia, 
1. General Introduction 
 
77 
 
2015).  Phosphorylation of AKT at serines 308 and 473 activates the 
kinase and allows its release from the membrane, leading to an 
interaction with a range of cytoplasmic and nuclear substrates (Feng 
et al., 2004a).  AKT-mediated phosphorylation is involved in many 
cell processes, including survival, growth, proliferation, glucose 
uptake, metabolism and angiogenesis. AKT is now known to include 
a family of three closely related, highly conserved cellular homologs, 
terms AKT1, AKT2 and AKT3. The encoded proteins are 
serine/threonine kinases which belong to the protein kinase B (PKB) 
family (Testa and Bellacosa, 2001, Testa and Tsichlis, 2005).   
Akt activates the downstream mTOR kinase through inhibition of a 
complex formed by tumour suppressor proteins  tuberous schlerosis 
1 and 2 (TSC1 and TSC2), also known as hamartin and tuberin 
(Altomare and Testa, 2005).  mTOR generally mediates cell growth 
and proliferation through regulation of ribosomal biogenesis and 
protein translation (Ruggero and Sonenberg, 2005) and has the 
ability to regulate nutrient response by restriction of progression 
through the cell cycle in the presence of suboptimal growth 
conditions  (Plas and Thompson, 2005).  
ii. The dysregulation of AKT in cancer 
 
Studies have shown that the PI3K/AKT signalling pathway 
components are frequently altered in cancer.  This pathway regulates 
cell proliferation and survival, cell growth (size), glucose metabolism, 
cell motility and angiogenesis (Testa and Tsichlis, 2005).   
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Following the identification of AKT activation as an important 
contributor to tumourigenesis, intense research began into the 
regulation of this pathway.  In recent years, it has been shown that 
this pathway plays a role not only in tumour development but also in 
the tumour’s response to cancer treatment (Hemmings and 
Restuccia, 2015).  
AKT has  been shown to be a central node in many cellular 
processes which are dysregulated in the development of progression 
of cancer and abberant AKT signalling is implicated in many sporadic 
human cancers (Altomare and Testa, 2005, Bellacosa et al., 2005).  
In addition, AKT is known to phosphorylate and inactivate the FOXO 
transcription factors, which mediate the expression of genes for 
apoptosis, such as the Fas ligand gene (Pommier et al., 2004, 
Altomare and Testa, 2005).  
AKT has also been shown to mediate cell cycle progression through 
the phosphorylation and consequent inhibition of glycogen synthase 
kinase 3β to avert cyclin D1 degradation (Liang and Slingerland, 
2003). Additionally, AKT directly antagonises the action of cell cycle 
inhibitors by phosphorylating a site located near their NLS to induce 
cytoplasmic retention of these inhibitors (Bellacosa et al., 2005, 
Testa and Bellacosa, 2001).  Moreover, phosphorylation of the 
AKT/mTOR kinases also results in an increase in translation of cycle 
D1, D4 and E transcripts (Muise-Helmericks et al., 1998, Altomare 
and Testa, 2005).  
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Recently, the involvement of the PI3K-AKT pathways in MMP 
regulation has been studied more thoroughly and AKT has been 
found to stimulate cell migration through its upregulation the 
secretion of MMP9 in fibrosarcomas (Kim et al., 2011b).  In addition, 
two other studies found that the MMPs are regulated by AKT, with 
one showing that AKT activation was correlated with MMP2 induction 
(Park et al., 2006) and another showing that, in ovarian cancer cells, 
PI3K-Akt mediates the fibronectin-dependent secretion of MMP9 
(Thant et al., 2000).   A study by Zhang and Brodt  in lung carcinoma 
cells (Zhang and Brodt, 2003) extended our knowledge of its 
mechanism, finding that PI3K-AKT plays an important role in the 
regulation of membrane type 1 matrix metalloproteinase (MT1-MMP) 
activation by the receptor for insulin-like growth factor (IGF-IR) and 
its ligands (IGFI and II).  MT1-MMP activates MMP2 and contributes 
directly to the invasive capacity of cells through degradation of 
collagen 1 and the adhesion molecule CD44 (Kohn and Liotta, 1995, 
Liotta and Kohn, 2001).  Another study presented a novel AMP-
activated protein kinase (ARK5) as a downstream effector of AKT-
induced tumour cell invasion which is also involved in MMP2 and 
MMP9 production (Suzuki et al., 2004).  
iii. Possible links of AKT to MDM2 and PSMA 
 
Several recent studies have also shown that p53-mediated apoptosis 
is inhibited under conditions in which the PI3K-AKT pathway in 
activated (Sabbatini and McCormick, 1999, Yamaguchi et al., 2001, 
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Mazzoni et al., 1999, Hong et al., 1999, Gottlieb et al., 2002).  It is 
thought that AKT may inhibit p21 (a cyclin-dependent kinase 
inhibitor) expression through its phosphorylation and subsequent 
activation of MDM2, leading to a downregulation of p53-mediated 
transcription of p21 (Mayo and Donner, 2001, Zhou et al., 2001).  It 
could be that PI3-AKT signalling is required but perhaps is not 
sufficient, to wholly account for the role of MDM2 in p53 protein level 
regulation (Mayo and Donner, 2001).  
Around 20% the amino acids comprising MDM2 are either serine or 
threonine residues and MDM2 is thus phosphorylated at multiple 
sites in vivo (Meek and Knippschild, 2003).  Two clusters of 
phosphorylation sites occur on MDM2, one at the amino terminal 
(amino acids 1-193) and the other in the central domain (amino acids 
194-293) (Hay and Meek, 2000).   It has been shown that AKT and 
MDM2 can interact directly and that human MDM2 contains putative 
AKT phosphorylation sites (serine 166, 186 and 188).  These motifs 
are proximal to the NLS and NES of MDM2 and are conserved in 
human, mouse, hamster and zebrafish, indicating a functional 
importance of these sites.  Downstream of the phospho-acceptor 
serine or threonine is a structural amino acid (serine, threonine), 
glycine or proline, which induces a tight turn in the peptide, providing 
the optimal structure for AKT recognition.  It was also suggested that 
MDM2 nuclear entry is reliant on PI3-kinase/AKT signalling and this 
signalling plays a role in p53 functional suppressor and degradation 
(Mayo and Donner, 2001, Zhou et al., 2001).  Although AKT is best 
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known for promoting cell survival and growth, it can also stimulate 
proliferation through multiple downstream targets impinging on cell-
cycle regulation.   
Moreover, a study by Feng et al. (Feng et al., 2004b), showed that 
AKT phosphorylation of sites serine 166 and 188 (no phosphorylation 
was seen at serine 186) inhibits MDM2 self-ubiquitination and thus 
stabilises the protein.  This self-ubiquitination feature of MDM2 is 
important for the regulation of protein levels in cells (Honda et al., 
1997, Honda and Yasuda, 1999, Fang et al., 2000).  Similar data 
were gained from another group (Ashcroft et al., 2002), who 
indicated that phosphorylation of MDM2 by AKT increased the ability 
of MDM2 to target p53 for ubiquitin-dependent degradation.  The 
group also showed a correlation of AKT phosphorylation with MDM2 
protein stability.   Furthermore, a third study suggested that AKT 
enhances the ubiquitination-promoting function of MDM2 by 
phosphorylating ser186, which results in a reduction of p53 protein 
(Ogawara et al., 2002). This work is backed up by data from human 
tumour cells where overexpression of AKT correlated with elevated 
levels of MDM2 phosphorylation (Feng et al., 2004b).   
PSMA has also been linked to phosphorylation of AKT at serine 473, 
with Guo et al. (Guo et al., 2014)  showing that, following knockdown 
of PSMA, the levels of phospho-AKT decreased, but total AKT levels 
remained the same.  Therefore, the group surmised that AKT 
phosphorylation at serine 473 may play a critical role as a 
downstream signalling target effector of PSMA.   
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1.8  The possible interplay between MDM2 and PSMA in 
cancer 
 
Recently, a paper was published which links the expression levels of 
PSMA and MDM2.  Xu et al. (Xu et al., 2013) used the LNCaP 
(PSMA positive) and PC3 (PSMA negative) prostate cancer cell lines 
to assess metastasis-related genes which were downregulated in 
cells with silenced PSMA.  It was found that MDM2 decreased over 
80 fold.  The paper also indicated that the treatment of the LNCaP 
cell line with PSMA-targeted siRNA led to an upregulation of MMP3 
and 13, and a downregulation of MMP2.  Since the degradation of 
the extracellular matrix and basement membrane by MMPs is pivotal 
to whether a tumour infiltrates and metastases, it may be deduced 
that PSMA and MDM2 are involved in the regulation of MMP 
secretion and they may interplay in order to modify their levels.  This 
theory is supported by the many reports linking both proteins to a 
number of MMPs (Conway et al., 2006, Yang et al., 2006, Rajabi et 
al., 2012, Chen et al., 2013) and we hypothesise that this interplay 
may be mediated by AKT.   
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1.9   Aims & objectives 
 
Although scientists now understand the general principles of the 
progressive properties of cancer, the molecular mechanisms behind 
how early cancer becomes metastasis is still not well understood. It 
is vital that we gain an understanding of the underlying processes in 
order to design specific therapeutics targeting the molecular 
dysregulation occurring.   
It was recently seen that a decrease in MDM2 gene expression 
followed PSMA knockdown.  Also, MDM2 and PSMA are implicated 
in similar pathways, including the PI3K/AKT pathway.  It has been 
shown that AKT and MDM2 can interact directly through 
phosphorylation and that human MDM2 contains putative AKT 
phosphorylation sites (serines 166, 186 and 188).  PSMA has also 
been linked to AKT serine 473 phosphorylation, with knockdown of 
PSMA leading to a decrease in the phosphorylation levels at this site.   
MDM2, PSMA and the AKT have also been linked to various MMPs 
(-2, -9).   
Additionally we identified c-JUN as a potential link of MDM2 and 
PSMA using GeneMANIA, an online gene function prediction tool. 
We hypothesise that there is a link between MDM2 and PSMA in 
breast cancer cell lines, through AKT or c-JUN phosphorylation, 
which may lead to a change in MMP secretion levels.  
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The aims of this study were:  
1. To screen and identify the expression profile of MDM2 and 
PSMA in breast cancer cell lines in order to select cell models 
for knockdown.  
2. To induce siRNA-mediated knockdown of MDM2 and PSMA in 
both of these molecules.  
3. To identify the roles of each of the molecules in the 
functionality of breast cancer cells.  
4. To assess the underlying signalling pathways of these 
functional changes and the involvement of the MMPs.   
5. To evaluate the role of AKT and c-JUN phosphorylation in the 
downstream signalling pathways of both MDM2 and PSMA. 
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Statement of undertaking 
All experiments in this thesis were undertaken my Robyn Bradbury, 
apart from collection of breast cancer tissue and subsequent RNA 
isolation and quantitative PCR. Statistical analysis of breast cancer 
cohort data was done by Professor Wen Jiang. 
2.1. Materials  
2.1.1. Cell lines 
 
The current study used eight breast cancer cell lines (BT-20, MCF-7, 
ZR-75.1, SK-Br-3, BT-483, MDA-MB-468, BT-549 and MDA-MB-231) 
and one immortalised normal breast cell line (MCF-10A), all 
purchased from America Type Culture Collection (ATCC; Middlesex, 
UK).  Human microvascular endothelial cells from adult dermis 
(HMVECad) were purchased from ThermoFisher (Waltham, MA, 
USA).  All cancer cells were maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM; ThermoFisher); apart from BT-483 and BT-
549 which were maintained in RPMI-1640 media (ThermoFisher).  
Both media were supplemented with 10% foetal bovine serum (FBS) 
and 1 x antibiotic cocktail mix (penicillin/streptomycin). MCF-10A cell 
line was maintained in MEBM media supplemented with MEGM kit 
(Lonza, Tewkesbury, UK) and 100 ng/ml cholera toxin (Sigma- 
Aldrich, Poole, Dorset, UK). The HMVECad cell  line was maintained 
in 131 Media (ThermoFisher) with microvascular growth supplements 
(all MVGS; Gibco, Paisley, UK) (The cell lines used in the current 
study are outlined in Table 2.1).    
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2.1.1. Collection of human breast cancer tissues 
 
148 fresh breast tissue samples were collected immediately after 
surgery and stored at -80˚C until use, with approval of the Bro Taf 
Health Authority local research ethics committee (01/4304; approval 
letter in Appendix).  The cohort contained 30 normal background 
breast tissue and 112 breast cancer tissue samples.  All patients 
provided written consent.   
Specimens were verified by a consultant pathologist and a routine 
follow-up was carried out after surgery and details were stored in a 
database.  The median follow-up period was 120 months.  
Section stored Samples were prepared in 1 ml TRI reagent and 
homogenised for 2 minutes. RNA extraction could then be 
undertaken as normal. 
2.1.2.  siRNA 
MDM2-, FOLH1- and Non-Targeting ON-TARGETplus siRNA 
reagents were obtained from Dharmacon (Layfayette, CO, USA). Dry 
siRNA pellet was diluted to a 20 µM stock using 1 x siRNA buffer 
(Dharmacon). 20 µl aliquots were produced to prevent degradation 
through freeze-thaw and stored at -20 ˚C for long-term storage.  
2.1.3.  Primers 
All primers used in the study were synthesised by Sigma-Aldrich and 
diluted upon receipt according to data sheet from the company. 
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Primers were stored at -20 ˚C. Details of primers used for 
quantitative polymerase chain reaction (qPCR) are detailed in Table 
2.2.   
2.1.4.  Antibodies 
Primary Antibodies  
Details of primary antibodies used in the study are given in Table 2.3.  
 
Secondary Antibodies 
The secondary antibodies used in the western blotting procedure in 
this study were horseradish peroxidase (HRP) conjugated anti-
mouse (A9044) and anti-rabbit (A0545) IgG antibodies, both 
purchased from Sigma-Aldrich.   
 
2.1.5. Inhibitors 
Marimastat (CAS 154039-60-8; Santa Cruz Biotechnology, Dallas, 
TX, USA) and ARP100 (CAS 704888-90-4; Santa Cruz 
Biotechnology) were used to inhibit MMP2 protein activity. 
Marimastat was diluted in dimethylsulphoxide (DMSO; Sigma-
Aldrich) to a 1 mM stock concentration, whilst ARP100 was diluted in 
DMSO to a 10 mM stock concentration.  MMP8 inhibitor I (CAS 
236403-25-1; Santa Cruz Biotechnology) was used to inhibit MMP8 
activity and was diluted in DMSO to a 1 mM stock concentration.  LY 
294002 hydrochloride (TOCRIS Bioscience, Bristol, UK) was used to 
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inhibit PI3-kinase activity and indirect phosphorylation of AKT (serine 
473) and was controlled by LY 303511, an inactive analogue 
(TOCRIS Bioscience).  Both compounds were diluted to 25 mM in 
DMSO. All diluted inhibitors were stored at -20 ˚C. When being 
further diluted for experimental purposes, the inhibitors were diluted 
in DMEM media (with or without serum, depending on experiment), 
and used alongside a DMSO control containing an equal volume of 
DMSO as present in the inhibitor treatment.  All inhibitors were used 
at concentration suggested by manufacturer. 
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Target Gene Direction Sequence 
AKT Forward CTACTACGCCATGAAGATCC 
AKT zReverse GGTCTGGAAAGAGTACTTCAG 
Caspase 3 Forward GGCGTGTCATAAAATACCAG 
Caspase 3 zReverse ACAAAGCGACTGGATGAA 
Caspase 7 Forward ACTTTTGTTTCGCTTTCGC 
Caspase 7 zReverse TGATCATCTGCCATCGTTC 
Caspase 8 Forward AGAAAGGAGGAGATGGAAAG 
Caspase 8 zReverse GACCTCAATTCTGATCTGCT 
Caspase 9 Forward AAGCCCAAGCTCTTTTC 
Caspase 9 zReverse GTTACTGCCAGGGGACTC 
GAPDH Forward AAGGTCATCCATGACAACTT 
GAPDH zReverse GCCATCCACAGTCTTCTG 
JUN Forward AAGATCCTGAAACAGAGCAT 
JUN zReverse GCTGGACTGGATTATCAGG 
MDM2 Forward GTTATCTCAGTGCCTTTTGC 
MDM2 zReverse AACAGACACATGTTCTACCC 
MMP1 Forward GGATGCTCATTTTGATGAAG 
MMP1 zReverse TAGAATGGGAGAGTCCAACA 
MMP2 Forward CAGGGAATGAGTACTGGGTCTATT 
MMP2 zReverse ACTCCAGTTAAAGGCAGCATCTAC 
MMP3 Forward TCTGAGGGGAGAAATCCTGA 
MMP3 zReverse GGAAGAGATGGCCAAAATGA 
MMP7 Forward AAATGGACTTCCAAAGTGGT 
MMP7 zReverse TTCCCCATACAACTTTCCTG 
MMP8 Forward AAAACTGTTCAGGACTACCT 
MMP8 zReverse ATCGCTGCATTTCTTTAAGC 
MMP9 Forward AACTACGACCGGGACAAG 
MMP9 zReverse GGAAAGTGAAGGGGAAGA 
Table 2.2. Primer sequences for all genes assessed through 
quantitative PCR (qPCR).  zReverse indicates those primers with the 
addition of a Z-sequence (ACTGAACCTGACCGTACA) to the 5’ end 
of the respective primers. 
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MMP10 Forward CATTCAGTCTCTCTACGGAC 
MMP10 zReverse CCGAAGGAACAGATTTTGTG 
MMP11 Forward GTGCCCTCTGAGATCGAC 
MMP11 zReverse CAGGGTCAAACTTCCAGTAG 
MMP12 Forward ACCCACGTTTTTATAGGACC 
MMP12 zReverse GATAACCAGGGTCCATCATC 
MMP13 Forward TCCCAGGAATTGGTGATAAAGTAGA 
MMP13 zReverse CTGGCATGACGCGAACAATA 
PSMA Forward ATTGCTCTGGGAAAATTGTA 
PSMA zReverse AGGAGCAAAGTAGTCAGCAG 
TIMP1 Forward CTTCACCAAGACCTACACTG 
TIMP1 zReverse TTTGCAGGGGATGGATGGATAAAC 
TIMP2 Forward ATGCAGATCTAGTGATCAGG 
TIMP2 zReverse TATATCCTTCTCAGGCCCTT 
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Table 2.3. Primary antibodies used in western blotting protocol. 
Antibody Code Company Species Dilution 
AKT sc 5298 Santa Cruz Mouse 1:200 
Phospho-AKT (ser473) sc 81433 Santa Cruz Mouse 1:200 
Caspase-3 sc 7148 Santa Cruz Rabbit 1:200 
Caspase-8 sc 70501 Santa Cruz Mouse 1:200 
Caspase-9 sc 17784 Santa Cruz Mouse 1:200 
GAPDH sc 32233 Santa Cruz Mouse 1:10,000 
MDM2 (SMP14) sc 965 Santa Cruz Mouse 1:200 
Phospho-MDM2 (ser166) 3521 Cell Signalling Rabbit 1:1000 
Phospho-MDM2 (ser186) Ab22710 Abcam Mouse 1:500 
Phospho-MDM2 
(ser186/188) 
Ab111617 Abcam Rabbit 1:200 
PSMA (D718E) 12815 Cell Signalling Rabbit 1:1000 
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2.2. Standard reagents and solutions 
2.2.1.  Solutions for use in laboratory  
Diethylpyrocarbonate (DEPC) Water 
500 μl Diethylpyrocarbonate (DEPC; Sigma-Aldrich) was made up to 
500 ml using deionised H20.  The solution was left overnight and then 
autoclaved.   
2.2.2. Solutions for use in cell culture 
Phosphate buffered saline (PBS) 
50 ml of 10x stock of PBS (Sigma-Aldrich) was diluted with 450ml of 
distilled water, and then autoclaved.   
100x Antibiotic Cocktail Mix 
5 g streptomycin, 3.3 g penicillin and 12.5 g amphotericin B in DMSO 
were dissolved in PBS and filtered. 5 ml was then added to a 500 ml 
bottle of media.  
2.2.3. Solutions for use in western blotting 
RIPA Buffer 
0.61 g Tris base was added to 75 ml distilled H20. 0.88 g of NaCl and 
0.19 g EGTA were then added to the solution and stirred until all 
solids were dissolved.  The pH value was adjusted to 7.5 using HCl.  
1ml of Triton x100 was then added and stirred until dissolved.  Finally 
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250ml of 400 mM EDTA solution was added and the volume was 
adjusted to 100 ml using distilled H20.  The RIPA buffer was stored at 
2-8 ˚C until ready to use.  Upon requirement of cell lysis, protease 
inhibitors were added to the basic RIPA.  For each 1 ml needed, 10 
µl aprotinin (1 mg/ml), 10 µl leupeptin (1mg/ml), 10 µl sodium 
vanadate (1 mg/ml) and 20 µl of sodium fluoride (1 mg/ml) (all bought 
as powder from Sigma-Aldrich) was added to 940 µl of basic RIPA 
buffer.  Just before use on cells, 10 µl phenylmethylsulfonyl fluoride 
(PMSF; 10 mg/ml) (Sigma-Aldrich) was added to the solution. 50 µl 
of RIPA buffer was used to lyse cells covering one well of a six-well 
plate.   
10% w/v Ammonium Persulphate (APS) 
1 g APS (Melford Laboratories Ltd, Suffolk, UK) was dissolved in 10 
ml distilled water and then stored at 4 ˚C for further use.  
Tris Buffered Saline (TBS) 
10% w/v TBS (0.5M Tris, 1.38 M NaCl, pH7.4) stock solution was 
prepared by dissolving 606 g of Tris (Sigma-Aldrich) and 765 g of 
NaCl (Melford Laboratories Ltd)) in 10 litres distilled water.  The pH 
was adjusted to 7.4 using HCl (Sigma-Aldrich) and stored at room 
temperature.   
0.1% v/v TBS/Tween (TBST) 
1ml of Tween 20 (Sigma-Aldrich) was added to 1 litre of TBS, 
prepared as detailed above.   
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Running Buffer 
1 litre of 10 x TRIS/glycine/SDS (T7777) (Sigma-Aldrich) was added 
to 9 litres of distilled H20.  
Transfer Buffer 
1 litre of 10 x TRIS/glycine concentrate (Sigma-Aldrich) was added to 
2 litres of methanol (ThermoFisher) and 7 litres of distilled H20. 
 
2.2.4. Solutions for use in immunocytochemical staining 
Diaminobenzidine (DAB) chromogen 
2 drops (approximately 50 µl) of wash buffer, 4 drops of DAB (Vector 
Laboratories, Inc., Burlingame, CA, USA) and 2 drops of H202 were 
added to 5 ml of distilled water and mixed well before use.   
ABC Complex 
The ABC complex was prepared by using a kit provided by Vector 
Laboratories Inc.  4 drops of each reagent A and B were added to 
20ml of wash buffer before being mixed thoroughly and left at room 
temperature for 30 minutes before use.  
2.2.5. Solutions for use in flow cytometric staining 
Wash buffer 
The wash buffer was produced through dissolving 2 mM EDTA 
(Sigma-Aldrich) in PBS.   
2. Materials & Methods 
 
97 
 
FACS Buffer 
FACS buffer was created through adding 5% v/v FCS to wash buffer.  
Blocking Buffer 
Blocking buffer was prepared by adding 1% v/v bovine serum 
albumin (BSA) (Sigma-Aldrich) to PBS-Tween (PBS with 0.05% 
Tween-20).   
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2.3. Cell culture, maintenance, storage and transfection 
2.3.1. Cell maintenance 
Cell lines were routinely split once a week and maintained in 25 cm2 
culture flasks (Grenier Bio-One Ltd, Kremunster, Austria) with a 
loosened cap and incubated at 37 ˚C, 95% humidification and 5% 
CO2.  Medium on cells was changed every 2-3 days. Mycoplasma 
contamination in cell cultures was estimated on a monthly basis 
using the EZ-PCR Mycoplasma Test Kit (Biological Industries, 
Israel).   
2.3.2. Trypsinisation (detachment) of adherent cells and 
cell counting 
Following the cells reaching a confluency of 80-90%, the medium 
was aspirated and the cells were washed briefly with sterile PBS.  
Adherent cells were then detached using 1-2ml of Trypsin/EDTA 
(Sigma Aldrich), then incubated at 37˚C for approximately 5 minutes 
until detachment can be seen under a light microscope.  At this point, 
an equal volume of serum-containing media was added to the cell 
suspension in order to quench the trypsin, and solution was added to 
a universal container. The suspension was centrifuged at 1700 x g 
for 5 minutes in order to collect the cell pellet.  The supernatant was 
aspirated from the universal container and the pellet was  
resuspended in an appropriate volume of serum-free media (if being 
used for siRNA treatment), or in normal culture media to be reseeded 
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into tissue culture flasks. Cells were counted using Counter II FL 
Automated Cell Counter (ThermoFisher) and then seeded at an 
appropriate concentration for experimental needs.  
2.3.3. Storing cells  
Cell stocks with low passage number were stored in liquid nitrogen.  
To do this, cells were trypsinised as detailed in 2.3.2 and 
resuspended in medium containing 10% v/v DMSO at a cell density 
of 1 x 106 cells/ml.  The cell suspension was then divided into 1ml 
aliquots and added to CRYO.S tubes (Grenier Bio-One), the tubes 
were wrapped in protective tissue paper, stored overnight at -80˚C 
and then transferred to liquid nitrogen tanks for long-term storage.  
2.3.4. Resuscitation of cells 
In order to resuscitate cells, they were removed from liquid nitrogen 
and rapidly thawed in warm water, before being transferred into a 
universal container containing 10 ml of pre-warmed medium and 
centrifuged at 1,000 x g for 7 minutes.  The supernatant was 
aspirated and the pellet was resuspended in 5 ml of serum-
containing media.  The cell suspension was then transferred into a 
fresh 25 cm2 culture flask and transferred to the incubator.  
2.3.5. Transfection of cells with siRNA 
1 ml of MDA-MB-231 or ZR-75.1 cells added per well of a six-well 
plate at a concentration 1.5 x 106 cells/ml in serum-free media, then 
allowed to attach overnight at 37 ˚C.  Cells were then transfected 
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with siRNA using 2 μl/ml DharmaFECT1 (ZR-75.1) or 1 μl/ml 
DharmaFECT4 (MDA-MB-231) according to manufacturer’s 
instructions (Dharmacon).  Cells were used for experiments 72 hours 
post-transfection.  
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2.4. Methods for RNA detection 
2.4.1. RNA isolation  
Medium on cells was aspirated and the monolayer was then washed 
twice with PBS.  0.5 ml of TRI reagent (Sigma-Aldrich) was added 
per well of a six-well plate. Cells were scraped into an Eppendorf and 
either stored at -20 ˚C for future use or, for continuation of the 
protocol, allowed to stand at room temperature for 5 minutes.  0.05 
ml of 1-bromo-3-chloropane (Sigma-Aldrich) was then added to the 
solution, shaken vigorously for 5 minutes and then allowed to stand 
for 15 minutes at room temperature. Following this, the suspension 
was centrifuged at 4 ˚C, for 15 minutes at 12,000 x g in the Hettich 
MIKRO 200R (DJB Labcare Ltd., Buckinghamshire, UK).  The 
solution separated into three phases: a red organic phase (protein), a 
white interphase (DNA) and a colourless upper aqueous phase 
(RNA).  The upper phase was carefully removed and put into a fresh 
tube.  0.25 ml of isopropanol (Sigma-Aldrich) was then added, 
shaken and allowed to stand for 10 minutes at room temperature. 
The solution was then centrifuged at 4 ˚C, for 10 minutes at 12,000 x 
g and the supernatant discarded.  The pellet was washed with 1 ml of 
75 % v/v ethanol (made with DEPC water) and vortexed.  This 
suspension was centrifuged at 7,500 X G for 5 minutes and then 
ethanol removed, avoiding pellet.  The RNA pellet was allowed to air 
dry for around 10 minutes and then dissolved in 15 µl of DEPC water. 
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The concentration and purity of resultant RNA was measured using 
the IMPLEN NanoPhotometer (Implen, Schatzbogen, Germany).  
2.4.2. Reverse transcription (RT) 
The GoScript™ Reverse Transcription System (Promega, Madison, 
WI, USA) was used to convert RNA into first-strand cDNA.  Using 
concentration gained from the protocol in 2.4.1., 500 ng of RNA was 
used, along with DEPC H20 to make up the solution to 4 µl, as well 
as 1 µl of the Primer Oligo(dT)15.  This mix was then heated to 70 ˚C 
for 5 minutes, then immediately chilled on ice.  The reverse 
transcription reaction mix with 4 µl GoScript™ 5X Reaction Mix, 1.2 
µl MgCl2, 1 µl PCR Nucleotide Mix, 0.5 µl Recombinant RNasin® 
Ribonuclease Inhibitor, 1 µl GoScript™ Reverse Transcriptase and 
7.2 µl DEPC H20.  The reverse transcription mix was added to 5 µl of 
RNA and primer mix.  The conditions used for the reverse 
transcription reaction were: 
 25 ˚C for 5 minutes 
 42 ˚C for 1 hour  
 70 ˚C for 15 minutes  
This was undertaken using Applied Biosystems 2720 Thermal Cycler 
(Life Technologies, Paisley, UK).  
2.4.3. Quantitative polymerase chain reaction (qPCR) 
cDNA produced in reverse transcription was diluted 1:8 with distilled 
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H20.  qPCR performed using Precision FAST 2x qPCR MasterMix 
(Primer Design, Southampton, UK) and Ampifluor™ Uniprimer™ 
Universal system (Intergen company®, NY, USA).   
The qPCR reaction mix was made as follows:  
 2x qPCR MasterMix – 5 μl. 
 Forward primer – 0.3 μl. 
 Reverse primer with z-sequence –  0.3 μl. 
 PCR H20 (dH20 sterilised through UV and autoclaving) – 3 μl. 
 cDNA sample – 1 μl. 
 Umix – 0.3 μl 
The ampifluor probe consists of a 3’ region specific to the Z-
sequence (ACTGAACCTGACCGTACA) present on the target-
specific primers and a 5’ hairpin structure labelled with a fluorophore 
(FAM).  When in this hairpin structure, the fluorophore is linked to an 
acceptor moiety (DABSYL) which acts to quench the fluorescence 
emitted by the fluorophore, preventing any signal from being 
detected.  During PCR, however, the probe becomes incorporated 
and acts as a template for DNA polymerisation in which DNA 
polymerase uses its 5’-3’ exonuclease activity to degrade and unfold 
the hairpin structure, thereby disrupting the energy transfer between 
fluorophore and quencher, allowing sufficient fluorescence to be 
detected. The fluorescent signal emitted during each PCR cycle can 
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then be directly correlated to the amount of DNA that has been 
amplified.  The process is illustrated in Figure 2.1.  
Each sample was loaded into a qPCR machine compatible 96-well 
plate  (BioRad Laboratories, Hemel Hampstead, UK) in triplicate, and 
then covered with optically clear Microseal® (BioRad Laboratories). 
Quantitative PCR amplification was performed using StepOnePlus™ 
Real-Time PCR System (ThermoFisher) with the following 
parameters:  
Predenaturation for 10 minutes at 95 ˚C  
(70 cycles) 
Denaturation 95 ˚C for 10 seconds 
Annealing 55 ˚C for 30 seconds  
Elongation 72 ˚C for 10 seconds.  
The fluorescent signal is detected at the annealing stage by a 
camera where its geometric increase directly correlates with the 
exponential increase of product.  This is then used to determine a 
threshold cycle (CT value) for each reaction and the transcript copy 
number depends on when fluorescence detection reaches a specific 
threshold.  Results were analysed using ΔΔCT normalisation to 
housekeeping gene, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) (Livak and Schmittgen, 2001).   
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.2.5.1. Western blotting 
Protein extraction and preparation of cell lysates 
When the correct time point was reached, the cell monolayer was 
washed 2 x with PBS.  Following this, 50 μl of 
radioimmunoprecipitation assay (RIPA) buffer (containing protease 
inhibitors) was added to each well of a 6-well plate. A scraper was 
then used to scrape off the cell monolayer and the resultant cell 
suspension was added to an Eppendorf tube and placed for an hour 
at 4˚C on a Labinco rotating wheel (Wolf Laboratories, York, UK) to 
allow cell lysis to take place.  Following this, the lysed cells were 
centrifuged at 13,000 X G for 15 minutes so cell debris formed a 
pellet.  The supernatant was then transferred to a fresh Eppendorf 
tube and the pellet was discarded.  The protein samples were then 
quantified for Sodium Dodecyl Sulphate (SDS)-polyacrylamide gel 
electrophoresis (PAGE), as explained below, or stored at -20 ˚C until 
further use.  
Protein quantification and preparation of samples for SDS-PAGE 
For the standardisation of protein samples being loaded on to the 
SDS-PAGE gel, the concentration of protein in each sample was 
quantified.  This was done using the BioRad DC Protein Assay kit 
(BioRad Laboratories).  In a 96-well plate, 50 mg/ml of bovine serum 
albumin (BSA) standard (Sigma-Aldrich) was serially diluted in lysis 
buffer down to a concentration of 0.78 mg/ml and used to set up a 
standard curve of protein concentration. 5 μl of either protein sample 
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or standard was added into each test well in triplicate, before 25 μl of 
‘working reagent A/S’ (prepared by adding 20 μl of reagent S per 
millilitre of reagent A), followed by 200 μl of reagent B.  After the 
samples were mixed, the plate was incubated at room temperature 
for 10 minutes to allow the colorimetric reaction to occur.  Once this 
was completed, the absorbance of each sample was measured at 
620 nm using the ELx800 plate reading spectrophotometer (BioTek, 
VT, USA).  A standard curve could be plotted from these readings, 
allowing an equation of the line to be produced, allowing protein 
concentration calculation.  The samples were then diluted with an 
appropriate amount of lysis buffer in order to normalise all of samples 
to the least concentrated sample.  This suspension was then further 
diluted through addition of 2X Llaemelli sample buffer concentration 
(Sigma-Aldrich) at a ratio of 1:1 before the samples were denatured 
by boiling at 95 ˚C for 3 minutes.  These samples were allowed to 
cool and then loaded onto an SDS-PAGE gel.   
SDS Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
The OmniPAGE CS10 vertical electrophoresis system (Cleaver 
Scientific, Rugby, UK) was used to carry out the SDS-PAGE system. 
Resolving gels of a required percentage (depending on protein size) 
were prepared in 15 ml aliquots (enough for two gels) by adding 
volumes of the constituents in Table 2.4. TEMED was added to the  
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Table 2.4. Components and volumes used in 10% resolving gel.  
 
 
 
 
Table 2.5. Components and volumes used in stacking gel.  
 
 
 
 
 
 
 
  
Chemical Volume (ml)
H₂0 5.9
30% acrylamide (Sigma Aldrich) 5.3
1.5M Tris (pH 8.8) (Sigma Aldrich) 5.0
10% w/v SDS (Melford) 0.2
10 w/v APS (Melford) 0.2
TEMED (Sigma Aldrich) 0.012
Chemical Volume (ml)
H₂0 3.4
30% acrylamide 0.83
1.0M Tris (pH 6.8) (Sigma Aldrich) 0.6
10% w/v SDS 0.05
10 w/v APS 0.05
TEMED 0.005
2. Materials & Methods 
 
109 
 
mixture just before loading, as this caused the gel to set.  The 
resultant mixture was poured between two glass plates held in place 
by a loading cassette, until the gel was around 1.5 cm below the top 
edge of the plate.  To prevent gel oxidation, the top of the resolving 
gel was covered with isopropanol as the gel was left to polymerise at 
room temperature for around 30 minutes, until set.  The excess 
isopropanol solution was poured away before the stacking gel was 
added (components and volumes listed in Table 2.5).  After the 
addition of the stacking gel, a well-forming Teflon comb was inserted 
and the gel was allowed to polymerise for around 20 minutes.  Once 
set, the loading cassette was transferred into an electrophoresis tank 
and covered with 1 x running buffer, before the well comb was 
removed.  3 μl of BLUeye Pre-Stained Protein Ladder (Geneflow Ltd, 
Lichfield, UK), was loaded onto the gel, followed by up to 30 μl of 
samples (dependent on concentration of protein in sample).  The 
gels were then run at 100V, 50mA and 50 watts for 1.75 hours to 
allow separation of proteins according to their charge and molecular 
weight.  
Western blot transfer of proteins onto polyvinylidene fluoride (PVDF) 
membrane  
Once the SDS-PAGE was complete, the protein samples were 
transferred onto Immobilon®-P PVDF membrane (Merck Millipore, 
MA, USA) by western blotting.  The electrophoresis equipment was 
dissembled and the glass plates were separated.  The stacking gel 
was cut from the resolving and discarded.  The resolving gel was 
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then placed on top of one sponge and three 7.5 cm x 7.5 cm pieces 
of filter paper (Whatman International Ltd, Maidstone, UK) pre-
soaked in transfer buffer.  The PVDF membrane was hydrated in 
methanol (Millipore Merck) and then placed on top of the gel.  
Following this, three more pre-soaked filter papers and a sponge 
were added on top of this. This ‘sandwich’ was then placed in a 
transfer cassette and placed into a wet transfer tank.  The tank was 
kept cool throughout the blotting process by being allowed to sit in an 
ice box.  Electroblotting was undertaken at 100 V, 300 mA and 50 
watts for 1 hour.  Once the proteins were transferred, the membranes 
were blocked for 1 hour in 5% w/v skimmed milk in TBST solution 
facing upwards in 50ml falcon tubes. This solution blocks the proteins 
on the membrane, disallowing non-specific binding of the primary 
antibody. Blocking was undertaken at room temperature on a roller 
mixer (Wolf Laboratories). 
Protein detection using specific immuno-probing 
Following blocking, the primary antibody was diluted to appropriate 
concentration (outlined in Table 2.4) in 5% milk solution and 
incubated at 4 ˚C overnight on a roller mixer.  The next morning the 
5% milk solution containing unbound antibody was poured away and 
the membrane was washed 3 x in TBST, for 5 minutes per wash. The 
membranes were further incubated with 5 ml of 1:1000 HRP-
conjugated secondary antibody (Sigma-Aldrich; dependent on the 
species of the primary antibody), diluted in 5% milk solution for 1 
hour at room temperature, with continuous rotation.  This was 
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followed by three 5- minute washes using TBST in order to wash off 
unbound secondary antibody.   
Chemiluminescent protein detection  
Chemiluminescent protein detection was carried out using EZ-ECL 
(Biological Industries) which comprises a highly sensitive 
chemiluminescent substrate which detects the horseradish 
peroxidase (HRP) used in the western blotting procedure.  Solutions 
A and B of the EZ-ECL were mixed in a 1:1 ratio, allowing 1 ml per 
membrane. The solution was allowed to develop for 2 minutes and 
then added to membranes.  Excess solution was drained onto a 
piece of tissue paper and then the chemiluminescent signal was 
detected using G:Box (Syngene, Cambridge, UK).  Semi-quantitative 
analysis was undertaken using Image J software (National Institutes 
of Health, NY, USA) in order to assess the levels of protein in the 
samples.  
2.5.2. Immunocytochemistry 
Following relevant treatment, 20,000 cells in 200 µl DMEM medium 
were seeded into each well of an 8-well NUNC Lab Tek® chamber 
slide (Thermo Scientific), and incubated overnight at 37˚C with 5% 
CO2.  The following morning, the cells were fixed using ice- cold 
100% ethanol for 30 minutes at 4˚C, before being rehydrated through 
30 minutes with PBS at room temperature.  Following this, cells were 
permeabilised using 0.1% v/v TritonX100 in TBS for 5-10 minutes at 
room temperature.  The slide was then blocked using a blocking 
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solution (1-2 drops of horse serum (Vector Laboratories) added to 
PBS) for 30 minutes at room temperature.  Following blocking, cells 
were washed three times with PBS before being incubated with 
primary antibody (1:100, diluted in blocking buffer) for one hour at 
room temperature.  Any unbound antibody was washed off through 
three washes with PBS, following this incubation period.  Cells were 
then incubated with secondary antibody (1:1000) in blocking buffer 
for 30 minutes at room temperature. Following this, three washes 
were undertaken and then cells were incubated with 200µl of working 
VECTASTAIN® Universal ABC Complex (Vector Laboratories).  This 
solution was subsequently removed through three washes with PBS 
before a few drops of DAB chromogen (Vector Laboratories) was 
added and incubated in the dark for 5 minutes.  Addition of the DAB 
causes the solution to turn brown and once this occurs, the DAB was 
washed off using distilled water before the cells were counterstained 
with Mayer’s haematoxylin for approximately 1 minute. Cells were 
visualised using a Leica DM 1000 LED microscope (Leica 
Microsystems, Milton Keynes, UK).   
2.5.3. Flow cytometric assessment of protein levels 
Following relevant treatment, the cells under assessment were 
washed using PBS and then HyQTase (GE Healthcare, Chicago, IL, 
USA) was used to detach cells from the plate.  Around 10 minutes 
were allowed for detachment and then cells were quenched using 
normal medium.  Cells were then transferred, through pipetting, to a 
15ml tube and centrifuged at 300 X G for 5 minutes. 2 ml of wash 
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buffer (PBS + 2mM EDTA) was added to cells and vortexed, before 
another centrifuge at 300 X G for 5 minutes.  Cells were then 
resuspended in 500 µl of wash buffer using Vortex Genie 2 (Scientific 
Industries, Inc, NY, USA). Cells were then fixed by adding an equal 
volume of IC Fixation Buffer (eBioScience, Hatfield, UK).  Solutions 
were then allowed to incubate in the dark at room temperature for 30 
minutes.  Following this, cells were centrifuged at 600 X G for 5 
minutes and the supernatant was discarded.  The cells were then 
resuspended in 1ml of ice cold 100 % methanol (Fisher Scientific, 
Loughborough, UK) vortexed and incubated on ice for 30 minutes.  
Cells were then washed using 5 ml of FACS Buffer and then 
centrifuged again at 600 X G for 5 minutes.  Cells were then counted 
using the Counter II FL Automated Cell Counter (ThermoFisher) and 
aliquoted to contain 1 x 106 cells per 100 µl in each flow tube, with 
tubes from each treatment for a negative control, an isotype control 
and the required antibodies.  Cells were then incubated with 1ml of 
blocking buffer (1% BSA in PBST) for 30 minutes to block the 
unspecific binding of the antibodies.  Following this, another 
centrifugation at 600 X G for 5 minutes was undergone and primary 
antibodies produced at 1:100, diluted with blocking buffer (primary 
antibodies listed in Table 2.6).  100 µl per tube of the diluted primary 
antibody was added, the cells were vortexed and then incubated for 
1 hour at room temperature. Following this, cells were washed twice 
using PBS and then centrifuged at 600 X G for 5  
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Table 2.6. Primary antibodies used in flow cytometric analysis of 
protein levels.   
 
 
Antibody Code Company Species Dilution 
AKT sc 5298 Santa Cruz Mouse 1/200 
Phospho-AKT 
(serine 473) 
sc 
81433 
Santa Cruz Mouse 1/200 
c-JUN  sc 7890 Santa Cruz Rabbit 1/200 
Phospho-c-JUN 
(serine 63) 
sc 1697 Santa Cruz Rabbit 1/200 
MMP2 sc 
53630 
Santa Cruz Mouse 1/200 
MMP8 sc 
137004 
Santa Cruz Mouse 1/200 
Normal mouse IgG sc 5877 Santa Cruz Mouse 1/200 
Normal rabbit IgG sc 3888 Santa Cruz Rabbit 1/200 
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minutes.  100 µl of diluted secondary Alexa Fluor 488 antibody 
(ThermoFisher Scientific). 
(1:500) was added to cells, vortexed and then incubated at room 
temperature, in the dark for 30 minutes.  Finally, cells were washed 
twice with PBS and then resuspended in 500 µl of FACs buffer. 
Following this, samples were run on the BD FACSCanto™ II flow 
cytometer (BD) using the FITC channel.  
Data were analysed on FCS Express 4 Cytometry (De Novo 
Software, Glendale, CA, USA), where side scatter area vs. forward 
scatter area of cells with Gate 1 around the main cell population 
(Figure 2.2 a).  This gate was then applied to forward scatter area vs. 
forward scatter height graph, producing Gate 2, which was then 
applied to each histogram produced (Figure 2.2.b).  
2.5.4. RayBio® C-Series Human Matrix Metalloproteinase 
Antibody Array C1 
Following 24 hours of treatment with siRNA, the cells were washed 
twice using PBS and then serum-free DMEM added.  After a further 
48 hours, the tumour-conditioned medium (TCM) was removed from 
the cells and centrifuged at 2,000 X G for 10 minutes.  This medium 
was then transferred to a fresh Eppendorf tube and frozen at -20 ˚C 
until needed.  The cells used to produce the TCM were lysed, as 
outlined in 2.5.1, in order to check knockdown of protein through 
western blotting.  When the TCM was due to be probed for the 
presence of the MMPs and TIMPs, it was thawed to room 
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temperature and then centrifuged at 10,000 X G for 5 minutes in 
order to remove any particulates which may interfere with detection.  
The membrane was removed from the RayBio® C-Series Human 
Matrix Metalloproteinase Antibody Array C1 kit (RayBiotech Inc., 
Georgia, USA) and all components were stabilised to room 
temperature. Following this, the membranes were placed in a plastic 
incubation tray and blocked using 2ml of the provided blocking buffer 
for 30 minutes, with gentle rocking.  After this incubation, the blocking 
buffer was removed and 1 ml of the TCM was added to each 
membrane.  This was incubated at 4 ˚C overnight.  The following 
morning, the TCM was removed from the wells and the membranes 
were washed three times with 1X wash buffer 1 and twice with 1 X 
wash buffer 2, each for 5 minutes.  The biotinylated antibody cocktail 
was produced by pipetting 2 ml of blocking buffer into the vial 
provided.  Following removal of all wash buffer, 1 ml of the 
biotinylated antibody cocktail was added to each membrane and 
incubated for 2 hours at room temperature, with gently rocking.  After 
this incubation period, the membranes were washed as previously 
outlined.  The HRP-Streptavidin was then produced through dilution 
of the provided 1,000X HRP-Streptavidin concentrate with blocking 
buffer, to produce 2 ml to incubate with each membrane.  This 
incubation was, again, undertaken for 2 hours at room temperature 
with gentle rocking.  The solution was then aspirated from each well
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Figure 2.2. Flow cytometric analysis strategy of 
protein expression in cell lines. a) Side scatter 
area vs. forward scatter area of cells with Gate 1 
around main cell population. b) Forward scatter 
area vs. forward scatter height of cells, with Gate 1 
applied, with Gate 2 around single cell population. 
2. Materials & Methods 
 
118 
 
 and washes were undertaken as before.  During the washing period, 
the provided Detection Buffers C and D were mixed in a 1:1 ratio, to 
produce 500 µl per membrane.  When washes were complete, the 
membranes were transferred onto chromatography paper to remove 
any excess wash buffer and then moved to the provided plastic 
sheeting.  The mixed detection buffers were then added to the 
membranes and allowed to incubate for 2 minutes.  Another plastic 
sheet was the placed on top of the membranes and excess solution 
removed by gently ‘rolling’ the plastic sheet and sandwiching the 
membrane. The membranes were then transferred to the G:Box 
(Syngene) for chemiluminescent detection.  The membranes were 
imaged, with the resultant image corresponding to Figure 2.3. 
Analysis was undertaken using ImageJ software (National Institutes 
of Health, NY, USA).  This was done through measuring the relative 
intensity of each of the spots, using the same rectangle to measure 
each area. An average was found for each of the duplicate spots (or 
six spots for the positive and negative control).  From here, the 
negative average was subtracted from the positive average and this 
was used to normalise each of the duplicate spots.  At this point, the 
varying intensities of the points on different membranes could be 
compared.   
2.5.5. Enzyme-linked immunosorbent assay (ELISA) 
ELISA-Ready-SET-GO® kits were purchased for both interleukin-6 
(IL-6) and interleukin-8 (IL-8) from eBioScience.  ELISA plates were 
coated with 100 μl per well of 100 μl 250x capture antibody specific 
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to IL-6 or IL-8, diluted to 1 x in coating buffer (diluted from 10 x in 
deionised (DI) water from Sigma-Aldrich).  These plates were 
incubated overnight at 4 ˚C.  The following day, the wells were 
aspirated and washed 3 x with 250 μl wash buffer (0.05% v/v Tween-
20 in PBS).  Between each wash step, 1 minute was allowed for 
soaking and then the plates were blotted on absorbent paper to 
remove any residual buffer.   The 5 x ELISPOT diluent was diluted to 
1 x with DI water and wells were blocked with 200 µl of this solution 
for 1 hour at room temperature.  Following this, plates were aspirated 
and washed once with wash buffer.  The lyophilised standards 
specific to each IL, provided in each kit, were reconstituted through 
addition of 1 ml of DI water (15 ng/ml), this was allowed to sit for 15 
minutes with gentle agitation.  Then, further dilution was undertaken 
in order dilute the standard to the top concentration (250 pg/ml 
through addition of 5.9 ml 1x ELISPOT diluent to 100 µl of standard).  
A two-fold serial dilution was undertaken in triplicate in order to 
produce an eight-point standard curve, with a final volume of 100 μl 
per well. The samples were diluted to appropriate concentrations with 
PBS and 100 µl loaded per wells.  Three wells were also loaded with 
just 1x ELISPOT diluent in order for this to serve as a blank.  The 
plate was sealed and incubated for two hours at room temperature.  
Following this, solutions were aspirated from the wells and 5 washes 
were undertaken. 100 μl per well of 250x detection antibody was then 
diluted in 1x ELISPOT diluent and the plates were sealed and 
incubated at room temperature for 30 minutes.  Again, wells were 
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aspirated and washed five times. Next, 100 µl of the 250x avidin-
HRP diluted in 1x ELISPOT diluent was added to each well, the plate 
was sealed and again incubated for 30 minutes at room temperature.  
After this, wells were aspirated and then washed seven times (this 
time two minutes soak was allowed between washes.  Finally, 100 
µl/well of 1x TMB solution was added and the plate was incubated at 
room temperature for 15 minutes.  Following this 50 µl, of stop 
solution (0.16 M sulphuric acid) was added to each well.  The plates 
could then be read at 450 nm.  The data were analysed through 
standard curve production and using the RFU (following subtraction 
of the blank) gained from the samples to assess the concentration of 
the sample in pg/ml.   
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2.6. In vitro cell function assays 
2.6.1. AlamarBlue® cell proliferation assay  
A total of 5 x 103 cells were seeded in 100 μl of serum-free medium 
(no antibiotics) per well in a black 96-well plate.  Six replicates were 
undertaken per condition and four identical plates were produced in 
total. Cells were allowed to attach overnight at 37 ˚C. Twelve hours 
later, cells were treated with siRNA and DharmaFECT solutions as 
specified in section 2.3.5. Six hours post-transfection, all media were 
changed for 100 μl of normal DMEM (with antibiotics).  At 24-hour 
intervals from the time of transfection, cell media was changes and 
10 μl of AlamarBlue® Cell Viability Solution (ThermoFisher) was 
added to each well.  The plate was incubated at 37 ˚C in the dark for 
four hours and then read on a GLOMAX® MULTI Detection System 
(Promega) at 570 nm in relative fluorescence units.  
2.6.2. Tumour-endothelium adhesion assay  
A total of 3 x 105 HMVECs/well were added to a 48-well plate and 
allowed to form a monolayer overnight.  Following 72 hours of siRNA 
treatment cancer cells were diluted to 1 x 106 cells/ml and 5 μl of 
Vybrant DiO cell-labelling solution (Invitrogen, ThermoFisher) were 
added per millilitre of cell suspension.  Cells were incubated for 20 
minutes and then washed three times using phosphate buffer 
solution (PBS).  Cells were resuspended at 2 x 105 cells/ml and 200 
μl added to the 48-well plate containing HMVEC monolayer.  Cells 
were allowed to attach for 30 minutes, after which the monolayer was 
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washed twice with PBS.  350 μl cell dissociation solution was then 
added to each well and the plates further incubated for 1 hour.  The 
cell suspension was aliquoted into a black 96-well plate and read on 
a GLOMAX® MULTI Detection System (Promega), at 495 nm 
excitation and 519 nm emission.   
2.6.3. Transwell migration assay 
Cells were harvested at the relevant time point using HyQTase cell 
detachment solution (GE Healthcare). Cells were resuspended in 
serum-free medium, at a density of 1 x 105 cells/ml.  DMEM (1ml) 
containing 10% v/v FBS (chemoattractant) was added to the receiver 
wells in triplicate, and 1ml of serum-free DMEM (no chemoattractant) 
was added to the receiver well of the control transwell.  An 8-µm-pore 
ThinCert™ 24-well plate insert (Grenier Bio-One Ltd.) was placed in 
each of the receiver wells and 500 μl of cell suspension was added to 
each transwell insert.  Following four hours of incubation, the 
transwells were washed gently with PBS and then incubated for a 
further hour in 350 μl cell dissociation solution [CDS (Sigma-
Aldrich)/Calcein AM (eBioscience)] at a ratio of 1.2 μl Calcein AM in 1 
ml CDS.  Following this, the cell suspension was aliquoted into a 
black 96-well plate and read on a GLOMAX® MULTI Detection 
System (Promega), at 495 nm excitation and 519 nm emission.  To 
analyse the total directed cell movement, the fluorescence of the well 
containing no chemoattractant was subtracted from that of the test 
wells.   
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2.6.4. Transwell invasion assay 
Transwells to be used for the invasion assay were set up the day 
before the assay was to be undertaken.  Defrosted Matrigel (Corning, 
BD, Oxford, UK) was added to serum-free medium to gain a 
concentration of 500 μg/ml, then 100 μl of this solution was added to 
8-µm-pore ThinCert™ 24-well plate inserts and allowed to dehydrate 
for 2 hours at 55°C.  Forty minutes prior to the experiment, the 
Matrigel was rehydrated with 100 μl of serum-free media. The rest of 
the invasion assay was undertaken in the same way as the migration 
assay (outlined in 2.6.3), except the running time of the experiment 
was 24 hours.   
2.6.5. Wound healing (scratch) assay 
Cells were harvested using HyQTase cell detachment solution (GE 
Healthcare) and seeded into a 24-well plate in 500 µl at a 
concentration of 7.5 x 105 cells/well in DMEM.  Cells were allowed to 
attach and reach confluence overnight at 37˚C.  The following 
morning, a pipette tip was sharpened to form a point, using a sterile 
scalpel, and the cells were scratched down the centre of the well.  
Cells were imaged using a Leica DM 1000 LED microscope (Leica 
Microsystems) each hour in an area determined by blue lines drawn 
across each well.  Images were analysed using ImageJ Software 
(National Institutes of Health) and the percentage healing of the 
wound was calculated.     
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2.6.6. Cell cycle assay 
Cells to be analysed were washed 2 x with PBS, then trypsinised.  
Following detachment of the cells, trypsin was quenched using 
serum-containing medium.  Cells were centrifuged at 1,700 X G for 5 
minutes and then resuspended in 5ml of ice cold PBS.  Cells were 
centrifuged again at 1,700 X G for 5 minutes.  Cells resuspended in 
1ml of ice cold 70% v/v ethanol and left on ice for 2 hours.  Following 
this, cells were again centrifuged using the same conditions and then 
resuspended in PBS at 1 x 106 cells in 100 μl for each sample.  150 
μl of 2 μg/ml propidium iodide (PI; ThermoFisher) was added to each 
of the samples, apart from the non-stained control.  Cells were then 
incubated at room temperature in the dark for 15 minutes.  Following 
this, samples were run on the BD FACSCanto™ II flow cytometer 
(BD) using the FL3 channel (575nm).  
2.6.7. Apoptosis assay 
In order to detect apoptotic cells, the Annexin V Kit (Santa Cruz 
Biotechnology) was used.  This kit contains fluorescent conjugated 
annexin V (FITC annexin V) and propidium iodide (PI) solution.  
The calcium-dependent phospholipid-binding protein annexin V binds 
to phosphatidylserine (PS), a phospho-lipid component of the cell 
membrane which is normally located on the cytoplasmic side of the 
cell membranes in normal live cells.  However, when the cells 
become apoptotic, PS translocates from the inner to the outer leaflet 
of the cell membrane, resulting in it being exposed to the external 
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cellular membrane. PI, on the other hand, is a red-fluorescent 
intercalating dye, capable of permeating only through the cell 
membranes of non-viable cells and binding to their nucleic acids.  
Therefore, any cells that have lost their membrane integrity will be 
stained red by the PI, whereas the apoptotic cells, which are 
impermeable to PI, will be stained green by the FITC annexin V only.  
Any live cells present in the solution will show little or no 
fluorescence.  This partial staining allows for easy identification with 
the BD FACSCanto™ II flow cytometer. 
Apoptosis was induced for 2 hours using 1μl of 1 nM staurosporine 
(Sigma-Aldrich).  Following this, medium was collected and then 
attached cells trypsinised.  Once cells were detached, they were 
added to the previously collected medium.  Cells were centrifuged at 
1,500 X G for 5 minutes.  The cells were then gently washed with 
PBS and centrifuged again, under the same conditions. Cells were 
then resuspended at a concentration of 5 x 105 cells in 200 µl of 1X 
annexin V binding buffer and aliquoted to suitable flow cytometry 
tubes, ensuring a control exists for each of the individual stains and 
no staining.  Following this, cells were stained using 3 μl of FITC 
annexin V (0.01 μg/ml) and 3 μl of PI (100 μg/ml), both provided as 
part of the annexin V kit.  
Following a 30-minute incubation period in the dark, at room 
temperature, 400 μl of 1X annexin-binding buffer was added and 
cells were analysed on the BD FACSCanto™ II flow cytometer, 
reading FITC on FL1 (488 nm) and PI on FL2 (575 nm).   
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2.7. Statistical analysis 
Statistical analysis was performed using GraphPad Prism (GraphPad 
Software, Inc., CA, USA).  Each experiment was performed at least 
three times and data presented (unless otherwise stated) shows the 
mean of the three repeats, with error bars shown the standard 
deviation or standard error.  T-test, one-way ANOVA or two-way 
ANOVA were performed to test for statistical significance, with a P-
value of <0.05 considered statistically significant. The Mann-Whitney 
U Test was used to assess significance of clinical samples.  Asterisk 
(*) notation was used to signify significances: * P<0.05, ** P<0.01, *** 
P<0.001 and **** P<0.0001.   
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3.1. Introduction 
Both MDM2 and PSMA expression have been implicated in the 
progressive properties of breast cancer (Turbin et al., 2006, McCann 
et al., 1995, Hori et al., 2002, Brekman et al., 2011, Toi et al., 1997, 
Onel and Cordon-Cardo, 2004, Wernicke et al., 2014, Nomura et al., 
2014, Ross et al., 2003, Haffner et al., 2009) and have been shown 
to be involved in the metastatic abilities of tumours.     
MDM2 is known to be a negative prognostic marker for breast cancer 
(Turbin et al., 2006) and protein overexpression is often seen in 
studies of human breast cancer (McCann et al., 1995, Onel and 
Cordon-Cardo, 2004).  Meanwhile, PSMA is heavily implicated on the 
progressive properties of prostate cancer (Chang and Heston, 2002), 
and has an emerging role in breast tumours (Wernicke et al., 2014, 
Nomura et al., 2014, Ross et al., 2003, Haffner et al., 2009). 
Recently, the expression of PSMA and MDM2 was linked, when Xu 
et al., (Xu et al., 2013) found that knockdown of PSMA in LNCaP 
prostate cancer cell lines led to a decrease in the gene expression 
levels of MDM2.   
In order to assess the roles of proteins in cells, researchers often 
decrease their levels using RNA interferences (RNAi).  Short 
interfering RNA (siRNA) is the most commonly used type of RNAi 
tool for the induction of short-term silencing (2-4 days) of protein 
coding genes (Elbashir et al., 2001, Reynolds et al., 2004).  A great 
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amount of effort has been used with the hope of using siRNA-based 
therapies to tackle genetic or viral diseases (Wilson and Doudna, 
2013).   
siRNA is a synthetic RNA duplex which is designed to target a 
specific messenger RNA (mRNA) for degradation.  This duplex 
comprises two strands of RNA, a guide (or antisense) strand and a 
passenger (or sense) strand.  These form a duplex which is 19 to 25 
base pairs in length with 3’ dinucleotide overhangs.  Following 
transfection of these duplexes into cells, the guide strand is loaded 
into an RNA-induced silencing complex (RISC). This activated 
complex of protein and nucleic acid can then cause gene silencing 
through perfectly complementary binding to a single target mRNA 
sequence and thus targeting it for cleavage and degradation 
(Carthew and Sontheimer, 2009, Wilson and Doudna, 2013). 
Therefore in this chapter we attempted to select two breast cancer 
cell lines which would be best for the study being undertaken. We 
then induced siRNA-mediated knockdown of both MDM2 and PSMA 
in each of these cell lines in order to verify the findings of Xu et al., 
(2013) in breast cancer cell lines.  In addition, a breast cancer cohort 
was screened for transcript expression levels of both MDM2 and 
PSMA (Xu et al., 2013). 
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3.2. Materials and methods 
Cell lines and treatments 
MDA-MB-231 and ZR-75.1 metastatic breast cancer cell lines, 
maintained in DMEM media with 10% FBS and antibiotics, were used 
in this chapter (further details of how cell lines used for screening 
were maintained given in Section 2.1.1). These cell lines were 
transiently transfected with MDM2-, PSMA- or non-targeting siRNA 
using Fect4 or Fect1 transfection reagents, respectively. All 
treatments were undertaken in a 6-well plate and a total volume of 
1ml of treatment was used in each case. Treatments were 
undertaken for 48 or 72 hours, dependent on the experiment.    
siRNA transfection 
1 ml of MDA-MB-231 or ZR-75.1 cells added per well of a six-well 
plate at a concentration 1.5 x 106 cells/ml in serum-free media, then 
allowed to attach overnight at 37 ˚C.  Cells were then transfected 
with siRNA using 2 μl/ml DharmaFECT1 (ZR-75.1) or 1 μl/ml 
DharmaFECT4 (MDA-MB-231) according to manufacturer’s 
instructions (Dharmacon).  Doses of 0, 10, 25, 50 and 100 nM siRNA 
were used and then the optimised dose was repeated for the RNA 
isolation at time points 0, 6, 12, 24, 48, 72 and 96 hours.   
RNA isolation and RT-PCR 
Following treatment of MDA-MB-231 and ZR-75.1 cells with MDM2-, 
PSMA- and non-targeting siRNA for time points 0, 6, 12, 24, 48, 72 
and 96 hours in a 6-well plate, TRI reagent was added to cells.  RNA 
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isolation and RT-PCR were then undertaken according to sections 
2.4.1 and 2.4.2.  
Quantitative PCR (qPCR) 
qPCR was undertaken using cDNA produced in reverse transcription 
detailed above, using primers for MDM2, PSMA and GAPDH (listed 
in Table 2.3), following the procedure outlined in 2.4.3.  CT values 
gained from these processes were analysed using 2-ΔΔCT 
normalisation to GAPDH. Each qPCR sample was set up in triplicate, 
with the experiment being independently set up three times.  Analysis 
was undertaken using unpaired t-test Welch’s correction of MDM2- 
and PSMA-targeting siRNA compared to NT.  
Western blotting  
Following 72 hours of treatment of MDA-MB-231 and ZR-75.1 with 
MDM2, PSMA and NT siRNA, cells were scraped from the 6-well 
plate into 50 µl RIPA buffer (with added inhibitors), left on a blood 
wheel for 1 hour at 4˚C, then centrifuge for 15 minutes at 13,000 X G.  
Following this an equal amount of 2 x Llaemelli and SDS-PAGE, 
western blotting and immune-probing using MDM2, PSMA and 
GAPDH (antibody list in Table 2.4) was undertaken as outlined in 
2.5.1.   
Collection of human breast tissue 
148 fresh breast tissue samples were collected immediately after 
surgery and stored at -80˚C until use, with approval of the Bro Taf 
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Health Authority local research ethics committee.  The cohort 
contained normal background breast tissue and breast cancer tissue 
samples.  RNA isolation and RT-qPCR were undertaken according to 
procedure outlined above. 
Statistical analysis 
Data was statistically analysed using unpaired t-test Welch’s 
correction, with a P-value of <0.05 considered statistically significant. 
Asterisk (*) notation was used to signify significances: * P<0.05, ** 
P<0.01, *** P<0.001 and **** P<0.0001.   
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3.3. Results 
Gene expression of MDM2 and PSMA in breast cancer cell lines 
Many breast cancer cell lines are currently available for use, all with 
varying ER, PR and HER2 statuses; some are from metastatic sites, 
whilst some are from primary tumours; there are cell lines from the 
majority of the different subtypes; and some have wild-type p53, with 
others being mutant.  Before embarking on this study, it was 
important to select the correct cell lines in order to gain the most 
relevant and novel information concerning the role of both MDM2 and 
PSMA in breast cancer cell lines.  Screening of transcript levels of 
MDM2 in breast cancer cell lines BT-20, MCF-7, ZR-75.1, SK-Br-3, 
BT-483, MDA-MB-468, BT-549 and MDA-MB-231, as well as the 
normal breast epithelium cell line MCF-10A, was undertaken in order 
to decide upon cell lines to use. This screening showed negligible 
expression of MDM2 was picked up in the normal MCF-10A cell line. 
Interestingly, those cell lines which were not reported to be triple-
negative breast cancer (TNBC) type showed higher expression of 
MDM2 than TNBC. Of the non-TNBC cells, ZR-75.1 cells showed the 
highest expression levels; whilst MDA-MB-231 showed the highest 
expression of MDM2 in TNBC lines (Figure 3.1a).  Following 
assessment of PSMA gene expression in each of the same cell lines, 
some similar trends were seen.  Again, very low expression of PSMA 
was seen in the normal epithelial breast cell line, MCF-10A.  Also, 
the non-TNBC lines again showed higher expression than the TNBC.  
In this case, SK-Br-3 showed the highest expression of PSMA  
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Figure 3.1. Breast cancer cell line gene expression levels a) Screening of 
MDM2 transcript expression levels from cell lines MCF-10A, BT-20, MCF-7, 
ZR-75.1, SK-Br-3, BT-483, MDA-MB-468, BT-549 and MDA-MB-231. b) 
Screening of PSMA transcript expression levels from cell lines MCF-10A, BT-
20, MCF-7, ZR-75.1, SK-Br-3, BT-483, MDA-MB-468, BT-549 and MDA-MB-
231.  (Blue shows cells which are non-TNBC and red shows cells which are 
TNBC.  Patterned bars show cells which have a mutated p53 gene). 
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in the TNBC lines (Figure 3.1b).  However, SK-Br-3 cells grow 
extremely slowly and are not particularly amenable to the kind of 
functional work which is intended for this study and so cell lines ZR-
75.1 and MDA-MB-231 were chosen to continue the work.   
Knockdown of MDM2 in breast cancer cell lines 
In order to achieve knockdown of MDM2 protein in breast cancer 
cells, MDM2-targerting siRNA, along with a NT control siRNA, was 
transfected into cells using Dharmacon Fect4 (MDA-MB-231) or 
Fect1 (ZR-75.1) transfection reagents. All gene expression data was 
normalised to NT control siRNA, following checks that there is no 
significant effect on cells by NT control at any time or dose.   
In MDA-MB-231 cells, at a time-point of 48 hours, four concentrations 
of the siRNA were assessed, along with one treatment solely 
transfection reagent. It was shown that 10nM MDM2 siRNA gave no 
significant change from NT control; but 25 (p=0.0206), 50 (p=0.0313) 
and 100 nM (p=0.0041) siRNA all showed a significant decrease in 
MDM2 gene expression levels (Figure 3.2a).  Since a gene-level 
knockdown of over 50% was hoped to be achieved, 100 nM MDM2 
siRNA was chosen as the concentration to achieve knockdown in 
further work. Following this, a time-course was undertaken using the 
chosen concentration of 100 nM of MDM2 siRNA at 0, 6, 12, 24, 48, 
72 and 96 hours (Figure 3.2b). It was seen that only from 24 hours 
does gene knockdown occur; with 24 (p=0.0021), 48 (p=0.0020), 72  
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Figure 3.2. Knockdown of MDM2 in MDA-MB-231 cell line. a)  Dose-
dependent knockdown of MDM2 gene at 0, 10, 25, 50 and 100 nM 
MDM2 siRNA concentrations (graph shows mean+SD; individual 
experiments carried out in triplicate; n=3). b) Time-course expression of 
MDM2 gene at 0, 6, 12, 24, 48 and 72 hours following 100nM MDM2 
siRNA treatment (graph shows mean+SD; individual experiments carried 
out in triplicate; n=3).  c) MDM2 protein expression following 72 hours of 
MDM2, PSMA or NT siRNA treatment (blot show representative data; 
n=3).  d) Percentage integrated density of NT control siRNA over three 
western blots (graph shows mean+SD; n=3).  (Statistical significance 
assessed through unpaired t-test with Welch’s correction between 
targeting siRNA and NT control expression levels, with * p<0.05, ** 
p<0.01).   
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 (p=0.0027) and 96 hours (p=0.0034) showing a significant decrease 
in MDM2 gene expression compared to the NT control siRNA 
Following this, MDM2 protein expression was assessed following 
MDM2, PSMA and NT siRNA treatment, with 65% protein 
knockdown being achieved in MDM2 siRNA treated cells, compared 
to the NT control siRNA treated cells (Figure 3.2c and d).   
In ZR-75.1 cells, the same set of experiments was carried out in 
order to determine the optimal dose and which time points showed 
knockdown.  MDM2 gene expression was seen to begin to 
significantly decrease at 25 nM (p=0.0106), but gene levels are only 
more than 50% decreased at 50 (p=0.0003) and 100 nM (p=0.0013) 
(Figure 3.3a).  Therefore, 50 nM MDM2 and NT siRNA were used to 
treat ZR-75.1 at time points 0, 6, 12, 24, 48, 72 and 96 hours (Figure 
3.3b).  A significant decrease in MDM2 gene expression in MDM2 
siRNA treated cells, compared to NT control siRNA, only occurs at 
24 hours (p=0.0053).  This knockdown continues at 48 (p=0.0005), 
72 (p=0.0004) and 96 hours (p=0.0017).  MDM2 protein knockdown 
was assessed in MDM2, PSMA and NT siRNA treated cells, after 72 
hours of treatment, with 73% knockdown being achieved (Figure 3.3c 
and d).   
Knockdown of PSMA in breast cancer cell lines 
Once again, these experiments were carried out in order to optimise 
the knockdown of PSMA in MDA-MB-231 and ZR-75.1 breast cancer 
cell lines.   
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Figure 3.3. Knockdown of MDM2 in ZR-75.1 cell line. a)  Dose-dependent 
knockdown of MDM2 gene at 0, 10, 25, 50 and 100 nM MDM2 siRNA 
concentrations (graph shows mean+SD; individual experiments carried out 
in triplicate; n=3). b) Time-course expression of MDM2 gene at 0, 6, 12, 24, 
48 and 72 hours following 100nM MDM2 siRNA treatment (graph shows 
mean+SD; individual experiments carried out in triplicate; n=3).  c) MDM2 
protein expression following 72 hours of MDM2, PSMA or NT siRNA 
treatment (blot show representative data; n=3).  d) Percentage integrated 
density of NT control siRNA over three western blots (graph shows 
mean+SD; n=3).  (Statistical significance assessed through unpaired t-test 
with Welch’s correction between targeting siRNA and NT control expression 
levels, with * p<0.05, ** p<0.01 and *** p<0.001).   
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Firstly, in MDA-MB-231, varying doses of PSMA siRNA were used, 
along with NT siRNA in order to assess the level of knockdown at 10, 
25, 50 and 100 nM concentrations.  The data showed that only at 50 
(p=0.0228) and 100 nM (p=0.0033) did the siRNA show a significant 
level of knockdown compared to the NT control (Figure 3.4a).  
However, since only at 100 nM was over 50% gene knockdown 
achieved, this concentration was again used in order to complete 
other PSMA siRNA treatments in MDA-MB-231.  Next, the level of 
knockdown at varying time points was assessed (Figure 3.4b).  This 
showed that knockdown was only seen at gene levels from 24 hours 
(p=0.0234) onwards, right through to 96 hours (p=0.0177).  Protein 
levels were then assessed following 72 hours of treatment and it was 
shown that PSMA siRNA at 100 nM leads to a 45% knockdown of 
PSMA protein from MDA-MB-231 cells (Figure 3.4c and d).   
Similarly, assessment of PSMA gene expression levels in ZR-75.1 
using varying concentrations of PSMA-targeted siRNA showed a 
significant decrease at 25 (p=0.0438), 50 (p=0.0036) and 100 nM 
(p=0.0107).  However, the decrease at 25nM was only 26% and so 
50 nM was chosen as the concentration of siRNA to be used for 
further experiments (Figure 3.5a).  Following this, a time course 
assessment was undertaken over a 96 hour period post-siRNA 
treatment at 50nM.    This work showed that PSMA gene expression 
was significantly decreased following 24 hours of siRNA treatment 
but only by  around 48% (p=0.0161); whereas at 48 (p=0.0043), 72 
(p=0.0030) and 96 (p=0.0008) hours, all knockdown in gene  
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Figure 3.4. Knockdown of PSMA in MDA-MB-231 cell line. a)  
Dose-dependent knockdown of PSMA gene at 0, 10, 25, 50 and 
100 nM PSMA siRNA concentrations (graph shows mean+SD; 
individual experiments carried out in triplicate; n=3). b) Time-
course expression of PSMA gene at 0, 6, 12, 24, 48 and 72 hours 
following 100nM PSMA siRNA treatment (graph shows mean+SD; 
individual experiments carried out in triplicate; n=3).  c) PSMA 
protein expression following 72 hours of MDM2, PSMA or NT 
siRNA treatment (blot show representative data; n=3).  d) 
Percentage integrated density of NT control siRNA over three 
western blots (graph shows mean+SD; n=3).  (Statistical 
significance assessed through unpaired t-test with Welch’s 
correction between targeting siRNA and NT control expression 
levels, with * p<0.05, ** p<0.01).   
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Figure 3.5. Knockdown of PSMA in ZR-75.1 cell line. a)  
Dose-dependent knockdown of PSMA gene at 0, 10, 25, 50 
and 100 nM PSMA siRNA concentrations (graph shows 
mean+SD; individual experiments carried out in triplicate; 
n=3). b) Time-course expression of PSMA gene at 0, 6, 12, 
24, 48 and 72 hours following 100nM PSMA siRNA 
treatment (graph shows mean+SD; individual experiments 
carried out in triplicate; n=3).  c) PSMA protein expression 
following 72 hours of MDM2, PSMA or NT siRNA treatment 
(blot show representative data; n=3).  d) Percentage 
integrated density of NT control siRNA over three western 
blots (graph shows mean+SD; n=3).  (Statistical significance 
assessed through unpaired t-test with Welch’s correction 
between targeting siRNA and NT control expression levels, 
with * p<0.05, ** p<0.01, p<0.001).   
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expression were greater than 50% compared to the NT control 
(Figure 3.5b).    Finally, protein expression following knockdown was 
assessed, with a 54% knockdown in PSMA expression following 
targeted siRNA treatment (p=0.0085) (Figure 3.5c and d).   
MDM2 knockdown leads to a decrease in PSMA gene expression 
and vice versa 
After 48 hours post-transfection of MDM2 siRNA into MDA-MB-231 
and ZR-75.1, mRNA levels of PSMA were assessed.  Interestingly, a 
significant decrease in PSMA levels were seen following MDM2 
siRNA (MDA-MB-231: p=0.0058; ZR-75.1: p=0.0021) (Figure 3.6a 
and b), as well as a significant decrease in MDM2 gene expression 
being seen following PSMA siRNA treatment (MDA-MB-231: 
p=0.0037; ZR-75.1: p=0.0129) (Figure 3.6c and d).   
In addition, dual treatment was undertaken in MDA-MB-231 cells with 
50 nM of each MDM2/PSMA, MDM2/NT or PSMA/NT siRNAs and 
was compared to 100nM of NT, giving an equal concentration of 
siRNA for each comparative experiment. This experiment showed a 
highly significant decrease in both MDM2 and PSMA expression, 
compared to NT siRNA (p<0.0001)  (Figure 3.7a and b).  
Assessment of MDM2 gene expression showed a greater decrease 
in transcript levels in the cells treated with MDM2/PSMA and 
MDM2/PSMA than PSMA/NT siRNAs.  On the other hand, PSMA 
gene expression showed a greater decrease when cells were treated 
with MDM2/PSMA or PSMA/NT siRNA, compared to those treated  
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Figure 3.6. Resultant expression of PSMA transcript following 
48 hours of MDM2 siRNA treatment in MDA-MB-231 and ZR-
75.1, and vice versa.  a) % PSMA gene expression following 
MDM2 siRNA treatment in MDA-MB-231 cells. b) % PSMA gene 
expression following MDM2 siRNA treatment in ZR-75.1 cells. c) % 
MDM2 gene expression following PSMA siRNA treatment in ZR-
75.1 cells.  D) % MDM2 gene expression following PSMA siRNA 
treatment in ZR-75.1 cells.  (Graphs show % expression compared 
to NT control siRNA treated cells +SD).  (Statistical significance 
assessed using unpaired t-test with Welch’s correction with * 
p<0.05 and ** p<0.01).  
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Figure 3.7.  48 hour dual siRNA treatment in MDA-MB-231 and ZR-
75.1 cell lines. a) Percentage expression of MDM2 transcript 
following treatment with NT, MDM2/PSMA, MDM2/NT or PSMA/NT 
siRNA in MDA-MB-231 cells.  b) Percentage expression of PSMA 
transcript following treatment with NT, MDM2/PSMA, MDM2/NT or 
PSMA/NT siRNA in MDA-MB-231 cells. c) Percentage expression of 
MDM2 transcript following treatment with NT, MDM2/PSMA, 
MDM2/NT or PSMA/NT siRNA in ZR-75.1 cells. d) Percentage 
expression of PSMA transcript following treatment with NT, 
MDM2/PSMA, MDM2/NT or PSMA/NT siRNA in ZR-75.1 cells. 
(Graphs show % expression compared to NT control siRNA treated 
cells +SD) (Statistical significance assessed using one way ANOVA 
with **** p<0.0001).  
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with MDM2/NT siRNA alone.  Analysis of the resultant effect on ZR-
75.1 cells treated with the same dual siRNAs showed similarly 
significant results, compared to NT siRNA (p<0.0001) (Figure 3.7c 
and d).  Again, the decrease in MDM2 transcript levels was most 
striking in those cells treated with MDM2/PSMA and MDM2/NT 
siRNA compared to PSMA/NT siRNA.   
 
Assessment of MDM2 and PSMA transcript levels in breast tissue 
Analysis of breast tissue samples containing 30 normal background 
breast tissue and 112 breast cancer tissues samples was 
undertaken.   When MDM2 transcript levels were assessed, no 
significant difference was seen between the normal and tumour 
tissue expression levels (p=0.536) (Figure 3.7a).  MDM2 gene 
expression levels were shown to increase from tumours of grade 1 to 
grade 2 (p=0.010) and to grade 3 (p=0.009); although no significant 
difference was seen between grade 2 and 3 (p=0.825).   No 
significant difference was seen between the different values of 
Nottingham Prognostic Index (NPI).  TNM stage 1 exhibited 
significantly higher than stage 2 (p=0.029) and stage 3 (p=0.001); but 
no significance was seen between any stage and stage 4.  Moreover, 
stage 3 was significantly decreased from stage 2 (p=0.0268).   There 
was no significant trend in the relation of MDM2 and clinical outcome, 
whether those patients were disease free at follow up or had a poor 
outcome. There was also no significant difference in MDM2 
expression whether the tumour was ductal, lobular or other.  A  
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Figure 3.8.  MDM2 transcript expression levels in breast 
tissue. a) Fold change in transcript expression of MDM2 in both 
normal and tumour breast tissue (Graph shows transcript no. + 
SD).  b) Clinical/pathological features of normal and tumour  
breast tissues with mean copy number, SD and p-value 
(Significances assessed using Mann-Whitney U Test; bold 
numbers represent those with a significant difference).   
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significant difference was seen between patients with negative and 
positive oestrogen receptor α (ERα), with ERα(-) showing a 
significantly higher mean than those which are ERα(+) (p=0.031).  
On the other hand, no significance was seen between patients who 
were ERβ negative and positive.  When survival analyses were 
carried out, it was noted that patients with higher levels of MDM2 
tend to have shorter overall (Figure 3.9a) and disease-free survival 
(Figure 3.9b), although the difference was not significant.  
When PSMA transcript levels were assessed in the same breast 
cancer cohort, no significant difference was seen in expression be-
tween the normal and tumour breast tissues (p=0.744) (Figure 
3.10a).  Analysis of PSMA transcript levels following the division of 
the tissues into their clinical features also showed no striking or sig-
nificant differences in expression.  However, comparison of ductal 
and lobular tumours showed a trend of very low PSMA transcript ex-
pression the lobules, compared to the ducts, although this did not 
reach significance (p=0.544) and neither reached significance when 
compared to other histological forms.  The one significant difference 
seen in this data was between the ERβ(-) and ERβ(+) patients, with 
those who were negative showing a significantly lower PSMA tran-
script level than those who were positive (p=0.028) (Figure 3.10b). In 
addition, there were no significant differences between patients with 
high and low PSMA levels in overall survival (p=0.359)(Figure 3.11a) 
or disease-free survival (p=0.079)(Figure 3.11b). 
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Figure 3.9. Survival analysis of breast cancer patients with low or high 
MDM2 transcript expression.  a) Overall survival (high level MDM2 median 
138.12 and low level MDM2 median 116.30). b) Disease-free survival (high 
level MDM2 median 132.53 and low level MDM2 median 111.53). (NPI2 used 
to dichotomise data; graphs show cumulative survival against survival time in 
months). 
p=0.177 
p=0.220 
n=73 
n=29 
95% CI 125.66 – 143.90 
95% CI 119.41 – 143.90 
 
n=73 
n=29 
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Figure 3.10.  PSMA transcript expression levels in breast 
tissue. a) Fold change in transcript expression of PSMA in both 
normal and tumour breast tissue (Graph shows transcript no. + 
SD).  b) Clinical/pathological features of normal and tumour  
breast tissues with mean copy number, SD and p-value 
(Significances assessed using Mann-Whitney U Test; bold 
numbers represent those with a significant difference).   
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Figure 3.11. Survival analysis of breast cancer patients with low or 
high PSMA transcript expression.  a) Overall survival (high level PSMA 
median 137.75 and low level PSMA median 106.77). b) Disease-free 
survival (high level PSMA median 133.84 and low level PSMA median 
97.12). (Data dichotomised using NPI2; graphs show cumulative survival 
against survival time in months). 
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3.4. Discussion 
MDM2 is implicated in the progressive properties and is 
overexpression in many types of cancer (Rayburn et al., 2005, 
Shangary et al., 2008, Wade et al., 2013, Onel and Cordon-Cardo, 
2004), including breast cancer (Turbin et al., 2006, McCann et al., 
1995, Brekman et al., 2011, Onel and Cordon-Cardo, 2004). 
PSMA was originally thought to be solely overexpressed in prostate 
cancer (Horoszewicz et al., 1987, Chang and Heston, 2002, Chang 
et al., 1999, Bostwick, 1998, Bostwick et al., 1998, Sweat et al., 
1998), however has been more recently found to be expressed in 
other types of cancers, including breast (Wernicke et al., 2014, 
Nomura et al., 2014, Ross et al., 2003, Haffner et al., 2009).  
A relatively recent study showed that in the prostate cancer cell line, 
LNCaP, PSMA knockdown led to a decrease in MDM2, amongst 
other gene expression changes (Xu et al., 2013). In addition, many 
pathways in which each of the proteins are implicated are the same, 
including: folate metabolism (Pinto et al., 1996, Yao et al., 2010, 
Maguire et al., 2008); PI3K/AKT (Guo et al., 2014, Ogawara et al., 
2002, Milne et al., 2004, Mayo and Donner, 2001); and the MMPs 
(Conway et al., 2006, Syed et al., 2012, Chen et al., 2013, Zhang et 
al., 2014).   
Therefore, this study was intended to assess if there was an interplay 
between MDM2 and PSMA in breast cancer cells, a line of study 
which has been, thus far, not explored. 
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As an initial step, all available breast cancer cell lines were screened 
for their transcript levels of MDM2 and PSMA.  Although this study 
was aiming to look at the activity of MDM2 independent to p53, the 
p53 status of the cell lines being used in a study must be taken into 
account.  Therefore, the intention was to choose one cell line which 
was p53 wild-type and one which was p53 mutant, in order for it to be 
possible to assess whether functional and signalling changes we 
were seeing through MDM2 knockdown were through p53 or another 
mechanism.  In addition we attempted to choose one TNBC cell line 
and one non-TNBC in order to cover a wider variety of breast cancer 
types.  Finally, the MDM2 and PSMA gene expression levels were 
assessed in order to choose correct cell lines.  It was seen that the 
highest expressing cell line of MDM2 transcript was ZR-75.1, 
followed by MCF-7, SK-Br-3 and then MDA-MB-231.  PSMA 
transcript, on the other hand, showed highest expression in the SK-
Br-3 cell line, followed by ZR-75.1, MCF-7 and MDA-MB-231.  When 
assessed in vitro, SK-Br-3 cells were extremely hard to culture, and 
with the types of functional experiments and tranfections we had in 
mind for this project, we needed cell lines which proliferated well and 
were amenable to a reasonable level of manipulation.  Therefore, 
with this in mind and our ideal breast cancer cell lines, as stipulated 
above, ZR-75.1 (p53 wild-type, ER(+), high MDM2 and high PSMA 
expression) and MDA-MB-231 (p53 mutant, TNBC, average MDM2 
and average PSMA expression) were chosen for this study.   
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One potential problem with using ZR-75.1 is that they are classed as 
having a low invasive capacity, with invasion being something we 
hoped to address following knockdown in this study.  However, other 
reports do indicate that they were able to gain results from ZR-75.1 in 
terms of changes to the invasive capacity of cells (Wang et al., 2015, 
Kato et al., 2005).   
MDA-MB-231 cells, on the other hand, are known to be highly 
invasive.  They are also known to express high levels of p53 
although this protein is mutated (Hui et al., 2006).  This mutation is 
known as R280K and is seen in MDA-MB-231 to affect the DNA-
binding domain of the molecule and occurs in 1.3% of breast tumours 
(Walerych et al., 2012, Bull et al., 2004).  Unlike many tumour 
suppressors genes whose inactivation occurs when they are deleted 
or truncated, the majority of the mutations which occur in the TP53 
gene are missense mutations. This means that the mutation is a 
simple base-pair substitution which results in the translation of a 
different amino acid in the protein.  It is known that many of these 
mutations can lead to a dominant-negative effect being exerted on 
the remaining wild-type allele, which allows an abrogation of the 
ability of p53 to inhibit transformation of a cell, especially when this 
mutant protein is expressed at much higher levels than its wild-type 
counterpart, which is often the case (Brosh and Rotter, 2009, Oren 
and Rotter, 2010, Freed-Pastor et al., 2012).   It is well established 
that the loss-of-function leads to an inability of wild type p53 to bind 
to responsive elements on DNA but it is also thought that these 
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missense mutations may cause a gain-of-function, with strong 
selection for these types of mutations suggesting a positive role for 
certain p53 mutants in tumorigenesis (Yeudall et al., 2012, Bae et al., 
2013, Freed-Pastor and Prives, 2012).  In particular, reports claim 
that mutant p53 may have the ability to promote the migration and 
metastasis of cells (Terzian et al., 2008, Adorno et al., 2009, Caulin 
et al., 2007, Muller et al., 2009).   
Though the use of cell lines is appropriate and requisite for this 
study, it is important to remember throughout the limitations of using 
cell lines to model the in vivo environment of tumour formation.  
Establishment of a new breast cancer cell line involves a pattern of 
growth which is characterised by an initially slow proliferation of cells 
which is then followed by an exponential expansion of a few cells, 
implying a clonal selection for cells which are particularly proliferative 
and amenable to cell culture (Vincent et al., 2015).  Cells are prone 
to genotypic and phenotypic drift through their continuous culture, 
where subpopulations with more rapid growth, differing hormone 
receptor content, karyotype and clonogenicity arise, leading to 
selection of clones within a population.  These variances lead to a 
high level of discrepancies between the same cell line used by 
different laboratories (Burdall et al., 2003). 
Another weakness of cell culture is the lack of the environment 
surrounding the cells.  In vivo cells are growing in a highly complex, 
partially hypoxic, 3D microenvironment.  However, in culture, the 
cells are supplemented with growth factors, maintained in nutrient-
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rich media and passaged indefinitely at relatively high atmospheric 
pressure (Vincent et al., 2015).   Culture of cells in conditions which 
are incorrect can also lead to a dramatic change in the cell 
morphology, cell-cell and cell-matrix interactions, cell polarity and 
differentiation (Holliday and Speirs, 2011, Yamada and Cukierman, 
2007, Streuli et al., 1991). Therefore, it is highly feasible that different 
cells will thrive in this environment and the cells may differ 
substantially from the tumours from which they came (Vincent et al., 
2015).   
However, despite these downfalls, cell lines have many advantages: 
they are easy to handle; they allow scientists an unlimited source of 
self-replicating cells which can be grown in huge quantities; they can 
be frozen and rethawed; and they are relatively homogeneous 
(Burdall et al., 2003).  In addition, cell lines are the current way in 
which it is possible to model the tumour environment to some extent 
in a cost- and time-effective manner, before experiments are moved 
on to the in vivo stages in promising studies.  
When selecting methods to be undertaken in order to achieve 
knockdown of MDM2 and PSMA, there were a variety of different 
method choices.  However, due to siRNA being cheap and quick to 
optimise, this transient form of knockdown was selected for use over 
the more expensive, time-consuming stable method of lentiviral 
knockdown.  The transient nature of siRNA knockdown was not a 
limitation for this study, since all of the assays undertaken were 
short-term and were not be affected by this aspect of the knockdown 
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method.  Therefore, our chosen cell lines: MDA-MB-231 and ZR-751, 
were used to optimise and decide on dose and time points to be 
used.  
Firstly, it is important to note that the same dose of siRNA was hoped 
to be used for both knockdowns, allowing the same concentration of 
NT siRNA to be used in each experiment, so that this could be used 
as a control for both MDM2 and PSMA siRNA.  In addition, it was 
hoped that choosing the same dose of siRNA for both knockdowns 
would allow for a more direct comparison, without having to take into 
account how the varying siRNA concentrations lead to a differing 
amount of off-target effects.  In addition, the same logic was used 
when choosing the time-points at which to undertake assays and 
take RNA and protein.  Moreover, at gene expression levels, we 
aimed for a >50% knockdown to be achieved, since knockdown is 
usually less apparent at protein level and in order to have the best 
chance of seeing significant results, a significant level of protein 
knockdown is needed.  A final important note is that, although the 
MDM2 protein half-life is extremely short, with a number of reports 
claiming this is around 30 minutes (Pan and Haines, 1999, Peng et 
al., 2001, Finlay, 1993), the PSMA half-life has been proved to be 
much longer.  Differing reports have claimed the protein has a half-
life of two days (Schulke et al., 2003) or 55 hours (Ghosh and 
Heston, 2004)and it is important to bear this in mind when assessing 
protein knockdown. 
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With all this in mind, in MDA-MB-231 a dose of 100 nM of siRNA was 
selected following gene knockdown, and transcript levels were seen 
to significantly decrease following both siRNA treatments compared 
to the NT control.  Time-course studies at this concentration then 
showed a significant knockdown in transcript expression through 
both siRNAs from 24, 48 and 72 hours onwards.  Due to the long 
half-life of PSMA, protein levels were assessed at 72 hours to show a 
greater level of knockdown, at this point, levels were decreased to 
around 50% when cells were treated with PSMA siRNA, which is 
what would be expected.  MDM2 protein levels were also seen to be 
significantly decreased following MDM2 siRNA. 
Similar results were seen in ZR-75.1 cells, although 50 nM of siRNA 
was highlighted to be enough to induce effective knockdown of both 
siRNAs.  Time-course studies showed similar results, with onwards 
of 24 hours of treatment showing a significant decrease in gene 
expression for both siRNAs.  Protein analysis also showed a 
significant knockdown at 72 hours of both siRNAs, with PSMA 
protein expression showing, again, a decrease of around 50% 
following PSMA siRNA treatment.  In addition, MDM2 knockdown 
was highly significant.    
Interestingly, assessment of the levels of MDM2 transcript following 
PSMA siRNA treatment in each cell line showed a significant 
decrease in expression compared to the NT control, which is in line 
with those results seen in LNCaP (Xu et al., 2013).  Additionally, 
assessment of PSMA transcript levels following MDM2 siRNA led to 
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a similar decrease in both cell lines.  However, this decrease, 
although highly significant at gene level, was not replicated at protein 
level.  This is a highly interesting phenomenon which is not unheard 
of.  In fact it is now well known that often mRNA and protein levels do 
not correlate well and only around 40% of time are cellular protein 
levels correctly predicted through mRNA measurements (Kendrick, 
2014).  Many groups have attempted to quantify this correlation 
through the use of the coefficient of determination (R2) and found 
surprisingly low values when mRNA and protein expression are 
compared. R2 values of 0.29 (Vogel and Marcotte, 2008), 0.35 (Tian 
et al., 2004) and 0.3 (Schwanhausser et al., 2011) have been 
reported.  Moreover Schwanhausser et al., (2011) found that the 
most important cellular regulators have the lowest correlation 
between mRNA and protein, due to their unstable mRNA and protein.  
On the other hand, they showed that it is the housekeeping proteins 
which have a relatively good correlation. It is well known that a 
multitude of post-translational mechanisms exist in order to control 
protein turnover.  Given this, it is not wholly unreasonable that we 
may only see a 40% correlation. 
Dual siRNA treatments were also undertaken in both cell lines and it 
was seen that both MDM2 and PSMA transcript expression is 
significantly decreased following treatment with 50 nM of each 
MDM2/PSMA, MDM2/NT or PSMA/NT, compared to 100nM NT 
siRNA alone.  
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Finally, MDM2 and PSMA transcript levels were assessed in a breast 
tissue cohort.  Comparison of normal and tumour breast tissue 
showed no significance in the transcript expression levels of either 
MDM2 or PSMA.  In terms of MDM2 transcript expression, there are 
varying reports on the amplification of gene expression in cancer.  
Some studies claim that amplification of the MDM2 gene is common 
in liposarcomas (Teodoro et al., 2007, Marino-Enriquez et al., 2014); 
however, it has been stated that amplification of MDM2 gene is very 
rare in primary breast cancer (Yu et al., 2014).  In addition, 
assessment of GEO datasets showed similar results, with  no 
difference between normal and tumour transcript expression of 
MDM2, or between normal lobular tissue and invasive lobular 
carcinoma, or normal ductal tissue and invasive ductal (GEO dataset 
GDS3139 & GDS2635) PSMA mRNA, on the other hand, has been 
seen to be overexpressed in prostate cancer (Schmittgen et al., 
2003).  However, no significance was seen when the same GEO 
data sets as analysed for MDM2, were assessed for PSMA 
transcript. 
The lack of significance in the difference in transcript expression 
levels between normal and tumour, although both proteins are known 
to be overexpressed in various cancer types.  This implies that the 
increased expression of both MDM2 and PSMA occurs post-
transcriptionally.   
Interestingly, in the cohort study, both MDM2 and PSMA transcript 
levels were seen to be significantly altered in relation to ER.  MDM2 
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transcript levels were significantly higher in ERα negative tumours, 
compared to ERα positive tumours.  On the other hand, PSMA 
transcript levels were significantly higher in those patients expressing 
ERβ.   
ERα and ERβ belong to a superfamily of nuclear receptors that 
regulate the transcription of multiple target genes upon binding to 
oestrogen response elements (ERE) present within the regulatory 
region of the genes (Green et al., 1986).   Expression of ERα in 
breast cancer is closely associated with tumour biology (Jensen et 
al., 2001).  The presence of ERα indicates a phenotype of a less 
aggressive nature and a more favourable prognosis (Nomura et al., 
1988).  The role of ERβ is much less well-characterised and its exact 
role remains elusive (Haldosen et al., 2014).  
MDM2 has been previously linked to oestrogen receptor, with a 
significant correlation between levels of MDM2 and ERα being seen 
in both breast cancer tissue and cell lines (Hideshima et al., 1997, 
Marchetti et al., 1995, Gudas et al., 1995). It was previously 
observed that all ERα-positive breast cancer cell lines studied show 
an increased level of MDM2 transcript, with the opposite seen in 
those negative for  ERα (Gudas et al., 1995), indicating some 
functional relationship between the two proteins, with one group 
suggesting that MDM2 is a p53-independent, positive regulator of 
ERα (Saji et al., 2001).  In addition, another group claimed that 
MDM2, through interactions with ERα, plays a role in the 
enhancement of ERα-mediating gene expression and oestrogen 
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responsiveness of breast cancer cells (Kim et al., 2011a); whilst 
another stated that oestrogen increases the protein levels of MDM2 
in the breast cancer cell line MCF-7 (Brekman et al., 2011).   
However, the cohort analysis in our own study showed data with the 
opposite correlation, with those patient samples lacking ERα showing 
higher MDM2 transcript levels than those with the receptor.   
On the other hand, PSMA has not been investigated alongside ER, 
apart from in one study of the neovasculature of breast carcinoma 
showing higher PSMA expression was seen in those patients who 
were ER-negative (Wernicke et al., 2014). Again, although this does 
not specify a type of ER receptor, this does not fit with what was 
seen in our cohort, with those patients who were negative for ERβ 
showing lower levels of PSMA transcript than those who were 
positive.  
MDM2 transcript levels were shown to decrease through TNM 
stages, whilst increasing through the tumour grade.  However, no 
significance was seen between the NPI scores.  This is very 
interesting, as both TNM staging and NPI take into account the 
tumour size and spread to lymph nodes, however TNM staging takes 
into account metastases, whereas NPI takes into account the grade.  
This insinuates that it is something in the metastasis of the tumour 
which leads to a lower level of MDM2 transcript expression.  This 
could be simply that, since the majority of the increase in expression 
is not reliant on amplification, and MDM2 protein levels are known to 
increase in more progressive tumours, that the cells are simply 
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attempting to restabilise MDM2 levels.  This feedback loop is, at 
least, known to occur when wild-type p53 is present (Moll and 
Petrenko, 2003).   However, it must be noted that there were only 
two patients in TNM stage 1 and a higher number would need to be 
used in order to draw firm conclusions from this data.  The other 
interesting finding is that there exists a trend between high levels of 
expression of both MDM2 and PSMA transcripts and shorter survival 
of the patients.  Although these trends do not reach statistical 
significance, owing largely to the size of the cohort in the present 
study, the trend does provide some support to the portrayed link 
between these two molecules and disease progression.  A larger 
cohort blended with analyses on gene transcripts and protein would 
be highly desirable. 
In summary, MDA-MB-231 and ZR-75.1 cells lines were chosen to 
continue the work throughout the project.  Interestingly, PSMA 
transcript levels were significantly decreased following MDM2 siRNA 
treatment and vice versa; however, this was not replicated at protein 
level.   
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Chapter IV 
Knockdown of MDM2 
and PSMA in breast 
cancer cell lines leads 
to a decrease in 
proliferative abilities 
and altered apoptotic 
ability and cell cycle 
progression 
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4.1. Introduction 
There are many facets to the development of cancer from a normal 
cell and one of these is the ability to proliferate in an uninhibited 
manner, through both sustained proliferative signalling and the 
evasion of growth suppressors.  Normal tissues carefully control the 
production and release of growth-promoting signals, but cancer cells 
are able to deregulate these signals, mostly conveyed through 
growth factors which bind cell-surface receptors.  Cancer cells can 
produce growth factor ligands; they may send signals into the 
tumour-associated stroma in order to induce paracrine signalling 
from normal cells; they can elevate the levels of receptor on the cell 
surface, causing hypersensitivity to ligand; and they can cause 
constitutive activation of components working downstream of 
receptors, meaning no receptor-ligand binding is needed for 
activation of the proliferative signalling (Hanahan and Weinberg, 
2000, Hanahan and Weinberg, 2011).   
In normal tissues, many anti-proliferative signals (including soluble 
growth inhibitors and immobilised inhibitors embedded in the ECM 
and on the surface of nearby cells) work to maintain cell quiescence 
and homeostasis.  However, in addition to their ability to increase 
proliferative signalling pathway activation, cancer cells can also gain 
the ability to evade this growth suppression (Hanahan & Weinberg, 
2000).   
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Previously, an increase in MDM2 has been linked to an increase in 
cell proliferation (Deb et al., 2014, Brekman et al., 2011) and use of 
the MDM2 inhibitor nutlin-3a was shown to suppress proliferation 
(Wang et al., 2012).  Similar results were seen in reports of PSMA, 
with Yao et al., (2006) reporting expression of PSMA leading to an 
increase in proliferation.  This sentiment was echoed in other reports 
(Yao et al., 2010, Zhang et al., 2013).   
The cell cycle is also often altered in cancer, leading to unscheduled 
proliferation (Massague, 2004, Malumbres and Barbacid, 2009).  
This process is controlled by many mechanisms which ensure 
correct cell division (mitosis).  Replication of the DNA occurs in what 
is known as the S phase, before this cells are in gap 1 phase (G1) 
where cells can enter a state known as G0, which accounts for the 
majority of cells which are non-growing and non-proliferating.  
Following this, a second gap phase (G2) occurs (Vermeulen et al., 
2003, Schafer, 1998).  Tumour-associated defects in the cell cycle 
are often mediated through changes in cyclin-dependent kinase 
(CDK) activity.  Cyclins are produced and then degraded at different 
points in the cycle in order to regulate the CDKs, which are essential 
for driving each phase of the cell cycle in a timely manner 
(Malumbres and Barbacid, 2009).  
Despite its known oncogenic ability, MDM2 has been shown to 
induce an arrest in cell cycle at G0/G1 phase in normal human and 
mouse cells (Frum and Deb, 2003, Brown et al., 1998).  In addition, 
p53 has been shown to control both the G2/M transition and G1 
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checkpoints of the cell cycle (Agarwal et al., 1995).    Meanwhile, 
PSMA was shown to play a part in mitosis, with an involvement in 
interphase (S phase) and an interaction with the anaphase promoting 
complex (APC) to promote chromosomal instability (Rajasekaran et 
al., 2008).   Studies using short hairpin knockdown of PSMA showed 
an increased in cells in G1 phase and a decrease in cells at S phase 
(Zhang et al., 2013).  
The ability of the tumour cell population to increase in number is not 
just dictated by rate of cell proliferation, but also by the rate of 
programmed cell death (apoptosis).  Apoptotic machinery can be 
broadly divided into two categories – sensors and effectors.  Sensors 
are responsible for monitoring the extracellular environment for 
normal or abnormal conditions and then regulate the effectors 
(Hanahan and Weinberg, 2000). The most commonly occurring loss 
of an apoptotic regulator through mutation involves the p53 tumour 
suppressor gene.  The mutation results in an inactivation of the p53 
protein and it is seen in over 50% of human cancers (Harris, 1996a, 
Hanahan and Weinberg, 2000).  The p53 protein is known to be 
negatively regulated by MDM2 (Moll and Petrenko, 2003) and MDM2 
overexpression is also very common in human cancers (Toi et 
al.¸1997; Baunoch et al.¸1996; Deb, 2003), leading to a similar 
phenotype as seen through a mutation in the p53 gene – an inability 
of p53 protein to act as it should. With this, it has been seen that loss 
of MDM2 in cells leads to an increase in apoptosis (de Rozieres et 
al., 2000, Ray et al., 2011, Dilla et al., 2000). The same result was 
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seen by one group from PSMA knockdown in prostate cancer cells 
(Huang, 2015).   
The caspases are a family of endoproteases which are involved in 
cell homeostasis through regulation of cell death.  Caspase-mediated 
processing of substrates can result in the generation of active 
signalling molecules which participate in ordered processes such as 
apoptosis and inflammation (McIlwain et al., 2016).  Caspases have 
been broadly classified into their known roles in apoptosis (caspase-
3, -7, -8 and -9) and inflammation (caspase-1, -4, -5 and -12).  In 
apoptosis, initiator caspases (-8 and -9) activate the executioner 
caspases (-3 and -7), which use their activity to degrade important 
structural proteins and activate other enzymes (Chang et al., 2003, 
Riedl and Shi, 2004, McIlwain et al., 2016).   
MDM2 has previously been linked to caspase-2 and -3.  One report 
claimed that caspase-2 mediates the cleavage of MDM2 (Oliver et 
al., 2011, Pochampally et al., 1999).  In addition, another report 
claimed that MDM2 is cleaved by caspase-3 (Pochampally et al., 
1998).  Thus far, PSMA has not been linked directly to any of the 
caspases.   
Therefore, in this chapter of research we aimed to assess the ability 
of MDM2 and PSMA knockdown to complete these initial stages 
during cellular metastasis.  
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4.2. Materials & Methods 
Cell lines and treatments 
MDA-MB-231 and ZR-75.1 metastatic breast cancer cell lines, 
maintained in DMEM media with 10% FBS and antibiotics, were used 
in this chapter. All cells were maintained at 37°C with 5% CO2. The 
breast cancer cell lines were transiently transfected with MDM2-, 
PSMA- or non-targeting siRNA using Fect4 (for MDA-MB-231) or 
Fect1 (for ZR-75.1) transfection reagents, respectively.  MDA-MB-
231 cells were treated with 100nM of each siRNA and ZR-75.1 cells 
were treated with 50nM, according to the manufacturer’s instructions, 
following our optimisation experiments.   
Proliferation assay 
5 x 103 cells were seeded in 100 µl of serum-free medium (no 
antibiotics) per well in a black 96-well plate.  Six replicates were 
undertaken per condition and four identical plates were produced.  
Twelve hours later, cells were treated with siRNA and DharmaFECT 
solutions, as specified in section 2.3.5.  Following this, a proliferation 
assay was carried out as outlined in Section 2.6.1.   
Cell imaging 
Cells were imaged following 72 hours of MDM2, PSMA, 
MDM2/PSMA and NT siRNA treatment using Leica DMi1 light 
microscope (Leica Microsystems, Wetzlar, Germany) at 
magnification 20x.   
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Cell cycle assay 
Cells were treated with siRNA as detailed above and then the assay 
was carried out as specified in Section 2.6.6.  
Apoptosis assay  
Cells were treated with siRNA as detailed above and then the assay 
was carried out as specified in Section 2.6.7 with annexin V-FITC 
and propidium iodide (PI).  
RNA isolation and RT-PCR 
Following treatment of MDA-MB-231 and ZR-75.1 cells with MDM2-, 
PSMA- and non-targeting siRNA for 72 hours in a 6-well plate, TRI 
reagent was added to cells.  RNA isolation and RT-PCR was then 
undertaken according to Sections 2.4.1 and 2.4.2.  
Quantitative PCR (qPCR) 
qPCR was undertaken using cDNA produced in reverse transcription 
detailed above, using primers for caspase-3, -7, -8 and -9, as well as 
GAPDH (listed in Table 2.3), following the procedure outlined in 
2.4.3.  CT values gained from qPCR were analysed using 2-ΔΔCT 
normalisation to GAPDH. Each qPCR sample was set up in triplicate, 
with the experiment being independently set up three times.  Analysis 
was undertaken using one-way ANOVA of MDM2- and PSMA-
targeting siRNA compared to NT.  
Western blotting 
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Following 72 hours of treatment of MDA-MB-231 and ZR-75.1 with 
MDM2-, PSMA- and non-targeting siRNA, cells were scraped from 
the 6-well plate into 50 µl RIPA buffer (with added inhibitors), left on a 
blood wheel for 1 hour at 4˚C, then centrifuged for 15 minutes at 
13,000 X G.  Following this, an equal amount of 2 x Llaemelli was 
added and SDS-PAGE, western blotting and immune-probing using 
caspase-3, caspase-8,caspase-9 and GAPDH (antibody list in Table 
2.4) was undertaken as outlined in 2.5.1.   
Statistical analysis 
Data was statistically analysed using either t-test or two-way ANOVA, 
with a P-value of <0.05 considered statistically significant. Asterisk (*) 
notation was used to signify significances: * P<0.05, ** P<0.01, *** 
P<0.001 and **** P<0.0001.   
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4.3. Results 
The effect of MDM2 and PSMA knockdown on breast cancer cell 
proliferation  
Assessment of proliferation of MDA-MB-231 and ZR-75.1 breast 
cancer cell lines was undertaken using the Alamar blue proliferation 
assay.  Cell proliferation was assessed at 24 hour intervals following 
MDM2, PSMA and NT siRNA treatment.  MDA-MB-231 cells showed 
no significant difference between MDM2, PSMA or both siRNAs 
compared to NT control at either the 24 or 48 hour time points.  
However, following 72 hours of treatment, the decrease in growth of 
all targeted treatments compared to the NT control became highly 
significant (MDM2 siRNA p=0.0002; PSMA siRNA p=0.0001; 
MDM2/PSMA siRNAs p=0.0008) (Figure 4.1.a).   
ZR-75.1 cells also showed no significant difference between the 
targeted treatments and then NT control at 24 hours, but did show a 
significance at both 48 (MDM2 siRNA p=0.002; PSMA siRNA 
p=0.0002; MDM2/PSMA siRNAs p=0.0001) and 72 hours post-
treatment (MDM2 siRNA p<0.0001; PSMA siRNA p<0.0001; 
MDM2/PSMA siRNAs p<0.0001) (Figure 4.1.b).  
When siRNA- treated cells were imaged, a significant change in the 
visible cell morphology was seen.  MDA-MB-231 cells seemed 
unable to form their usual spindle-shape and ZR-75.1 cells were 
unable to form their typical clusters.  PSMA siRNA treatment, on the 
other hand, conveyed no visible effect on cell morphology and the  
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Figure 4.1. Proliferation ability of MDA-MB-231 and ZR-75.1 breast cancer 
cells following 72 hours of MDM2 or PSMA siRNA treatment.  a) 
Proliferation of MDA-MB-231 cells following 24, 48 and 72 hours of MDM2-, 
PSMA- or non-targeting siRNA treatment.  Graph shows mean RFU+SD 
(representative data; individual experiments carried out with six repeats; n=3).  
b) Proliferation of MDA-MB-231 cells following 24, 48 or 72 hours of MDM2-, 
PSMA- or non-targeting siRNA treatment.  Graph shows mean RFU+ SD 
(representative data; individual experiments carried out with six repeats; n=3). 
(All data statistically analysed using two-way ANOVA, with *** p<0.001 and 
**** p<0.0001).  c) 72 hour cell images of MDA-MB-231 cells treated with 
MDM2, PSMA, MDM2/PSMA or NT siRNA.  d) 72 hour cell images of ZR-75.1 
cells treated with MDM2, PSMA, MDM2/PSMA or NT siRNA. 
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cells treated with both siRNAs exhibited an intermediate phenotype 
(Figure 4.1.c and d).   
The effect of MDM2 and PSMA siRNA treatment on cell cycle in 
breast cancer cells 
To assess any changes in cell cycle, MDA-MB-231 and ZR-75.1 cells 
were treated with MDM2, PSMA or NT siRNA for 72 hours and then 
assessed for their involvement in the various stages using flow 
cytometry. 
Comparing MDM2 siRNA treatment to NT siRNA, MDA-MB-231 cells 
showed a 3.9% increase in cells in G1 phase (p=0.0037), a 2.5% in-
crease in G2 phase (p=0.0262) a 4.3% decrease in cells in S phase 
(p=0.0003). On the other hand, PSMA siRNA treatment showed a 
3.1% decrease in G1 phase (p=0.0232), a 4.2% increase in G2 
phase (p=0.0015) and a 2.9% increase in S phase (p=0.023) (Figure 
4.2a-c representative; Figure 4.2d).           
In ZR-75.1 cells, MDM2 siRNA treatment led to a 6.6% increase of 
cells in G1 phase (p=0.0046), a 4.3% increase in G2 phase 
(p=0.0035) and a 7.5% decrease in S phase (p=0.0002), compared 
to the NT control.  PSMA siRNA led to an increase of 5.2% in G1 
phase (p=0.0058), 4.1% decrease in G2 phase (p=0.0058) but no 
significant change in the percentage of cells in S phase (Figure 4.3a-
c representative; Figure 4.3d). 
4. Chapter IV: Results 
 
175 
 
Figure 4.2. The effect of 72 hours of MDM2 and PSMA siRNA on 
MDA-MB-231 cell cycle. a) % of cells in stages of ce ll cycle 
following NT siRNA treatment. b) % of cells in stages of cell cycle 
following MDM2 siRNA treatment. c) % of cells in stages of cell 
cycle following PSMA siRNA treatment. d) Percentage of MDA-MB-
231 cells in gap 1 (G1), gap 2 (G2) and synthesis (S) phases 
following NT, MDM2 and PSMA siRNA treatment.(Graph shows % 
of cells in stage+SD; n=3).  (Data statistically analysed using 
unpaired t-test: *p<0.05, ** p<0.01 and p<0.001).  
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Figure 4.3. The effect of 72 hours of MDM2 and PSMA siRNA ZR-75.1 cell 
cycle. . a) % of cells in stages of cell cycle following NT siRNA treatment. b) % 
of cells in stages of cell cycle following MDM2 siRNA treatment. c) % of cells in 
stages of cell cycle following PSMA siRNA treatment. d) Percentage of ZR-75.1 
cells in G1, G2 and S phases following NT, MDM2 and PSMA siRNA treatment. 
(Graphs show % of cells in stage+SD; n=3).  (Data statistically analysed using 
unpaired t-test: *p<0.05, ** p<0.01 and p<0.001).  
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The effect of MDM2 and PSMA knockdown on breast cancer 
apoptosis 
MDA-MB-231 and ZR-75.1 breast cancer cells, following treatment 
with MDM2, PSMA or NT siRNA were assessed for their apoptotic 
ability, as well as their resistance to an apoptotic agent 
(staurosporine).  MDA-MB-231 cells showed a significant increase 
(p=0.0274) in early stage apoptosis in those cells treated with MDM2 
siRNA, compared to those treated with the NT control siRNA.  When 
these cells, treated with MDM2 siRNA, were also subjected to 
treatment with staurosporine, there was an even more significant 
increase (p=0.0055) (Figure 4.4a shows representative figure; Figure 
4.4b shows n=3) in the percentage of MDM2 siRNA-treated cells in 
early stage apoptosis, compared to the NT control (Figure 4.4c).     
A similar result was seen in the ZR-75.1 cells (representative data 
shown in Figure 4.5a), with a significant increase in cells undergoing 
early stage apoptosis both untreated and treated with staurosporine 
(Figure 4.5b) (before: p=0.0101; after p=0.0461) when treated with 
MDM2 siRNA, compared to the NT control siRNA.  In addition, 
MDM2 siRNA treated ZR-75.1 cells, also showed a significant 
decrease in live cells when left untreated (p=0.0155).   
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Figure 4.4. Early and late apoptosis of MDA-MB-231 cells treated with 
MDM2 or PSMA siRNA. a) Percentage of live (bottom left), early apoptotic 
(bottom right) or late apoptotic (top right) MDA-MB-231 cells following 72 
hours of treatment with NT, MDM2 or PSMA siRNA (representative data). b) 
Percentage of live, early apoptotic or late apoptotic MDA-MB-231 cells 
following 72 hours of treatment with NT, MDM2 or PSMA siRNA, followed 
by 1.5 hours of staurosporine treatment (representative data). c) 
Percentage of cells in each cell stage (live, early apoptosis and late 
apoptosis following 72 hours of siRNA treatment (graphs show % cells+SD; 
n=3). d) Percentage of cells in each cell stage (live, early apoptosis and late 
apoptosis following 72 hours of siRNA treatment and 1.5 hours of 
staurosporine treatment (graphs show % cells+SD; n=3).  (All data 
statistically analysed using unpaired t-test, with * p<0.05 and ** p<0.01).  
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Figure 4.5. Early and late apoptosis of ZR-75.1 cells treated with MDM2 or 
PSMA siRNA. a) Percentage of live (bottom left), early apoptotic (bottom right) or 
late apoptotic (top right) ZR-75.1 cells following 72 hours of treatment with NT, 
MDM2 or PSMA siRNA (representative data). b) Percentage of live, early apoptotic 
or late apoptotic ZR-75.1 cells following 72 hours of treatment with NT, MDM2 or 
PSMA siRNA, followed by 1.5 hours of staurosporine treatment (representative 
data). c) Percentage of cells in each cell stage (live, early apoptosis and late 
apoptosis following 72 hours of siRNA treatment (graphs show % cells+SD; n=3). 
d) Percentage of cells in each cell stage (live, early apoptosis and late apoptosis 
following 72 hours of siRNA treatment and 1.5 hours of staurosporine treatment 
(graphs show % cells+SD; n=3).  (All data statistically analysed using unpaired t-
test, with * p<0.05 and ** p<0.01).  
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 The effect of MDM2 and PSMA knockdown on caspase levels in 
breast cancer cells 
Following the changes seen in apoptosis in both breast cancer cell 
lines, caspase levels were assessed for alterations in comparison to 
the NT control.  
 Initially, MDA-MB-231 cells were assessed for their caspase gene 
and protein levels, 72 hours of siRNA treatment of the same time of 
siRNA treatment as well as 1.5 hours of staurosporine treatment.  
Caspase-3 gene levels was seen to significantly increase (p=0.0094) 
in those MDA-MB-231 cells with MDM2 siRNA + staurosporine 
treatment, compared to when cells were untreated (Figure 4.6.a). No 
significant differences in caspase-7 gene levels were seen compared 
to NT control, or when comparing no treatment to staurosporine 
(Figure 4.6.b). Caspase-8 gene levels were seen to significantly 
increase following PSMA siRNA + staurosporine treatment 
(p=0.0048) (Figure 4.6.c), compared to no staurosporine treatment.  
Also, PSMA siRNA treated cells showed a significantly higher 
expression of caspase-8 than NT siRNA following staurosporine 
treatment (p=0.0025)   No significant differences in caspase-9 
expression were seen following any treatments (Figure 4.6.d).
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Figure 4.6. Assessment of caspase levels in MDA-MB-231 cells 
following 72 hours of siRNA treatment and with or without 1.5 hours of 
staurosporine treatment. a) Caspase-3 gene levels as a percentage of NT 
siRNA untreated with staurosporine expression. b) Caspase-7 gene levels 
as a percentage of NT siRNA untreated with staurosporine expression. c) 
Caspase-8 gene levels as a percentage of NT siRNA untreated with 
staurosporine expression. d) Caspase-9 gene levels as a percentage of NT 
siRNA untreated with staurosporine expression. (All graphs show % NT 
control with no treatment+SD; n=3) (Data statistically analysed using 
unpaired t-test with ** p<0.01).  e) Western blot of caspase -3, -8 and -9 
expression following MDM2, PSMA or NT siRNA treatment, with or without 
staurosporine treatment. (Blots show representative data; n=3).  
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Assessment of caspase-3, -8 and -9 protein levels showed a similar 
increase in caspase-3 following MDM2 siRNA + staurosporine 
treatment compared to those untreated with staurosporine.  In 
addition, caspase-3 levels were shown to increase in those cells 
treated with MDM2 siRNA + staurosporine, and decrease in cells 
treated with PSMA siRNA + staurosporine, compared to NT siRNA + 
staurosporine.  Unfortunately, protein assessment of caspase-7 
levels was unsuccessful (data not shown). Caspase-8 protein 
expression increased following staurosporine treatment; however, no 
differential expression was seen between each siRNA treatment.  
When caspase-9 protein expression was analysed, PSMA siRNA-
treated cells were shown to express the protein at high levels 
following staurosporine treatment, compared to both PSMA siRNA 
with no treatment and NT siRNA + staurosporine (Figure 4.6.e).   
Following this, ZR-75.1 cells were treated in the same way and gene 
and protein levels were assessed.  Gene expression studies showed 
no significance between any of the siRNA treatment, with or without 
staurosporine treatment (Figure 4.7.a, b, c & d). However, assess-
ment of protein levels still showed some differentiation in expression 
throughout the treatment.  MDM2 siRNA + staurosporine treatment 
showed high levels of caspase-3 expression compared to both 
MDM2 siRNA with no treatment and NT siRNA + staurosporine.   
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Figure 4.7. Assessment of caspase levels in ZR-75.1 cells following 72 
hours of siRNA treatment and with or without 1.5 hours of staurosporine 
treatment. a) Caspase-3 gene levels as a percentage of NT siRNA untreated 
with staurosporine expression. b) Caspase-7 gene levels as a percentage of NT 
siRNA untreated with staurosporine expression. c) Caspase-8 gene levels as a 
percentage of NT siRNA untreated with staurosporine expression. d) Caspase-9 
gene levels as a percentage of NT siRNA untreated with staurosporine 
expression. (All graphs show % NT control with no treatment+SD; n=3) (Data 
statistically analysed using unpaired t-test).  e) Western blot of caspase -3, -8 
and -9 expression following MDM2, PSMA or NT siRNA treatment, with or 
without staurosporine treatment (Blots show representative data; n=3).  
 
4. Chapter IV: Results 
 
184 
 
Caspase-8 expression was shown to be decreased in MDM2 siRNA 
+ staurosporine treatment compared to NT control +staurosporine.  
MDM2 siRNA showed an increase in caspase-9 protein expression in 
both no treatment and staurosporine treated cells compared to other 
treatments (Figure 4.7.e). 
4. Chapter IV: Results 
 
185 
 
4.4. Discussion 
Within the primary tumour, and subsequent tumours which may form, 
it is important for cells to gain the ability to proliferate in an 
uncontrolled manner, as well as to evade apoptosis.  This chapter 
aims to assess these functional abilities of breast cancer cells which 
harbour MDM2 or PSMA knockdown.  
Assessment of proliferation in MDM2 and PSMA treated MDA-MB-
231 and ZR-75.1 cells showed a decrease from both knockdowns 
over a 72 hour period.  However, ZR-75.1 showed a significant 
change in proliferation at an earlier stage post-siRNA treatment, with 
a highly significant difference being seen between MDM2, PSMA or 
both siRNAs and the NT control at both 48 and 72 hour time points.  
On the other hand, MDA-MB-231 cells only showed a significant 
difference of each treatment compared to the NT control at 72 hours, 
and the significance was less than the 72 hour time point of ZR-75.1 
cells.  This may be due to the more significant knockdown of both 
MDM2 and PSMA in ZR-75.1 compared to MDA-MB-231 cells, 
leading to a more profound effect on proliferative abilities of the cells.  
It could also, at least in terms of MDM2 expression, be explained by 
the fact that ZR-75.1 carry wild-type p53, whereas MDA-MB-231 
carry a mutated version of the gene.  It has long been known that in 
cancer cells, MDM2 overexpression leads to an increased 
proliferative ability of cells (Teoh et al., 1997, Wang et al., 2012).  
This effect was thought to be due to the negative regulatory role 
played by MDM2 towards p53 leading to a decrease in the ability of 
4. Chapter IV: Results 
 
186 
 
p53 to halt the cell cycle, and thus an increased cell proliferation. 
This hypothesis is supported in many reports by different groups with 
one group reporting that using nutlin-3a, an inhibitor of the interaction 
between MDM2 and p53 led to a decrease in the proliferative ability 
of osteosarcoma cells (Wang et al., 2012).   Qi et al., (Qi et al., 2014) 
suggested a p53-dependent stabilisation of MDM2 through direct 
binding with the DNAJ/heat shock protein 40, DNAJB1, in MCF7 
breast cancer cell proliferation.  However, a later study by the same 
group indicated another way in which MDM2 suppression could 
inhibit proliferation may be p53-independent via translational 
regulation in retinoblastoma cells (Qi and Cobrinik, 2016). Another 
study also supports this hypothesis and claims that MDM2 is also 
involved in p53-independent activities and plays a role in oestrogen-
activated MCF7 breast cancer cell proliferation, with p53 not being 
the key target of MDM2 in this pathway (Brekman et al., 2011).  
Therefore, this could provide reasoning as to why we see a decrease 
in proliferation in both p53 mutant and wild-type cell lines harbouring 
MDM2 knockdown. It is also to bear in mind that although the 
proliferation changes were statistically significant, the actual changes 
were not very obvious and so perhaps in vivo setting, may not be 
very significant.  
In terms of the current view on PSMA involvement in cancer cell 
proliferation, it is widely believed that the molecule is a positive 
regulator of proliferation of prostate cancer cells, though currently no 
data exists in breast cancer cells.  Yao et al., (Yao et al., 2010) found 
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that a PSMA increase in PC3 cell lines increases the folate uptake 
ability of cells and thus confers a proliferative advantage.  In addition, 
the same group has published multiple papers assessing how PSMA 
knockdown in prostate cancer LNCaP cells affects them, with a 
conclusion that PSMA decrease leads to a lowered proliferative 
ability of cells and a suggestion that PSMA may be a novel regulator 
of p38 (Guo et al., 2011, Zhang et al., 2013, Guo et al., 2014).  
Therefore, the results seen in my work are strongly supported by 
current literature.  
Also, interestingly, when MDM2, PSMA, MDM2/PSMA and NT siRNA 
cells were imaged, a change in morphology could be visualised in 
those cells treated with MDM2 siRNA.  These cells were unable to 
form their typical spindle shape in MDA-MB-231 and clusters in ZR-
75.1.  Changes in cellular morphology following MDM2 knockdown 
have been reported before (Yang et al., 2006), with this group 
claiming that decreased MDM2 reduces the level of E-cadherin, 
which leads to the loss of cell-cell contract and changes in cell 
morphology.  
When the differences in cell cycle were assessed in the cell lines 
treated with MDM2 and PSMA siRNA, it was shown that MDM2 
siRNA leads to similar changes in both MDA-MB-231 and ZR-75.1 
cell lines, in that each show an increase in the G1 and G2 phases 
and a decrease in those in S phase.  However, the difference is more 
profound in the ZR-75.1 cell line, with the percentage of cells being 
almost double that shown in MDA-MB-231.  Again, this could be due 
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to the higher level of knockdown or the p53 state of the cells.  
Currently, studies show that MDM2 can induce cell cycle arrest at G1 
stage in normal human and murine cells (Brown et al., 1998, Frum 
and Deb, 2003) and that p53 is involved in the G2 to M transition, as 
well as the G1 checkpoint (Shaw, 1998; Agarwar et al., 1995). This 
could explain why MDM2 knockdown shows an increase in the 
percentage of cells in G1 phase and subsequently why we see a 
decrease in the percentage of cells at S phase.  However, it does not 
explain why the number of cells in G2 phase also increases.  The 
data imply, however, that the decrease in the number of cells in S-
phase may be the reason for the decrease in proliferation we see 
following MDM2 siRNA treatment.  It also implies that MDM2 may 
cause cell cycle arrest at both G1 and G2 stages of the cell cycle.  It 
is also important to point out that the arrest of cell cycle by MDM2 
goes against what we know about the protein.  However, it has been 
reported in previous studies and it could be that the percentage 
changes are so small, although significant, that the arrests at G1 and 
G2 are cancelled out by the increase in cells at S-phase, which is 
why MDM2 leads to a decrease in proliferation of cells overall.  
Cell cycle analysis of breast cancer cells following PSMA knockdown 
showed highly interesting results.  The MDA-MB-231 and ZR-75.1 
cell lines showed opposing results to one another.  PSMA 
knockdown in MDA-MB-231 led to a decrease in the percentage of 
cells in G1 phase and an increase in S and G2 phases.  However, 
ZR-75.1 cells showed an increase in the percentage of cells in G1 
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phase and a decrease in those in G2 phase, with no change in the 
percentage of cells in S phase.  This implies that PSMA may play 
different roles in different types of breast cancers, in terms of its 
effect on the cell cycle.  Previous reports in the literature have shown 
differing effects of PSMA on cell cycle.  Rajasekaran et al., (2009) 
identified a role of PSMA in mitosis and showed that ectopic 
expression of PSMA in PC3 prostate cancer cell lines led to an 
increase in the exit from mitosis for cells.  Later studies showed that 
inhibition of PSMA increases G1 phase and decreases S and G2 
phases (Zhang et al., 2012, Guo et al.¸2014).  These results are 
similar to those seen in the ZR-75.1 cell line, although no significant 
change in S-phase was observed in our data; but oppose those seen 
in MDA-MB-231.   
Since proliferation and the cell cycle are often known to be altered in 
cancer cells, we also investigated another process which is often 
circumvented by tumour cells– apoptosis. Annexin V-FITC and PI 
were used in order to assess the number of cells which were alive, in 
early stage apoptosis or in late stage apoptosis/undergoing necrosis.   
 Initially, cells were treated with each siRNA for 72 hours and then 
either left untreated or treated with the apoptotic agent staurosporine 
for 1.5 hours.  In MDA-MB-231 cells, MDM2 siRNA treatment led to a 
significant increase in early stage apoptosis from the NT siRNA.  A 
trend of decrease in live cells was also seen following MDM2 siRNA 
treatment; however, this was not significant over three repeats.  The 
same was seen in ZR-75.1 cells, with MDM2 siRNA treatment again 
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leading to an increase in early stage apoptosis from NT siRNA in 
both untreated and staurosporine treated cells.    In addition, the 
number of live cells significantly decreased from NT siRNA in 
untreated cells with MDM2 siRNA treatment.  This implies that cells 
either just begun to undergo apoptosis, or that cells are maintained in 
this state, without crossing through to late stage or dying.  In addition, 
it is worth noting that the increase in early stage apoptosis from NT to 
MDM2 siRNA was of a higher percentage in ZR-75.1 cells.  In 
untreated cells, the increase was over two-fold, compared to MDA-
MB-231 where the increase was just 1.25-fold.  Following 
staurosporine treatment, ZR-75.1 again showed an over two-fold 
increase in early stage apoptotic cells, whilst MDA-MB-231 showed a 
1.45-fold change.  This is what would be expected since ZR-75.1 is 
p53 wild-type and when MDM2 is knocked down in these cells, p53 is 
no longer governed and so cell death may occur.  However, MDA-
MB-231 following MDM2 siRNA knockdown also showing an 
increase in early stage apoptosis implicates MDM2 in other, p53-
independent, apoptotic regulatory processes.   
It is also interesting to note that, although the data did not reach 
significance over the three repeats, following staurosporine 
treatment, both MDM2 siRNA and PSMA siRNA treated MDA-MB-
231 cells showed a decrease in the number of cells in late stage 
apoptosis/necrosis.  In addition, both of the targeted siRNA cell 
treatments led to an increase in the number of live cells, although 
again this was not significant over the three experiments undertaken.  
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In ZR-75.1 cells, MDM2 siRNA followed by staurosporine treatment 
showed, although not to significance, a decrease in the number of 
cells in late stage apoptosis/necrosis; but no difference in the number 
of live cells compared to the NT control siRNA.  However, 
interestingly, PSMA siRNA followed by staurosporine treatment 
showed a trend of increase in late stage apoptosis/necrosis and a 
decrease in the number of live cells.  Therefore, opposing effects 
were seen from PSMA siRNA treatment on the two different cell 
lines.   
In terms of what is reported in the literature, it is well known that a 
decrease in MDM2 results in p53 tumour suppressor being free to 
halt cell cycle progression and cause cellular apoptosis (Rozieres et 
al., 2000), and so data has already been presented showing that 
MDM2 promotes apoptosis in many reports (Wang et al., 2012, Lai et 
al., 2012).  However, the only study which breaks down the stages of 
apoptosis is by Daniele et al., (Daniele et al., 2015) and this reports 
that a significant increase of both early and late stage apoptosis is 
seen following treatment of Glioblastoma Multiforme cancer stem 
cells when cells are treated with MDM2 inhibitor ISA27.  On the other 
hand, there are papers which suggest that MDM2 may play a p53-
independent role in the promotion of apoptosis (Dilla et al., 2011; Lee 
et al., 2015; Bouska et al., 2009).   
Only one report of the link between PSMA and apoptosis has been 
published, with Huang et al., (2014) stating that inhibition of PSMA 
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promotes apoptosis. This falls in line with the trend we have seen in 
ZR-75.1 cells but is the opposite from what is seen in MDA-MB-231.  
Following this, caspase levels were assessed in order to find a 
possible link between these molecules and what was seen in the 
apoptosis assays. In MDA-MB-231 cells, caspase-3 gene expression 
levels were seen to significantly increase in those cells treated with 
MDM2 siRNA, from untreated to staurosporine treated.  This was 
echoed at protein level.  In addition, caspase-3 protein levels in cells 
treated with MDM2 siRNA were increased and those treated with 
PSMA siRNA were decreased from NT siRNA, following 
staurosporine treatment. Caspase-8 gene expression levels were 
seen to increase from untreated to staurosporine treatment and an 
increase in protein levels was seen between all of the untreated and 
treated samples.  No differences were seen in caspase-9 gene 
expression levels but protein levels were shown to be heightened in 
those cells treated with PSMA siRNA with staurosporine, both over 
the NT control with staurosporine and the PSMA siRNA untreated 
cells.  This implies that although some protein level increases did 
agree with their gene expression changes, there is likely to be post-
transcriptional regulation of caspase levels following knockdown of 
MDM2 and PSMA. Thus far, there are no studies connecting PSMA 
to the caspases and those which link MDM2 to the molecules identify 
them to be working upstream (Oliver et al., 2011; Pochampally et 
al.¸1998; Pochampally et al., 1999).   
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In ZR-75.1 cells treated with each of the siRNAs, with or without 
staurosporine, no significant differences were seen in gene 
expression although a general trend of increased caspase 
expression was seen between those cells untreated and treated with 
staurosporine.  However, differences were still seen at protein level, 
with MDM2 siRNA + staurosporine treatment compared to MDM2 
siRNA without treatment and also compared to NT control + 
staurosporine treatment.  In this cell line, caspase-3 protein levels in 
PSMA siRNA treated cells were unchanged compared to the NT 
control following staurosporine treatment. Caspase-8 protein levels 
were decreased and caspase-9 levels increased after MDM2 siRNA 
treatment compared to NT siRNA following staurosporine treatment.   
A difference in expression of caspase protein was seen between the 
two different cell lines following each treatment and may indicate that 
MDM2 and PSMA play varying roles in caspase expression 
regulation between different types of breast cancer.  
 It is interesting to see that in ZR-75.1 cells, PSMA siRNA treatment 
results in no changes to caspase protein levels, whereas in MDA-
MB-231 caspase-3 levels are lower than in the NT following 
staurosporine treatment, although caspase-9 levels are increased.  
Caspase-9 is an initiator caspase and is responsible for the activation 
of executioner caspases such as caspase-3 (Chang et al.¸2003; 
Riedl & Shi, 2004; McIlwain et al., 2016).  Therefore, even though the 
levels of caspase-9 is increased, if there is no caspase-3 to be 
activated, the level of caspase-3 degradation will still be lower.  
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Interestingly, caspase-3 has been linked to the regulation of PS 
externalisation of erythrocytes (Mandal et al., 2002) and if this were 
to be the same in cancer cells, the lack of caspase-3 may explain 
why MDA-MB-231 cells show a decreased level of cell death with 
PSMA knockdown, but ZR-75.1 show an increase, which is what 
would be expected from the results of other studies (Huang et al., 
2014).   
Therefore, in conclusion, it seems that MDM2 and PSMA show 
similar effects on breast cancer cell proliferation but varying effects in 
terms of apoptotic ability of cells as well as the part they play in the 
cell cycle.  It is also important to note that PSMA seems to play 
different roles in the two cell lines which were used, suggesting 
possible multiple roles for this protein dependent on breast cancer 
cell type.  
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Chapter V 
Knockdown of MDM2 
and PSMA in breast 
cancer cell lines leads 
to a decrease in their 
migratory and invasive 
capacity through the 
action via matrix 
metalloproteinases 
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5.1. Introduction 
The spread of cancers via the movement of tumour cells relies on a 
number of vital biological processes which allow the cells to break 
down, migrate and invade the extracellular matrix (ECM) and 
subsequently metastasise.  Cancer cells have many ways in which 
they can influence this situation, most significantly by altering the 
expression of components key to these processes (Hanahan & 
Weinberg, 2011).  
  A family of molecules heavily implicated in the migration and 
invasion of cells through the ECM is the matrix metalloproteinases 
(MMPs).  The MMPs are known to break down the components of 
the ECM, with different family members playing varying roles and 
targeting different molecules (Page-McCaw et al., 2007).  
Studies have linked both MDM2 and PSMA to the MMPs, as well as 
more generally to migration and invasion of cells.   MDM2 has been 
connected to MMP9 in numerous studies, with immunohistochemical 
(IHC) staining of IDC showing a significant correlation between the 
expression of MDM2 and MMP9 (Chen et al.¸2013), as well as the 
expression of the two proteins being linked in the oncogenesis of 
lung cancer in rats (Zhang et al., 2014).  Studies have also linked 
MDM2 to invasion, both in vitro (Yang et al., 2006) and in 
vivo (Rajabi et al.¸2012).  PSMA has been positively correlated with 
MMP9 expression in mouse prostate cancer cells (Zhao et al.¸2012).  
In addition, PSMA has been linked to MMP2, through which it is 
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believed to work to generate small peptides which can augment the 
invasive and adhesive abilities of endothelial cells (Conway et al.¸ 
2013).   Moreover, a study was recently published in which PSMA 
knockdown in the prostate cancer cell line, LNCaP, was linked to the 
gene expression of MMP2, MMP3 and MMP13, as well as MDM2 
(Xu et al., 2013).    
Therefore, we aimed to investigate the functional consequences of 
MDM2 and PSMA knockdown in breast cancer cell lines, and what 
this means in terms of MMP expression, in order to elucidate a 
possible interplay between the two proteins under study.  
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5.2. Materials & Methods 
Cell lines and treatments 
MDA-MB-231 and ZR-75.1 metastatic breast cancer cell lines, 
maintained in DMEM media with 10% FBS and antibiotics, were used 
in this chapter. These cell lines were transiently transfected with 
MDM2, PSMA or non-targeting (NT) siRNA using Fect4 or Fect1 
transfection reagents, respectively. All treatments were undertaken in 
a 6-well plate and a total volume of 1ml of treatment was used in 
each case. MDA-MB-231 cells were treated with 100 nM of each 
siRNA and ZR-75.1 cells were treated with 50 nM, according to the 
manufacturer’s instructions, following optimisation experiments.  
Treatments were undertaken for 48 or 72 hours, dependent on the 
experiment.    
Transwell migration assay 
MDA-MB-231 and ZR-75.1 cells were treated with MDM2, PSMA and 
NT siRNA for 48 or 72 hours. The experiments were carried out three 
independent times over a 4 hour period and the individual 
experiments as outlined in 2.6.3.  Data were analysed using unpaired 
t-test of each MDM2- and PSMA-targeting siRNA compared to NT.   
Scratch wound healing assay 
MDA-MB-231 and ZR-75.1 cells were treated with MDM2, PSMA and 
NT siRNA for 72 hours.  Following this, cells were scratched using a 
pipette tip and imaged at time points depending on the healing speed 
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of the cells.  Each experiment was carried out in triplicate, with the 
full protocol is shown in 2.6.5.  Data were analysed using two-way 
ANOVA of MDM2 and PSMA siRNA compared to NT.  
Transwell invasion assay 
MDA-MB-231 and ZR-75.1 cells were treated with MDM2, PSMA and 
NT siRNA for 48 or 72 hours.  The experiments were carried out 
three independent times over a 24 hour period and the individual 
experiments were undertaken as outlined in 2.6.4.  Data were 
analysed using unpaired t-test with Welch’s correction of each MDM2 
and PSMA siRNA compared to NT.   
Endothelial cell adhesion assay 
A HMVEC monolayer was allowed to form in a 24-well plate by 
seeding 3 x 105 cells/well.  Following 72 hours of siRNA treatment, 
cancer cells were fluorescently stained and 4 x 104 cells/well were 
allowed to adhere to the monolayer for 30 minutes as Section  2.6.2.  
Western blotting  
Following 48 and 72 hours of treatment of MDA-MB-231 and ZR-75.1 
with MDM2, PSMA and NT siRNA, cells were scraped from the 6-
well plate into 50 µl RIPA buffer (with added inhibitors), left on a 
blood wheel for 1 hour at 4˚C, then centrifuge for 15 minutes at 
13,000 X G.  Following this an equal amount of 2 x Llaemelli and 
SDS-PAGE, western blotting and immune-probing using MDM2, 
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phospho-MDM2 (serine 166) and GAPDH (antibody list in Table 2.4) 
was undertaken as outlined in 2.5.1.   
Immunocytochemistry 
MDA-MB-231 and ZR-75.1 cells were treated with MDM2, PSMA and 
NT siRNA for 48 hours and then 20,000 cells in 200 µl DMEM was 
added to each well of a chamber slide, before overnight incubation at 
37 ˚C.  The following morning the protocol outlined in 2.5.2. was 
undertaken using MDM2 (serine 166 antibody). 
RNA isolation and RT-PCR 
Following treatment of MDA-MB-231 and ZR-75.1 cells with MDM2, 
PSMA and NT siRNA for 72 hours in a 6-well plate, TRI reagent was 
added to cells.  RNA isolation and RT-PCR was then undertaken 
according to sections 2.4.1 and 2.4.2.  
Quantitative PCR (qPCR) 
qPCR was undertaken using cDNA produced in reverse transcription 
detailed above, using primers for MMP1, MMP2, MMP3, MMP7, 
MMP8, MMP9, MMP10, MMP11, MMP12, MMP13, TIMP1,TIMP2 
and GAPDH (listed in Table 2.3), following the procedure outlined in 
2.4.3.  CT values gained from this processes were analysed using 2-
ΔΔCT normalisation to GAPDH. Each qPCR sample was set up in 
triplicate, with the experiment being independently set up three times.  
Analysis was undertaken using unpaired t-test Welch’s correction of 
MDM2- and PSMA-targeting siRNA compared to NT.  
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RayBio® C-Series Human Matrix Metalloproteinase Antibody Array 
C1 
Following MDA-MB-231 and ZR-75.1 treatment with MDM2, PSMA 
and NT siRNA for 24 hours, serum-free media was added to the cells 
and this tumour-conditioned media (TCM) was harvested at 72 hours 
post-treatment.  This TCM was the assessed for MMP secretion by 
cancer cells according to the protocol outlined in section 2.5.4.  
Flow cytometric analysis of MMP2 and MMP8 levels 
Following treatment of MDA-MB-231 and ZR-75.1 cells with MDM2, 
PSMA and NT siRNA for 72 hours, intracellular MMP2 and MMP8 
expression was assessed as detailed in 2.5.3.  
MMP inhibitor studies 
To inhibit MMP2 in MDA-MB-231 and ZR-75.1, cells were treated 
with 6nM ARP100 and 12nM Marimastat.  To inhibit MMP8, cells 
were treated with 4nM MMP8 inhibitor. Following this, proliferation, 
migration and invasion assays were undertaken as detailed in 2.6.1, 
2.6.3 and 2.6.4.  
IL-6 and IL-8 ELISA 
Following 48 hours of MDM2, PSMA and NT siRNA treatment, cells 
were washed with PBS and 500 µl serum-free media added to the 
well.  At 72 hours post-treatment, this media was removed from the 
cells and centrifuged at 1700 X G for 10 minutes to remove cellular 
debris.  The samples from MDA-MB-231 were diluted 1:5 and those 
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from ZR-75.1 were diluted 1:2.  The assays were then carried out as 
specified in Section 2.5.5. 
Statistical analysis 
Data was statistically analysed using either unpaired t-test with 
Welch’s correction or two-way ANOVA, with a P-value of <0.05 
considered statistically significant. Asterisk (*) notation was used to 
signify significances: * P<0.05, ** P<0.01, *** P<0.001 and P<0.0001.   
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5.3. Results  
The effect of MDM2 and PSMA knockdown on breast cancer cell 
migration 
Following MDM2-, PSMA- and non-targeting (NT) siRNA treatment 
on MDA-MB-231 and ZR-75.1 breast cancer cells for both 48 and 72 
hours, transwell migration assays were undertaken in order to 
elucidate the change in chemotactic migration, if any, over a 6 hour 
period, resulting from a decrease in MDM2 and PSMA protein levels.  
This assay involves the movement of cells towards a chemotactic 
factor, in this case FCS and aims to partially replicate the in vivo 
migration of cells from a primary tumour site, into the blood stream, 
which may then result in metastases occurring.  MDA-MB-231 cells 
exhibited a significant decrease in migration following MDM2-
targeting siRNA treatment, compared to the NT control at both 48 
hours (51.8% decrease, p=0.0099) and 72 hours (52.0% decrease, 
p=0.0193) (Figure 5.1a). The same was seen following PSMA-
targeting siRNA treatment, with 48 hours of treatment leading to a 
64.20% decrease in migratory capacity (p=0.0005) and 72 hours 
causing a 72.4% decrease (p<0.0001) (Figure 5.1b).   
Similar results were seen in the ZR-75.1 breast cancer cell line, with 
MDM2-targeting siRNA treatment resulting in a 67.4% decrease in 
migration through the transwell (p=0.0132) after 48 hours and a 
72.9% decrease after 72 hours of treatment (p=0.0072) (figure 5.1c).  
Again, PSMA-targeted siRNA led to a decrease in migratory 
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Figure 5.1. Migration capacity of MDA-MB-231 and ZR-75.1, over a 4 
hour period, of siRNA treated cells after 48 and 72 hours of treatment.  
a) Migration of MDA-MB-231 treated with MDM2 siRNA. b) Migration of 
MDA-MB-231 treated with PSMA siRNA. c) Migration of ZR-75.1 treated 
with MDM2 siRNA. d) Migration of ZR-75.1 treated with PSMA siRNA.  (All 
graphs are shown as % of NT control siRNA-treated cells +SD; n=3; each 
experiment undertaken in triplicate; significant differences calculated by un-
paired t-test with Welch’s correction; * p<0.05, ** p<0.01, **** p<0.0001).  
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tendencies in ZR-75.1, with 48 hours of treatment leading to a 
64.26% decrease in cell movement across the transwell (p=0.0001) 
and 72 hours causing a decrease of 89.6% (p<0.0001) (Figure 5.1d). 
Similar results were seen in the ZR-75.1 breast cancer cell line, with 
MDM2-targeting siRNA treatment resulting in a 67.4% decrease in 
migration through the transwell (p=0.0132) after 48 hours and a 
72.9% decrease after 72 hours of treatment (p=0.0072) (figure 5.1c).  
Again, PSMA-targeted siRNA led to a decrease in migratory 
tendencies in ZR-75.1, with 48 hours of treatment leading to a 
64.26% decrease in cell movement across the transwell (p=0.0001) 
and 72 hours causing a decrease of 89.6% (p<0.0001) (Figure 5.1d).      
In order to support this observation, wound healing (scratch) assays 
were carried out on both cell lines following treatment with each 
siRNA.  MDA-MB-231 cells completely healed within 3 hours, with a 
significant difference between the healing capability of the cells, 
compared to NT siRNA, when treated with MDM2 siRNA at 2 hours 
(p<0.0001).  However, the difference between PSMA and NT siRNA 
almost reaches significance after 1 hour (p=0.0645) and then the 
time to heal is significantly slower in cells treated with PSMA siRNA 
than NT at the 2 and 4 hour time points (2 hours p=0.0212; 4 hours 
p=0.0256) (Figure 5.2a and b). ZR-75.1 cells, on the other hand, took 
over 24 hours to heal and the NT siRNA-treated cells showed a stark 
and significantly higher wound healing capacity, compared to both 
MDM2 and PSMA siRNA treated cells (Figure  5.2c and d).  
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Figure 5.2. Scratch wound healing assay of siRNA-treated MDA-MB-231 and ZR-
75.1 cells. a) Representative images of wounded MDA-MB-231 treated with siRNA, 
over a 4 hour period of healing.   b) Assessment of the healing at three points on 
wounded MDA-MB-231 (% wound coverage ± SD) with p values of MDM2 and PSMA 
siRNA compared to NT shown in table, with statistically significant time points shown in 
red. c) Representative images of wounded ZR-75.1 treated with siRNA, over a 48 hour 
period of healing.   d) Assessment of the healing at three points on wounded ZR-75.1 
cells (% wound coverage ± SD) with p values of MDM2 and PSMA siRNA compared to 
non-targeting shown in table, with statistically significant time points shown in red. 
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The effect of MDM2 and PSMA knockdown on breast cancer cell 
invasion 
In the same way as the transwell migration assays were undertaken, 
invasion of cells over a 24 hour period, following knockdown of 
MDM2 and PSMA, was investigated.  This involved coating a 0.8µ 
pore transwell in Matrigel and allowing the siRNA-treated cells to 
invade, towards the chemoattractant in the receiver well. It was 
repeatedly seen that after 48 hours, MDM2 knockdown led to an 
enhanced invasive capacity of MDA-MB-231 which increased around 
36.5% compared to the non-targeting siRNA (p=0.0012).  However, 
72 hours after treatment, this was no longer the case, with a 
significant decrease in invasion of more than 50.8% being seen in 
both MDA-MB-231 (p=0.0004) (Figure 5.3 a).   Cells treated with 
PSMA siRNA showed no difference at 48 hours in MDA-MB-231 
cells. However,  the decrease in invasion was highly marked after 72 
hours of siRNA treatment, with MDA-MB-231 cells decreasing in their 
invasive capacity by 55.1% (p=0.0099) (Figure 5.3 b). 
A similar trend was seen in ZR-75.1 cells following 48 hours treat-
ment with MDM2 siRNA, and the invasive capacity increased by over 
100% (p=0.0004) (Figure 5.3c). Again, after 72 hours, with cells de-
creasing in their invasive capability by more than 50.2% (p=0.0308).  
PSMA-targeted siRNA treatment of ZR-75.1 cells led to a 43.3% de-
crease in invasion (p=0.0075) after 48 hours and an almost 90.9% 
decrease after 72 hours (p<0.0001) (Figure 5.3 d).  
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Figure 5.3. Invasion capacity of MDA-MB-231 and ZR-75.1, over a 24 hour 
period, of siRNA treated cells after 48 and 72 hours of treatment.  a) 
Invasion of MDA-MB-231 treated with MDM2 siRNA. b) Invasion of MDA-MB-
231 treated with PSMA siRNA. c) Invasion of ZR-75.1 treated with MDM2 
siRNA. d) Invasion of ZR-75.1 treated with PSMA siRNA.  (All graphs are 
shown as % of NT control siRNA-treated cells +SD; n=3; each experiment 
undertaken in triplicate; significant differences calculated by t-test with Welch’s 
correction; * p<0.05, ** p<0.01).  
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The effect of MDM2 and PSMA knockdown on breast cancer cell 
adhesion 
Following 72 hours of treatment with siRNA, the ability of 
fluorescently stained MDA-MB-231 and ZR-75.1 cells to adhere to an 
endothelial cell monolayer was assessed.  Following 30 minutes of 
time for cells to adhere, the number of cancer cells were assessed 
using a fluorescent plate reader.  The adherence of MDA-MB-231 
was seen to be highly effected by each knockdown; with MDM2 
siRNA, PSMA siRNA and both siRNAs all showing a highly 
significant decrease compared to the NT siRNA (p<0.0001) (Figure 
5.4a).  The effect of ZR-75.1 cell adhesion was less profound, 
although a significant decrease in the ability of the cells to adhere 
compared to NT siRNA from MDM2 siRNA (p=0.002), PSMA siRNA 
(p=0.020) and both siRNAs (p<0.0001) (Figure 5.4b).   
Phospho-MDM2 (ser166) levels 48 and 72 hours post-MDM2 siRNA 
treatment  
In an attempt to elucidate why 48 and 72 hours of MDM2-targeted 
siRNA treatment led to such surprisingly opposing results, 
phosphorylation levels of MDM2 at ser166 were investigated.  It was 
seen that 48 hours after MDM2 knockdown, phosphorylation of 
serine 166 on MDM2 was actually increased significantly compared 
to the non-targeting control in both MDA-MB-231 (Figure 5.5a) and 
ZR-75.1 (Figure 5.5b).  However, at 72 hours post-treatment, these 
levels have completely diminished (Figure 5.5c and d).   
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Figure 5.4. Adhesion capability of MDA-MB-231 and ZR-
75.1 cells to an endothelial cell monolayer. a) Adhesion of 
MDA-MB-231 treated with MDM2, PSMA, MDM2/PSMA or 
NT siRNA. b) Adhesion of ZR-75.1 treated with MDM2, 
PSMA, MDM2/PSMA or NT siRNA. (All graphs shown as 
RFU + SD; n=3; each experiment undertaken in triplicate; 
significant differences assessed using one-way ANOVA; * 
p<0.05, ** p<0.01 and **** p<0.0001).  
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Figure 5.5. MDM2 (serine 166) phosphorylation following MDM2 siRNA 
treatment. a)   MDM2 and MDM2 (serine 166) phosphorylation levels in 
MDA-MB-231 following 48 hours of MDM2 siRNA treatment. b) MDM2 and 
MDM2 (serine 166) phosphorylation levels in ZR-75.1 following 48 hours of 
MDM2 siRNA treatment.  c) MDM2 (serine 166) phosphorylation levels in 
MDA-MB-231 cells following 72 hours of MDM2 siRNA treatment. d) MDM2 
(serine 166) phosphorylation levels in ZR-75.1 cells following 72 hours of 
MDM2 siRNA. (All western blots are representative data; n=3).  e) 
Immunocytochemical staining of MDA-MB-231 cells treated with NT or 
MDM2 siRNA for 48 hours and stained with MDM2 (serine 166) antibody 
(representative images). 
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In addition, immunocytochemical staining was undertaken following 
treatment of MDA-MB-231 with MDM2 or NT siRNA for 48 hours.  
These cells were then probed with the phospho-MDM2 (serine 166) 
antibody.  Cells treated with NT siRNA showed medium positive 
staining of MDM2 phosphorylated at ser166 in both the cytoplasm 
and the nucleus.  However, those cells treated with MDM2 siRNA 
showed a distinct decrease in cytoplasmic staining and a strongly 
positive nuclear staining (Figure 5.5e).   
The effect of MDM2 and PSMA expression on matrix 
metalloproteinase (MMP) and tissue inhibitor of matrix 
metalloproteinase (TIMP) gene expression 
Following 72 hours of siRNA treatment, gene expression levels of 
MMP and TIMP were assessed in the MDM2 and PSMA siRNA-
treated cells compared to those treated with the NT siRNA control.  
MMP1 expression was seen to be unchanged following MDM2 
siRNA treatment in MDA-MB-231 cells but significantly 
downregulated following treatment with PSMA siRNA (p<0.0001).  
ZR-75.1 cells showed a significant decrease in MMP1 expression 
following treatment with each of the siRNAs (p<0.0001). MMP2 
expression was seen to be downregulated by each of the treatments 
in both cell lines (MDM2 siRNA p=0.0003; all others p<0.0001).  
MMP3 expression significantly increased following MDM2 siRNA 
treatment of MDA-MB-231 (p=0.0004) and ZR-75.1 (p<0.0001) cells, 
and after PSMA siRNA treatment (p=0.0482 and p<0.0001, 
respectively).  MMP7 expression levels were unchanged in both cells  
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lines following MDM2 siRNA treatment, but significantly increased 
following PSMA siRNA treatment (MDA-MB-231 p<0.0001; ZR-75.1 
p=0.0411).   
There were no significant changes in MMP8 expression following 
MDM2 and PSMA siRNA treatment in either cell lines.  An MMP9 
expression decrease was seen in both cell lines following MDM2 
siRNA treatment (MDA-MB-231 p<0.0001; ZR-75.1 p=0. 0003); 
however, PSMA treatment did not lead to significant change in 
expression levels.  MMP10 was seen to significantly increase in both 
cell lines after each treatment (MDA-MB-231: MDM2 siRNA 
p=0.0115, PSMA siRNA p=0.0014; ZR-75.1: MDM2 siRNA 
p<0.0001, PSMA siRNA p=0.0084).  MMP11 expression only 
increased significantly in MDA-MB-231 cells following PSMA siRNA 
treatment (p=0.0039), whilst the other treatments did not cause 
significant changes in either cell line.  There were no significant 
changes in MMP12 expression in either cell lines after any treatment.  
MMP13 expression was seen to significantly increase following both 
MDM2 siRNA (MDA-MB-231 p=0.0002; ZR-75.1 p<0.0001) and 
PSMA siRNA (MDA-MB-231 p<0.0001; ZR-75.1 p<0.0001).  TIMP1 
expression was not significantly changed in MDA-MB-231 cells 
following MDM2 siRNA treatment; however, treatment with PSMA 
siRNA led to a significant increase in expression (p=0.0008).  ZR-
75.1 cells showed a significant increase in expression following 
treatment with both MDM2 siRNA (p<0.0001) and PSMA siRNA 
(p<0.0001). Finally, TIMP2 expression was unchanged through 
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treatment with MDM2 siRNA and significantly increased following 
treatment with PSMA siRNA in both cell lines (MDA-MB-231 
p=0.0111; ZR-75.1 p<0.0001) (Figure 5.6). 
The effect of MDM2 and PSMA expression on matrix 
metalloproteinase (MMP) and tissue inhibitor of matrix 
metalloproteinase (TIMP) protein secretion 
To assess the MMP and TIMP secretion from breast cancer cell 
lines, the tumour-conditioned media was collected from siRNA-
treated MDA-MB-231 and ZR-75.1 cell lines and levels assessed 
using the RayBioTech Human MMP Array C1.  MDA-MB-231 cells 
showed a significant decrease was seen in MMP2 (MDM2 siRNA: 
p=0.0021; PSMA siRNA: p=0.0081) and MMP8 (MDM2 siRNA: 
p=0.0325; PSMA siRNA: p<0.0001). TIMP4 levels were also 
decreased to an almost significant level when MDM2 siRNA treated 
cells were compared to NT control treated cells (p=0.0597) (Figure 
5.7.b and c). In the ZR-75.1 cell line, again, MMP2 (MDM2 siRNA: 
p=0.0324; PSMA siRNA: p=0.0242) and MMP8 (MDM2 siRNA: 
p=0.0459; PSMA siRNA: p=0.0440) levels were seen to significantly 
altered in both cell lines treated with each siRNA.  In addition, a 
significant decrease in MMP9 secretion was seen in this cell line 
following each siRNA treatment, compared to the NT control (MDM2 
siRNA: p=0.0359; PSMA siRNA: p=0.0271) (Figure 5.7. b and d).   
Flow cytometric analysis was then undertaken in order to assess the 
internal MMP2 and MMP8 levels following 72 hours of treatment.   
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Figure 5.6. Gene expression of matrix metalloproteinases (MMPs) and 
tissue inhibitors of matrix metalloproteinases (TIMPs) in MDA-MB-231 
and ZR-75.1 following siRNA treatment.  (Data are mean fold change in 
expression compared to NT control + SD; n=3; individual experiments carried 
out in triplicate; significant differences calculated using unpaired t-test with 
Welch’s correction with * p<0.05, ** p<0.01, *** p<0.001 and p<0.0001).   
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Figure 5.7. Protein expression of MMPs and TIMPs following siRNA 
treatment in MDA-MB-231 and ZR-75.1. a) Human MMP array blot layout. 
b) Representative human MMP array blots following treatment with MDM2, 
PSMA and NT siRNA in MDA-MB-231 and ZR-75.1 cell lines. c) Secretion 
of MMPs and TIMPs in MDA-MB-231 following MDM2 and PSMA siRNA as 
a percentage of NT control (n=2; each experiment undertaken in duplicate; 
graphs show % of NT control +SD; significant differences calculated by t-
test with Welch’s correction, with * p<0.05, ** p<0.01, ****p <0.0001). d) 
Secretion of MMPs and TIMPs in ZR-75.1 following MDM2 and PSMA 
siRNA as a percentage of NT control (n=2; each experiment undertaken in 
duplicate; graphs show % of NT control +SD; significant differences 
calculated by t-test with Welch’s correction with * p <0.05, ** p<0.01).  
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Both cell lines showed a decrease in MMP2 protein levels when 
treated with MDM2- or PSMA-targeted siRNA, compared to the NT 
control.  In MDA-MB-231 cells, following gating to remove readings 
from any cellular debris or clusters, it was shown that MDM2 and 
PSMA siRNA resulted in a significantly lower level of MMP2 protein 
expression [MDM2 siRNA= 41.11% (p=0.0010) of cells and PSMA 
siRNA=17.83% of cells (p=0.0001)] compared to NT siRNA treated 
cells (72.02% of cells) (Figure 5.8a-d).  Similar results were seen in 
the ZR-75.1 cell line, with 80.88% of cells expressing MMP2 when 
treated with NT siRNA, but MDM2 and PSMA siRNA-treated cells 
showing a substantial decrease in expression [MDM2 
siRNA=35.47% of cells (p=0.0003) and PSMA siRNA=20.23% of 
cells(p<0.0001)] (Figure 5.9a-d).     
When MMP8 intracellular expression was monitored, it was seen that 
no differences in protein expression were seen, implying that the 
differences seen in MMP8 levels were due to a change in secretion 
of MMP8, not protein levels (Figures 5.10a-d and 5.11a-d). 
The effect of MMP2 and MMP8 inhibition on breast cancer cells 
In order to validate the hypothesis that matrix metalloproteinase se-
cretion decrease is the reason for the decrease in growth, migration 
and invasion of breast cancer cell lines, two MMP2 inhibitors were 
used: ARP100 (specific to MMP2 at 6nM) and Marimastat (specific to 
MMP2 at 12nM).   The proliferative potential of MDA-MB-231 cells 
following treatment with ARP100 showed a significant decrease in 
proliferation at all time points using two-way  ANOVA  (24 hours: 
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Figure 5.8. Flow cytometric analysis of MMP2 expression in 
MDA-MB-231. a) MMP2 expression of MDA-MB-231 treated with NT 
siRNA. b) MMP2 expression of MDA-MB-231 treated with MDM2 
siRNA. c) MMP2 expression of MDA-MB-231 treated with PSMA 
siRNA. (All graphs show representative data of MMP2 protein 
expression in each siRNA treatment compared to isotype control).  
d) Summary of MMP2 flow cytometric data (n=3; graph shows mean 
+ SD) (Significance assessed through unpaired t-test: ** p<0.01, *** 
p<0.001). 
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Figure 5.9. Flow cytometric analysis of MMP2 expression in 
ZR-75.1. a) MMP2 expression of ZR-75.1 treated with NT siRNA. 
b) MMP2 expression of ZR-75.1 treated with MDM2 siRNA. c) 
MMP2 expression of ZR-75.1 treated with PSMA siRNA. (All 
graphs show representative data of MMP2 protein expression in 
each siRNA treatment compared to isotype control).  d) 
Summary of MMP2 flow cytometric data (n=3; graph shows 
mean + SD) (Significance assessed through unpaired t-test: ** 
p<0.01, *** p<0.001). 
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Figure 5.10. Flow cytometric analysis of MMP8 expression in 
MDA-MB-231. a) MMP8 expression of MDA-MB-231 treated with 
NT siRNA. b) MMP8 expression of MDA-MB-231 treated with 
MDM2 siRNA. c) MMP8 expression of MDA-MB-231 treated with 
PSMA siRNA. (All graphs show representative data of MMP2 
protein expression in each siRNA treatment compared to isotype 
control).  d) Summary of MMP8 flow cytometric data (n=3; graph 
shows mean + SD) (Significance assessed through unpaired t-
test). 
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Figure 5.11. Flow cytometric analysis of MMP8 expression in 
ZR-75.1. a) MMP8 expression of ZR-75.1 treated with NT siRNA. b) 
MMP8 expression of ZR-75.1 treated with MDM2 siRNA. c) MMP8 
expression of ZR-75.1 treated with PSMA siRNA. (All graphs show 
representative data of MMP2 protein expression in each siRNA 
treatment compared to isotype control).  d) Summary of MMP8 flow 
cytometric data (n=3; graph shows mean + SD) (Significance 
assessed through unpaired t-test). 
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p=0.0221; 48 hours: p=0.0198; 72 hours: p<0.0001) .  However, 
treatment with Marimastat showed less significance, with no signifi-
cant difference from the DMSO control after 24 or 48 hours 
(p=0.0791 and p=0.2961, respectively) but a significant difference at 
72 hours (p=0.0039) (Figure 5.12a). Following this, migration and in-
vasion with each of the inhibitors were evaluated.  Migration was 
seen to decrease following treatment of both cell line with inhibitor 
compared to the relevant DMSO control.  Moreover, the DMSO con-
trol showed no significant difference from the wild-type cells in each 
case (data not shown) MDA-MB-231 cells showed a 53.4% decrease 
in migratory capacity when treated with 6nM ARP100 (p=0.0296), 
and a 56.7% decrease with 12nM Marimastat (p=0.0369) (Figure 
5.12b).  A decrease in invasion was also seen following both treat-
ments (6nM ARP100: p=0.0405; 12nM Marimastat p=0.0019) (Figure 
5.12c).   
Similarly, ZR-75.1 cells showed a decrease in their ability to prolifer-
ate when MMP2 was inhibited.  ARP100 treatment resulted in a de-
crease in proliferation only after 72 hours (p=0.0069) (Figure 5.13a), 
whereas a more obvious result was seen from Marimastat, which 
showed a growth decrease at 48 (p=0.0002) and 72 hours 
(p<0.0001) (Figure 5.13a). Migration (ARP100: 57.3% decrease, 
p=0.021; Marimastat: 48.7%, p=0.0342) (Figure 5.13b) and invasion 
(ARP100: 56.7%, p=0.0105; Marimastat: 41.2%, p=0.0127) (Figure 
5.13c) were also decreased following treatment of ZR-75.1 with both 
inhibitors.   
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Figure 5.12.  Effect of MMP2 inhibitors on MDA-MB-231 cell proliferation, 
migration and invasion. a) Proliferative capabilities of MDA-MB-231 cells following 
24, 48 and 72 hours of MMP-2 inhibitors (6nM ARP100 and 12nM Marimastat) 
(representative data; graphs show mean RFU+SD; n=3; each individual experiment 
carried out six times; significances calculated using two-way ANOVA). b) Migratory 
capacity of MDA-MB-231 cells following treatment with 6nM ARP100 and 12nM 
Marimastat (graphs are shown as % of NT control siRNA-treated cells +SD; n=3; each 
experiment undertaken in triplicate; significant differences calculated by unpaired t-
test with Welch’s correction).  c). Invasive capacity of MDA-MB-231 cells following 
treatment with 6nM ARP100 and 12nM Marimastat (graphs are shown as % of NT 
control siRNA-treated cells+SD; n=3; each experiment undertaken in triplicate; 
significant differences calculated by unpaired t-test with Welch’s correction).  Asterisks 
show significances:  * p<0.05, ** p<0.01, ****p<0.0001.   
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Figure 5.13.  Effect of MMP2 inhibitors of ZR-75.1 cell proliferation, migration 
and invasion. a) Proliferative capabilities of ZR-75.1 cells following 24, 48 and 72 
hours of MMP-2 inhibitors (6nM ARP100 and 12nM Marimastat) (representative 
data; graphs show mean RFU+SD; n=3; each individual experiment carried out six 
times; significances calculated using two-way ANOVA). b) Migratory capacity of ZR-
75.1 cells following treatment with 6nM ARP100 and 12nM Marimastat (graphs are 
shown as % of NT control siRNA-treated cells +SD; n=3; each experiment 
undertaken in triplicate; significant differences calculated by unpaired t-test with 
Welch’s correction).  c). Invasive capacity of ZR-75.1 cells following treatment with 
6nM ARP100 and 12nM Marimastat (graphs are shown as % of NT control siRNA-
treated cells+SD; n=3; each experiment undertaken in triplicate; significant 
differences calculated by unpaired t-test with Welch’s correction).  Asterisks show 
significances:  * p<0.05, ** p<0.01, ***p<0.001, ****p<0.0001).  
5. Chapter V: Results 
 
225 
 
As no difference in MMP8 transcript level was seen at 48 hours, oth-
er time points following MDM2 or PSMA siRNA treatment were as-
sessed, with no significant difference in MMP8 transcript seen, com-
pared to the NT control, at 6, 18 or 24 hours (Figure 5.14a-d).  Fol-
lowing this, 4nm of an MMP8 inhibitor was used to assess the result 
of decreased MMP8 activity and no functional differences were seen 
upon assessment of growth (Figure 5.14e and f), migratory (Figure 
5.11 g and h) and invasive (Figure 5.14I and j) ability of both MDA-
MB-231 and ZR-75.1 cells.   
IL-6 and IL-8 ELISA  
To assess if MMP8 levels were truly changed in the TCM, an ELISA 
of IL-6 and IL-8 levels were examined, since MMP8 has previously 
been linked to these two interleukins in breast cancer cells (Thirkettle 
et al., 2013).  Interestingly, it was seen that following both MDM2 and 
PSMA knockdown, a significant decrease in both IL-6 and IL-8 oc-
curred. IL-6 levels were highly decreased in MDA-MB-231 following 
PSMA siRNA treatment compared to NT control (p=0.0006; de-
creased by 141 pg/ml), but less decreased after MDM2 siRNA 
(p=0.0027; decreased by 75 pg/ml) (Figure 5.15a).  However, in ZR-
75.1 cells, MDM2 siRNA treatment led to a greater decrease in se-
creted IL-6 levels, with a decrease of 60 pg/ml compared to the NT 
control (p=0.0019), whilst PSMA siRNA led to a decrease of 44 pg/ml 
(p=0.0415), just reaching significance (Figure 5.15b).  IL-8 levels 
were also decreased in both cell lines following both siRNA treat-
ments, with levels less significantly decreased in MDA-MB-231  
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Figure 5.14.  Effect of MMP8 inhibitor on MDA-MB-231 and ZR-75.1 cell 
proliferation, migration and invasion. a) MMP8, MDM2 and PSMA gene level in 
MDA-MB-231 following 6, 18 and 24 hours of MDM2 siRNA treatment. b) MMP8, 
MDM2 and PSMA gene levels in MDA-MB-231 following 6, 18 and 24 hours of PSMA 
siRNA treatment. c) MMP8, MDM2 and PSMA gene levels in ZR-75.1 following 6, 18 
and 24 hours of MDM2 siRNA treatment. d) MMP8, MDM2 and PSMA gene levels in 
ZR-75.1 following 6, 18 and 24 hours of PSMA siRNA treatment. e) Proliferative ability 
of MDA-MB-231 cells following 24 48 and 72 hours of treatment with MMP8 inhibitor 
(Graphs show RFU+SD; n=3; individual experiments carried out six times; significance 
tested using two-way ANOVA). f) Proliferative ability of ZR-75.1 cells following 24, 48 
and 72 hours of treatment with MMP8 inhibitor (Graphs show RFU+SD; n=3; individual 
experiments carried out six times; significance tested using two-way ANOVA).  g) 
Migratory capacity of MDA-MB-231 cells treated with MMP8 inhibitor. h) Invasive 
capacity of ZR-75.1 cells treated with MMP8 inhibitor. i) Migratory capacity of MDA-
MB-231 cells treated with MMP8 inhibitor. j) Invasive capacity of ZR-75.1 cells treated 
with MMP8 inhibitor. (Graphs are shown as % of NT control siRNA-treated cells+SD, 
unless otherwise stated; n=3; each experiment undertaken in triplicate; significant 
differences calculated by t-test with Welch’s correction).  Asterisks show significances:  
* p<0.05, ** p<0.01. 
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5.15. Secreted IL-6 and IL-8 levels of MDA-MB-231 and ZR-75.1 
following 72 hours of MDM2 or PSMA siRNA treatment, as estimated 
by ELISA. a) IL-6 secretion in pg/ml from MDA-MB-231 cells following NT, 
MDM2 or PSMA siRNA treatment. b) IL-6 secretion in pg/ml from ZR-75.1 
cells following NT, MDM2 or PSMA siRNA treatment. c) IL-8 secretion in 
pg/ml from MDA-MB-231 cells following NT, MDM2 or PSMA siRNA 
treatment. d) b) IL-8 secretion in pg/ml from ZR-75.1 cells following NT, 
MDM2 or PSMA siRNA treatment. (Graphs show mean pg/ml +SD; n=3; 
experiments carried out in triplicate; significance assessed using unpaired t-
test with * p<0.05, ** p<0.01 and *** p<0.001).  
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(MDM2 siRNA: p=0.0146, decreased by 7pg/ml; PSMA siRNA: 
p=0.0105, decreased by 4 pg/ml) (Figure 5.15c) , than ZR-75.1 
(MDM2 siRNA: p=0.0098, decreased by 3.5 ng/ml; PSMA siRNA: 
p=0.0071, 3.8 pg/ml) (Figure 5.15d).  
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5.4. Discussion 
Tumour cell migration and invasion are crucial steps in the spread of 
cancer through the tissues.  These processes are key for the 
formation of metastases from the primary tumour, which are the main 
cause of death from cancer.  The cells in these metastases are much 
more resistant, aggressive and efficient than those forming the 
primary tumour, as these cells have had to migrate and invade to 
form a colony at a new site (Bozzuto et al., 2010).  
Migration assays undertaken following MDM2 and PSMA knockdown 
using targeting siRNA showed that cells possess a decrease in the 
migratory capacity through the pores of a transwell and also in the 
closing of a wound.  Yang et al., (2006) already linked MDM2 
overexpression to an increase in cell motility and PSMA knockdown 
has been linked to a decrease in migration (Guo et al., 2014; Zhang 
et al., 2013).   
  Interestingly, it can be seen that PSMA knockdown led to a greater 
decrease in the ability of both breast cancer cell lines to migrate 
through the transwell, than MDM2 knockdown, despite knockdown 
only being around 50% efficient.  This could indicate that PSMA 
plays an extremely important role in the migration of cells during the 
progression of breast cancer and slight changes in protein levels may 
incur large changes.  
It is the general consensus in the literature that MDM2 is positively 
correlated with the invasion capacity of cancer cells (Chen et al., 
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2013; Rajabi et al., 2012).  However, through the use of MDM2 
siRNA, this study showed that 48 hours post-treatment, an increase 
in invasive capacity was seen, as well as an increase in 
phosphorylation at serine 166 on MDM2.  On the other hand, at 72 
hours, invasion was decreased, as was the phosphorylation at serine 
166.   
 This is a very interesting phenomenon and it can be partially 
explained by the literature, which claims that phosphorylation of sites 
on MDM2 protein may increase the stability and half-life of the 
protein (Batuello et al., 2015, Feng et al., 2004b).  Due to the 
important and multifunctional role played by MDM2 in the cell, 
particularly its regulation of p53 tumour suppressor (Moll & Petrenko, 
2003), a sudden drop in MDM2 levels may lead to an attempt at 
sequestration of the protein in order for the cell to avoid apoptosis 
through activation of p53. However, it seems that 72 hours is enough 
for this process to no longer be ongoing and MDM2 levels are seen 
to drop (both total and serine 166 phosphorylation).  These results 
indicate an increase in MDM2 ser166 phosphorylation correlates with 
an increased invasive capacity, and vice versa, may link 
phosphorylation of MDM2 at this site to the ability of cancer cells to 
invade.    
PSMA knockdown resulted in a decrease in invasion at both 48 and 
72 hours in ZR-75.1 cells, but only 72 hours showed a significant 
decrease in MDA-MB-231 cells.  This may be due to the higher levels 
of PSMA expression ZR-75.1 cells, compared to MDA-MB-231 cells, 
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with a similar percentage decrease resulting in a larger effect 
functionally.  Other studies have been undertaken to assess how 
PSMA levels affected the invasion capacity of cells and yielded 
varying results, with Dassie et al., (Dassie et al., 2014) showing that 
overexpression of PSMA results in an increase in invasion, but 
Ghosh et al. (2005) claiming the opposite.  However, results gained 
in the current study and the increasing expression of PSMA in more 
progressed cancers (Perner et al., 2007, Kasperzyk et al., 2013) 
indicate that the former paper was correct.   
When the adhesion of cancer cells to an endothelial cell monolayer 
was assessed, a significant decrease was seen in each of the 
knockdowns, including the dual knockdown, compared to the NT 
siRNA.  However, the effect on adherence of cells in the MDA-MB-
231 cell line was more pronounced than ZR-75.1.  This is interesting 
as through the study, ZR-75.1 has shown more significant effects 
after knockdown, which is potentially due to their greater level of 
knockdown compared to the MDA-MB-231 cell line.  However, the 
reason for these results in terms of adhesion may be due to ZR-75.1 
cells being less adherent and perhaps the length of time the cells 
were left was not long enough to show the true extent of the 
difference between the NT, MDM2 and PSMA siRNA treatment.  
Since the MMP family is known to be associated with both migration, 
invasion and adhesion of cancers, this seemed like an informed 
place to start.  Therefore, gene and secreted protein levels of the 
MMP and TIMP family members were studied following knockdown 
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of each of the molecules.  Upon analysis of gene expression levels 
after knockdown, many of the family members were seen to be 
significantly altered.  However, assessment of the secreted levels of 
MMPs and TIMPs into the tumour-conditioned media showed that 
only MMP2 and MMP8 in both MDA-MB-231 and ZR-75.1 were seen 
to be significantly altered, although ZR-75.1 cells showed a 
significant decrease in MMP9 levels following both knockdowns.  In 
each cell line, MMP2 gene and protein levels were significantly 
decreased following both MDM2 and PSMA knockdown. This 
indicates that the changes seen following MDM2 and PSMA protein 
levels were realised through decreased transcription of the gene.  
However, although secreted MMP8 secreted protein levels were 
decreased following both knockdowns, there was no significant 
changes to gene level or intracellular protein levels, implying that 
changes to MMP8 levels was undertaken after the transcriptional 
process, or that secretion of MMP8 from the cell, was affected.  It is 
also important to note that both cell lines do show a gene level 
decrease in MMP9 following MDM2 siRNA treatment, although a 
resultant change in MMP9 protein secretion level is only reflected in 
ZR-75.1 cell lines.  However, ZR-75.1 also show a decrease in 
MMP9 protein secretion following PSMA siRNA treatment, but this is 
not shown at gene level.  This indicates that MMP9 expression in ZR-
75.1 is regulated through different pathways after MDM2 and PSMA 
knockdown.   
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It is important to note that due to monetary constraints, the MMP 
blots were undertaken only twice and the results analysed are the 
averages of two spots per blot.  It would be a highly valuable 
undertaking to repeat this experiment, in order to check the 
significances and differences seen in secretion levels.   
In order to investigate the hypothesis that MMP2 protein levels were 
decreased due to a decrease in transcript levels, whereas MMP8 
protein levels were decreased due to a change after transcription or 
in secretion of the molecules, flow cytometry was used to assess the 
intracellular levels of the two proteins.  As expected, it was seen that 
MMP2 intracellular levels were decreased following knockdown of 
both MDM2 and PSMA, compared to levels seen in those cells 
treated with NT control siRNA.  Although, interestingly, the % of cells 
which expressed MMP2 was much higher in ZR-75.1 than MDA-MB-
231, even though it can be seen from the blots that MDA-MB-231, as 
a culture, secrete more of the protein.  This could mean that a higher 
number of cells secrete MMP2, but each individual MDA-MB-231 cell 
which does secrete the molecule, secretes much more. On the other 
hand, MMP8 levels were seen to remain the same, in spite of their 
siRNA treatment.  This result indicates that MMP8 levels change 
following MDM2 and PSMA knockdown due to a decrease in 
secretion of the protein, rather than a change in actual protein levels 
in the cell.   
Therefore, to further link MMP2 and MMP8 to the functionality of the 
cells following each knockdown, MMP2 inhibitors ARP100 and 
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Marimastat and MMP8 inhibitor were used in the assessment of 
growth, migration and invasion following treatment.  It was seen that 
the MMP2 inhibitors show a decrease in growth, migration and 
invasion capacity following inhibitor treatment, compared to the 
DMSO control.  Therefore, the decrease in MMP2 levels following 
each knockdown could be the reason for the decrease in migration 
and invasion seen. On the other hand, MMP8 inhibitor showed no 
significant change in growth, migration or invasion capacity.  This 
data suggests that MMP2, but not MMP8, may be, in part, 
responsible for the decrease in growth, migration and invasion seen 
following MDM2 and PSMA knockdown.  
Interestingly, in cancer studies, neither MDM2 nor PSMA have been 
directly linked to MMP2 or MMP8 protein levels in previous literature; 
however, both have been linked to MMP9.  MDM2 has been linked to 
MMP9 levels in clinical samples of IDC (Chen et al., 2013) and 
further work in breast cancer cell lines, including MDA-MB-231 
showed a significant decrease in gene expression levels of MMP9 
through RT-PCR, which correlates with the current study.  A 
significant correlation in expression was also seen between the two 
molecules in the oncogenesis of lung cancer in rats (Zhang et al., 
2014).  PSMA expression has been linked to MMP9 levels following 
induced overexpression of PSMA in prostate cancer cell line, RM-1; 
with immunohistochemistry indicating MMP9 levels were distinctly 
higher in mice injected with the cells overexpressing PSMA.  The 
group also backed this up in vitro, showing an increase in protein 
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levels using western blotting (Zhao et al.¸2012).  Therefore, it is 
interesting that MDA-MB-231 and ZR-75.1 show differing expression 
patterns of MMP9 protein following MDM2 or PSMA knockdown.  
However, this could be due to the vast difference in the cell types 
used.  This decrease in MMP9, as well as MMP2, could go some 
way in explaining the heightened decrease in migration and invasion 
showed by ZR-75.1 cells following MDM2 and PSMA knockdown.  
In terms of roles of MMP2 and MMP8 in cancer, it may be expected 
that a decrease inMMP2 levels may occur following the knockdowns, 
taking into account the decrease in the progressive properties of the 
cells, as the literature clearly states that MMP2 is correlated with the 
migration and invasion of tumour cells(Jezierska and Motyl, 2009).  
On the other hand, MMP8 has also been shown to be a metastasis-
suppressor, though its expression is deleterious to long-term growth 
(20 days), as well as inducing IL-6 and IL-8 factors which promote 
malignancy in breast cancer cells (Thirkettle et al., 2013). Moreover, 
MMP8 has been said to have a protective role against lymph node 
metastasis, following a study of inflammatory breast cancer patients 
(Decock et al., 2008).   
Finally, we assessed the levels of IL-6 and IL-8 in breast cancer 
cells, since MMP8 has previously been linked to their expression.  
Thirkettle et al., (2013) previously identified MMP8 as an inducer of 
IL-6 and IL-8 expression in breast cancer cells.  Our data showed the 
same result, with MMP8 decrease due to MDM2 and PSMA siRNA 
leading to a decrease in both IL-6 and IL-8.  This indicates that, since 
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MMP8 levels are only changed outside the cells, that MMP8 
somehow regulates the levels of IL-6 and IL-8 outside the cells, 
perhaps through proteolytic cleavage.  Interestingly, PSMA has 
previously been linked to regulation of IL-6 expression through 
activation of the MAPK pathway in prostate cancer cells (Colombatti 
et al., 2009, Ben Jemaa et al., 2013) and it has been claimed that IL-
6 can downregulate p53 expression (Brighenti et al., 2014).   IL-6 has 
been seen to play a role in regulation of the tumour 
microenvironment (Fisher et al., 2014), stem-cell-like cell production 
in breast cancer (Xie et al., 2012), metastasis (Miao et al., 2014) and 
DNA methylation alterations (Gasche et al., 2011). In addition, 
patients with advanced cancers show high IL-6 blood levels (Hussein 
et al., 2004, Salgado et al., 2003).   IL-8 has been suggested to 
promote angiogenic response in endothelial cells, increase 
proliferation and survival or endothelial and cancer cells and increase 
the migration of cancer cells and endothelial cells (Waugh and 
Wilson, 2008).  
In conclusion, it seems that MDM2 and PSMA knockdown result in a 
similar functional response of breast cancer cells and this could be 
executed through their ability to decrease the levels of MMPs in the 
tumour-conditioned media.  This decrease could also result in a 
decrease in the secretion of IL-6 and IL-8 from breast cancer cells.    
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6.1. Introduction  
 
The online toolwww.genemania.com lists genes with potential inter-
actions by searching large, publicly available datasets to find related 
genes.  This relationship may be protein-protein, protein-DNA and 
genetic interactions, pathways, reactions, gene and protein expres-
sion data, protein domains and phenotypic screening profiles.  
Through this, the database can suggest possible links and potential 
pathways of a large number of genes.   Using the search terms 
‘MDM2’, ‘PSMA’, ‘MMP2’ and ‘MMP8’ led to the discovery of a poten-
tial interaction of these molecules with c-JUN.   
c-JUN, when activated, is thought to play an important role in cancer 
progression and malignancy. This activation occurs when extra- or 
intracellular signalling such as growth factors, UV radiation or trans-
forming oncoproteins stimulate the phosphorylation of c-JUN at ser-
ines 63 and 73 (Vleugel et al., 2006).  Studies have linked c-JUN ex-
pression to an increase in the progressive properties of breast cancer 
(Zhang et al., 2007, Vleugel et al., 2006). 
In addition, the literature shows that there may be a link between 
both MDM2 and PSMA with AKT.  It has been shown that knockdown 
of PSMA leads to a decrease in the levels of serine 473 phosphoryla-
tion, whilst total levels of AKT remain the same (Guo et al., 2002).  In 
addition, AKT is heavily implicated in the phosphorylation of MDM2 at 
multiple sites, although different groups report a number of findings.  
There are varying reports on the involvement of AKT phosphorylation 
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on MDM2 nuclear entry. For instance, Mayo & Donner (2001) claim-
ing that serine 166 and 186 phosphorylation promote nuclear entry. 
However, Ogawara et al., (2002) disputed this, claiming that phos-
phorylation of MDM2 sites showed no effect on subcellular localisa-
tion.  Feng et al., (2004) claimed that serine 166 and 186 are phos-
phorylated by AKT serine 473 and this inhibits MDM2 self-
ubiquitination and thus its stability, but serine 186 is reported to be 
unphosphorylated.  Moreover, p53 tumour suppressor is consistently 
linked to AKT signalling.   The molecules play opposing roles in the 
transduction of apoptosis and it seems that conflicting signals gov-
erned by each of the molecules are integrated into each of the two 
pathways involved (Sabbatini & McCormick, 1999; Yamaguchi et al., 
2001; Hong et al.¸1999; Mazzoni et al., 1999; Gottlieb et al.¸2002). 
Therefore, in this chapter we aimed to assess the roles of both c-JUN 
and AKT phosphorylation in the interaction of MDM2 and PSMA in 
breast cancer cells.  
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6.2. Materials & Methods 
 
Cell lines and treatment 
MDA-MB-231 and ZR-75.1 metastatic breast cancer cell lines were 
maintained in DMEM media with 10% FBS and antibiotics.  These 
cell lines were transiently transfected with MDM2, PSMA or non-
targeting (NT) siRNA using Fect4 or Fect1 transfection reagent, re-
spectively.  All treatments were undertaken in a 6-well plate and a 
total volume of 1ml per well was used in each case.  MDA-MB-231 
cells were treated with 100 nM of each siRNA and ZR-75.1 cells 
were treated with 50 nM, according to manufacturer’s instructions, 
following optimisation experiments.  Treatments were undertaken for 
24, 48 or 72 hours, dependent on the experiment.   
RNA isolation and RT-PCR 
Following treatment of MDA-MB-231 and ZR-75.1 cells with MDM2, 
PSMA and NT siRNA in a 6-well plate, TRI reagent was added to 
cells.  RNA isolation and RT-PCR were then undertaken according to 
sections 2.4.1 and 2.4.2.   
Quantitative PCR (qPCR) 
qPCR was carried out using cDNA produced in reverse transcription 
detailed above, using primers for JUN, AKT and GAPDH (listed in 
Table 2.3), following the procedure outlined in 2.4.3.  CT values 
gained from this were analysed using 2-ΔΔCT normalisation to GAPDH. 
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Each qPCR sample was set up in triplicate, with the experiment be-
ing independently set up three times.  Each reading was expressed 
as a percentage of NT control and statistical analysis was undertak-
en using unpaired t-test with Welch’s correction, comparing each 
MDM2 and PSMA siRNA to NT control.   
Western blotting 
Following 72 hours of treatment of MDA-MB-231 and ZR-75.1 with 
MDM2,PSMA and NT siRNA, cells were scraped from the 6-well 
plate into 50 µl RIPA buffer (with added inhibitors), left on a blood 
wheel for 1 hour at 4˚C, then centrifuged for 15 minutes at 12,000 X 
G.  Following this protein was quantified and a standard concentra-
tion decided upon.  Then an equal amount of 2 x Llamelli was added 
and SDS-PAGE, western blotting and immuno-probing using anti- 
AKT, anti-phospho-AKT (serine 473), anti-phospho-MDM2 (serine 
186/188), anti-phospho-MDM2 (serine 186) and anti- GAPDH (anti-
body list in Table 2.4) was undertaken as outlined in 2.5.1.  
Flow cytometric analysis of c-JUN and AKT levels 
Following treatment of MDA-MB-231 and ZR-75.1 cells with MDM2, 
PSMA and NT siRNA for 72 hours, intracellular c-JUN, phospho-c-
JUN (serine 63) and phospho-AKT (serine 473) were assessed as 
detailed in 2.5.3.   
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AKT inhibitor studies 
To inhibit AKT in MDA-MB-231 and ZR-75.1, cells were treated with 
5 µM of AKT inhibitor (124005).  Following this, RNA isolation, re-
verse transcription and qPCR were carried out as detailed above.  
Statistical analysis 
Data were statistically analysed using either unpaired t-test or un-
paired t-test with Welch’s correction, with a p-value of <0.05 consid-
ered statistically significant.  Asterisk (*) was used to signify p-values: 
* p<0.05, ** p<0.01, *** p<0.001 and **** p<0.0001. 
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6.3. Results 
The proteins which may link MDM2 and PSMA  
Using Genemania (www.genemania.com), a plug in of Cytoscape, to 
assess which proteins may be involved in the interplay between 
MDM2, PSMA and MMP2 and MMP8 led to the discovery of an 
interaction of these molecules with c-JUN (Figure 6.1a). Additionally, 
searching the literature revealed that both MDM2 and PSMA have 
been linked to AKT and its phosphorylation at site 473.  Moreover, 
both c-JUN and AKT have previously been linked to a possible 
regulation of the MMPs (Figure 6.1b), and so their study may indicate 
a way in which MDM2 and PSMA proteins interplay to regulate MMP 
secretion.   
c-JUN gene and protein expression following MDM2 and PSMA 
knockdown in breast cancer cells 
Following MDM2, PSMA or NT siRNA treatment, JUN gene, as well 
as c-JUN protein and phosphorylation levels were assessed through 
RT-qPCR and flow cytometry, respectively.  Assessment of JUN 
gene levels at 24, 48 and 72 hours revealed no significant changes in 
transcript expression following either of the knockdowns, compared 
to the JUN expression of the NT control treated MDA-MB-231 breast 
cancer cells (Figure 6.2a) and this was also shown using flow 
cytometry upon assessment of total c-JUN expression levels (Figure 
6.2b-d).  However, observation of the phosphorylation levels of c-
JUN at serine 63, following each of the knockdown showed a  
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Figure 6.1. Results of GeneMANIA search with ‘MDM2’, ‘FOLH1/PSMA’, 
‘MMP2’ and ‘MMP8’ outlined as search terms. GeneMANIA searches 
online databases to show potential interactions between genes.  The 
database lists physical interactions, pathways, co-expression and shared 
protein domain links between genes.  Use of this database enables the 
prediction of interactions between a number of genes and how these 
interactions may fall into a pathway or a set of interactions.   
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Figure 6.2. JUN gene and c-JUN protein expression and phosphorylation levels 
following 72 hours of MDM2 and PSMA siRNA treatment MDA-MB-231 cells. a) 
Gene expression levels of JUN following MDM2, PSMA and NT siRNA treatment 
(Graph shows % of NT control siRNA-treated cells +SD; each experiment undertaken 
in triplicate; significant difference calculated by t-test with Welch’s correction).  b) Flow 
cytometric analysis of NT control siRNA-treated cell expression of cJUN total protein. 
c) Flow cytometric analysis of MDM2 siRNA-treated cell expression of cJUN total 
protein. d) Flow cytometric analysis of PSMA control siRNA-treated cell expression of 
cJUN total protein. e) Flow cytometric analysis of NT siRNA-treated cell expression of 
cJUN phosphorylation at ser63. f) Flow cytometric analysis of MDM2 siRNA-treated 
cell expression of cJUN phosphorylation at serine 63. g) Flow cytometric analysis of 
PSMA siRNA-treated cell expression of cJUN phosphorylation at serine 63. (All flow 
cytometry graphs show representative data; percentages show cells expressing the 
protein being assessed). h) Summary of total and phosphorylation (serine 63) cJUN 
levels following NT, MDM2 and PSMA siRNA treatment (n=3; Graph shows % of cells 
expressing cJUN/p-cJUN (serine 63)+SD; significant difference against NT control 
calculated by t-test; *** p<0.001).   
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significant increase in phosphorylation of this serine when MDM2 
knockdown was carried out (p=0.0005) (Figure 6.2e-h).   
Similarly, in the ZR-75.1 breast cancer cell line, qPCR assessment of 
JUN transcript levels showed no significant change after any 
knockdown, at any time-point (Figure 6.3a), as well as no change of 
total c-JUN protein levels shown through flow cytometry (Figure 
6.3b,c and d).  Assessment of serine 63 phosphorylation following 
each knockdown bore similar results in terms of MDM2 siRNA 
treatment, with a significant increase in phosphorylation of this site 
being seen, compared to the NT control (p=0.0015) (Figure 6.3e and 
f).  However, this cell line also exhibited an increase in 
phosphorylation at this site following PSMA knockdown (p=0.0015) 
(Figure 6.3e and g) (all data summarised in Figure 6.3h).    
AKT gene and protein expression following MDM2 and PSMA 
knockdown in breast cancer cells 
AKT levels were also assessed following treatment with MDM2 and 
PSMA siRNA.  It can be seen that transcript levels of AKT were 
significantly increased following 72 hours of PSMA siRNA treatment 
in MDA-MB-231 cells (p=0.0049; Figure 6.4a) and this was also seen 
at protein level (Figure 6.4b). In addition, MDM2 siRNA treatment 
also seemed to increase the levels of total AKT protein.  
Phosphorylation of AKT at serine 473 is highly important for the 
activity of the protein, as well as being implicated in possible 
interaction with both MDM2 (Ogawara et al.¸2002; Singh et al.¸2013) 
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Figure 6.3. JUN gene and c-JUN protein expression and phosphorylation 
levels following 72 hours of MDM2 and PSMA siRNA treatment ZR-75.1 cells. 
a) Gene expression levels of JUN following MDM2, PSMA and NT siRNA 
treatment (Graph shows % of NT control siRNA-treated cells +SD; each 
experiment undertaken in triplicate; significant difference calculated by t-test with 
Welch’s correction).  b) Flow cytometric analysis of NT control siRNA-treated cell 
expression of c-JUN total protein. c) Flow cytometric analysis of MDM2 siRNA-
treated cell expression of c-JUN total protein. d) Flow cytometric analysis of PSMA 
siRNA-treated cell expression of cJUN total protein. e) Flow cytometric analysis of 
NT siRNA-treated cell expression of cJUN phosphorylation at serine 63. f) Flow 
cytometric analysis of MDM2 siRNA-treated cell expression of cJUN 
phosphorylation at serine 63. g) Flow cytometric analysis of PSMA siRNA-treated 
cell expression of cJUN phosphorylation at serine 63. (All flow cytometry graphs 
show representative data; percentages show cells expressing the protein being 
assessed). h) Summary of total and phosphorylation (serine 63) c-JUN levels in 
cells following NT, MDM2 and PSMA siRNA treatment (n=3; Graph shows % of 
cells expressing cJUN/phosphorylated cJUN (serine 63)+SD; significant difference 
against NT control calculated by t-test; ** p<0.01).   
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and PSMA (Guo et al.¸2014).   Therefore, phosphorylation levels at 
this site were assessed following knockdown of both MDM2 and 
PSMA, compared to NT control.  Interestingly, western blots of MDA-
MB-231 cells treated with the siRNAs showed a modest, yet 
consistent, decrease in the phosphorylation of AKT at this site 
following both MDM2 and PSMA siRNA treatment (Figure 6.4b).  As 
the decrease was small when visualised through western blotting, the 
phosphorylation levels in MDA-MB-231 were also assessed using 
flow cytometry.  This showed that there was indeed a decrease in the 
percentage of cells with serine 473 phosphorylation after both MDM2 
siRNA (15.2%; figure 6.4.c and d) and PSMA siRNA (20.11%; figure 
6.4.c and e), compared to the NT control siRNA. When all data were 
accumulated from n=3 experiments, it was seen that the decrease in 
phosphorylation levels was significant for both MDM2 (p=0.0162) and 
PSMA siRNA (p=0.0008) (Figure 6.4f).  
When ZR-75.1 cells were treated with MDM2, PSMA or NT siRNA, 
similar results were seen, with a significant increase in AKT transcript 
levels in cells treated with PSMA siRNA at both 48 (p=0.0391) and 
72 hours (p=0.0009) (Figure 6.5a) and again this increase was seen 
at protein level through western blotting (Figure 6.5b).  As in the 
MDA-MB-231 cells, levels of phosphorylation at serine 473 were 
significantly decreased following PSMA siRNA compared to NT 
control. However, in this cell line it seems that MDM2 siRNA did not 
have an effect on the phosphorylation levels of this site (Figure 6.5b).   
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Figure 6.4. AKT gene, protein and phosphorylation levels following 72 hours 
of MDM2 and PSMA siRNA treatment in MDA-MB-231 cells. a) Gene 
expression of AKT following MDM2, PSMA and NT siRNA treatment (Graphs show 
% expression of NT control+SD; each experiment carried out in triplicate; 
significant difference from NT control calculated by t-test with Welch’s correction). 
b) Western blot of total AKT and phosphorylation levels of AKT at serine 473 
following PSMA, MDM2 and NT control siRNA treatment (representative data; 
n=3). c) Flow cytometric analysis of NT control siRNA-treated cell AKT 
phosphorylation (serine 473). d) Flow cytometric analysis of MDM2 control siRNA-
treated cell AKT phosphorylation (serine 473). e) Flow cytometric analysis of PSMA 
control siRNA-treated cell AKT phosphorylation (serine 473). (All flow cytometry 
graphs show representative data; percentages show cells expressing the protein 
being assessed). f) Summary of phosphorylated (serine 473) AKT levels following 
NT, MDM2 and PSMA siRNA treatment of cells (n=3; graph shows % of cells 
expressing phosphorylated AKT (serine 473) +SD; significant difference against NT 
control calculated by unpaired t-test; * p<0.05; ** p<0.01 and *** p<0.001).   
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Figure 6.5. AKT gene, protein and phosphorylation levels following 72 
hours of MDM2 and PSMA siRNA treatment in ZR-75.1 cells. a) Gene 
expression of AKT following MDM2, PSMA and NT siRNA treatment (Graphs 
show % expression of NT control+SD; each experiment carried out in triplicate; 
significant difference from NT control calculated by t-test with Welch’s correction). 
b) Western blot of total AKT and phosphorylation levels of AKT at serine 473 
following PSMA, MDM2 and NT control siRNA treatment (representative data; 
n=3). c) Flow cytometric analysis of NT control siRNA-treated cell AKT 
phosphorylation (serine 473). d) Flow cytometric analysis of MDM2 control 
siRNA-treated cell AKT phosphorylation (serine 473). e) Flow cytometric analysis 
of PSMA control siRNA-treated cell AKT phosphorylation (serine 473). (All flow 
cytometry graphs show representative data; percentages show cells expressing 
the protein being assessed). f) Summary of phosphorylated (serine 473) AKT 
levels following NT, MDM2 and PSMA siRNA treatment of cells (n=3; graph 
shows % of cells expressing p-AKT (serine 473) +SD; significant difference 
against NT control calculated by unpaired t-test; *** p<0.001 and **** p<0.0001).   
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These levels were checked using flow cytometry and, interestingly, it 
was seen that MDM2 siRNA shows no difference in phosphorylation 
of AKT at serine 473 compared to NT siRNA in the ZR-75.1 cell line 
(Figure 6.5c and d).  However, PSMA siRNA treatment was 
confirmed to show a significant decrease in phosphorylation levels 
compared to the NT siRNA (28%; Figure 6.5c and e).  When three 
repeats of this experiment were analysed, the decrease in 
phosphorylation at serine 473 on AKT was seen to be highly 
significant in ZR-75.1 harbouring PSMA knockdown (p<0.0001).   
Phosphorylation of MDM2 at serines 186 and 188 following MDM2 
and PSMA knockdown in breast cancer cell lines 
Due to recent advancement in the literature showing that AKT may 
be involved in the phosphorylation of MDM2 at serines 186 and 188, 
western blots were undertaken in order to ascertain whether any 
difference in the phosphorylation levels of these sites following each 
of the siRNA treatment.  Also, a specific serine 188 antibody does 
not exist and so a process of elimination had to be undertaken by 
using an antibody which recognises both serine 186 and 188 and 
one which recognises serine 186 alone.    
As expected, MDM2 siRNA treatment of both cell lines leads to a 
decrease in the level of phosphorylation at both sites.  However, 
strikingly, probing of cell lysates with the serine186/188 antibody 
showed a decrease in phosphorylation following PSMA siRNA 
treatment, but with the serine 186 antibody showed no decrease 
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(Figure 6.6a and b).  This leads to the surmising that PSMA is 
involved in the phosphorylation of MDM2 at site 188, possibly 
through its effect on AKT phosphorylation at serine 473 (Figure 6.6c).   
The effect of a PI3K inhibitor on gene levels of MDM2, PSMA and the 
MMPs in breast cancer cell lines 
Since PI3K is known to be important in the phosphorylation of AKT at 
serine 473 (Scheid et al., 2002), a PI3K inhibitor (LY 294002) was 
used in order to indirectly also inhibit phosphorylation at this site. 
Transcript levels were assessed following 24 hours of treatment with 
either LY 294002 or its control (LY 303511), in both MDA-MB-231 or 
ZR-75.1 cells. As expected, since the inhibitor works at protein level, 
transcript levels of AKT were unchanged between the inhibitor and 
control treated cells (Figure 6.7a).  Interestingly, a significant 
decrease in MDM2 (MDA-MB-231: p=0.0111; ZR-75.1: p=0.0036) 
and PSMA gene expression (MDA-MB-231: p=0.0042; ZR-75.1: 
p=0.0082) (Figure 6.7b and c). Assessment of MMP2 levels showed 
a significant decrease following treatment with the inhibitor, 
compared to control (MDA-MD-231: p=0.0129; ZR-75.1 p=0.0262) 
(Figure 6.7d), whereas MMP8 transcript was unchanged compared 
to the control (Figure 6.7e).  
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Figure 6.6. Phosphorylation of MDM2 at serines 186 and 188 
following 72 hours of MDM2 and PSMA siRNA treatment in MDA-
MB-231 and ZR-75.1 cells. a) Western blot showing phosphorylation of 
MDM2 at serine 186/188 and serine 186 alone following NT, PSMA and 
MDM2 siRNA treatment in MDA-MB-231 cells . b) Western blot showing 
phosphorylation of MDM2 at serine 186/188 and serine 186 alone 
following NT, PSMA and MDM2 siRNA treatment in ZR-75.1 cells. (All 
data representative; n=3). 
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Figure 6.7. The effect of 50 µM LY 294002 hydrochloride or LY 303511 on 
gene levels of MDM2, PSMA and the MMPs in MDA-MB-231 and ZR-75.1 
cells. Transcript levels following 24 hour 50 µM AKT inhibitor (LY 294002) 
treatment: a) AKT. b) MDM2. c) PSMA. d) MMP2. e) MMP8. f. (All graphs show 
% of LY 303511 control + SD; n=3) (Statistical significance assessed using 
unpaired t-test with Welch’s correction, with * p≤0.05 and ** p≤0.01). 
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6.4. Discussion  
 
Whilst an understanding of the functionality of cells and how 
particular molecules affect this is important in the study of cancer, the 
real purpose of cancer studies is to disentangle the molecular 
mechanisms involved which result in this functionality.  In this way, 
therapeutics can be specifically designed for the targeting of different 
types of molecular dysregulation.   
Following a Genemania search of MDM2, PSMA and the MMPs 
which were shown to be downregulated following MDM2 and PSMA 
siRNA treatment (MMP2 and MMP8), c-JUN was highlighted as a 
possible checkpoint between each of the molecules.  Therefore, 
gene and protein levels were assessed in MDA-MB-231 and ZR-75.1 
cells following MDM2 and PSMA knockdown.  Gene levels were 
seen to be unchanged after each of the treatment, compared to the 
NT control siRNA treatment.  Flow cytometry was then used to 
assess the protein levels of c-JUN, as well as phosphorylation levels 
at serine 63.   
c-JUN 
c-JUN  
 
Both cell lines showed no difference in total c-JUN levels; however, 
varying results were seen between the two cell lines concerning 
phosphorylation levels of c-JUN at serine 63. MDA-MB-231 cells 
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showed that, following MDM2 siRNA knockdown, c-JUN serine 63 
phosphorylation levels were significantly increased but PSMA knock-
down showed no difference in phosphorylation levels. However, ZR-
75.1 cells showed that both MDM2 and PSMA knockdown led to a 
significant increase in serine 63 phosphorylation of c-JUN. These re-
sults are interesting for a number of reasons. Firstly, c-JUN was pre-
viously reported to work in a p53-dependent manner in its regulation 
of the cell cycle (Dunn et al., 2002), as well as c-JUN being known to 
play a direct role in regulation of p53 stability and transcriptional ac-
tivity (Fuchs et al., 1998a, Fuchs et al., 1998b), with one group find-
ing that c-JUN regulates transcription of p53 negatively through bind-
ing to a variant of the AP-1 site in the promoter of p53 (Schreiber et 
al., 1999). Moreover, studies have shown that c-JUN null fibroblasts 
express elevated levels of p53 and their cell cycle defects can be re-
verted by simultaneous deletion of p53 (Hilberg et al., 1993, 
Schreiber et al., 1999). The increase in c-JUN serine 63 phosphory-
lation was seen in cell lines which were both p53 wild-type and mu-
tant, indicating that this upregulation of c-JUN phosphorylation by 
MDM2 is p53-independent. Since it is known that both c-JUN and 
MDM2 negatively regulate p53, the decrease in MDM2 levels may 
lead to an increase in the phosphorylation and thus activation of c-
JUN in an attempt to continue the negative regulation of p53, in an 
attempt to keep the cells alive.  
PSMA has previously only been linked to c-JUN N-terminal kinase 
(JNK) in the prostate cancer cell line LNCaP, with a group reporting 
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that a decrease in PSMA protein levels in these cells led to a de-
crease in phosphorylation of JNKs (Huang, 2015). JNKs are proteins 
which bind to the c-JUN transactivation domain and phosphorylate 
serine 63 and 73 (Ip and Davies, 1998). Beyond this, however, the 
topic of a possible interaction of PSMA and c-JUN has not been 
broached, apart from when the two were suggested for potential in-
terplay in a human functional protein interaction network (Wu et al., 
2012). If the fact that these kinases phosphorylate c-JUN is taken in-
to account with the fact that it was reported that PSMA knockdown 
led to a decrease in phosphorylation of JNK, it would be expected 
that PSMA decrease would lead to a decrease in the phosphorylation 
of serine 63 at c-JUN. However, in both breast cell lines studied, this 
was not seen. MDA-MB-231 cells showed no significant change in 
phosphorylation at this site and ZR-75.1 showed a significant in-
crease in serine 63 phosphorylation.   
It is important to remember that the work linking PSMA and JNKs 
was undertaken in prostate cancer and, more importantly, LNCaP 
cells which are hormone-dependent, meaning that they are still sen-
sitive to androgen treatment. c-JUN has been shown to interact with 
androgen receptor (AR) (Bubulya et al., 1996, Bubulya et al., 2000, 
Chen et al., 2006, Tinzl et al., 2013) and JNKs interact with andro-
gens (Lozena and Saatcioglu, 2008). Moreover, PSMA and AR have 
been shown to be concomitantly downregulated following androgen 
deprivation by one group studying LNCaP cells (Liu et al., 2012b), 
while in other cells lines (VCaP and derived forms) PSMA levels 
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were seen to increase following androgen deprivation therapy. 
Therefore, applying this study in an androgen-dependent cell line to 
the wider field of cancer, especially when it concerns molecules 
which have previously been linked to the androgen receptor and 
shown sensitivity to androgen therapy in the past, is something we 
must be careful of.  
Another reason the upregulation seen in c-JUN phosphorylation fol-
lowing the knockdown of MDM2 and PSMA in breast cancer cell lines 
is interesting, is that c-JUN is known to have an involvement in the 
progression of cancers (Vleugel et al., 2006; Zhang et al., 2007), with 
its overexpression being reported in human cancers, as well as in 
vitro cell studies correlating c-JUN with a more tumourigenic, inva-
sive phenotype (Smith et al, 1999). With this, it may be sensible to 
infer that the phosphorylation of serine 63, which causes activation of 
c-JUN protein, would also lead to this more aggressive phenotype. 
However, we have seen that this increased phosphorylation of serine 
63 of c-JUN occurs following knockdown of two pro-oncogenes, 
MDM2 and PSMA, which are both known to be involved in the pro-
gressive properties of cancer (Bradbury et al., 2016, Dassie et al, 
2014, Guo et al., 2014, Chen et al, 2013, Yang et al., 2006). This 
seems like a paradoxical state of events, when it may be natural, with 
all the evidence to hand, to assume that knockdown of MDM2 and 
PSMA would lead to a decrease in the phosphorylation of c-JUN at 
serine 63. This could indicate that serine 63 phosphorylation does 
not play an important role in this scenario, with other effectors of 
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MDM2 and PSMA playing a more significant role and dampening the 
phenotypic effect of this activation, or that serine 63 phosphorylation 
may play an anti-cancer role which is, as of yet, undiscovered. The 
latter theory is not wholly far-fetched as, although most reports show 
c-JUN in a tumour contributory role, there are some which show that 
it may have alternative roles working against tumour formation. One 
study highlighted the role of c-JUN in preventing promoter methyla-
tion of p16INK4a, a tumour suppressor, leading to a prevention of 
gene silencing (Kollmann et al., 2011). Another report claimed that 
tylophorine, a plant-derived alkoid with anti-tumoural activity, may act 
through c-JUN (Yang et al., 2013). 
One point to take into consideration in terms of this phosphorylation 
at serine 63 on c-JUN, is that, since siRNA was used for the knock-
down of MDM2 and PSMA, it is unknown for how long this phosphor-
ylation occurs. Phosphorylation can be transient or longer sustained 
and it is important to remember that the increase observed could, in 
fact, be a highly transient increase seen around the 72 hour mark, 
perhaps in an attempt to rebalance cellular signalling following 
knockdown of an important molecule to cellular homeostasis.  
To further understand the increased phosphorylation of c-JUN, it 
would also be interesting to assess the role of serine 73, another im-
portant phosphorylation site of c-JUN (Ip & Davis, 1998), following 
each knockdown.  
 
6. Chapter VI: Results 
 
260 
 
AKT 
Another potential interactor of both MDM2 and PSMA is AKT.  One 
study reported that, through its effect on the phosphorylation of 
MDM2 at serine 166 and 186, the PI3K/AKT pathway is able to 
promote nuclear entry of MDM2, leading to diminished levels of p53.  
Furthermore, they found that mutants of these phosphorylation sites 
in MDM2 are unable to enter the nuclear and therefore increase p53 
activity (Mayo & Donner, 2001).  However, this was contested by 
another group, who claimed that AKT phosphorylation of serine 186 
showed no effect on subcellular localisation of MDM2 but did 
increase the ubiquitination and therefore degradation of p53.  Using 
immunoprecipitation, this group found that MDM2 and AKT directly 
associate in MCF-7 cells under serum-free conditions (Ogawara et 
al., 2002).  This could imply that it is the phosphorylation by AKT at 
serine 166 which is the important site for localisation of MDM2 to the 
nucleus.  Another group suggested that AKT can be destructed in a 
p53-dependent manner suggesting, with reports of AKT negatively 
regulating p53 levels through MDM2 phosphorylation taken into 
account, that AKT may be involved in a feedback loop involving 
MDM2 and p53.  
Most importantly for this study, however, other groups have found 
that AKT phosphorylates serine 188 of MDM2.  The first study claims 
that AKT inhibits MDM2 self-ubiquitination through phosphorylation of 
serine 166 and 188, implying that phosphorylated AKT(serine 473) 
plays an important role in regulating MDM2 stability in mouse 
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embryonic fibroblasts (MEFs) (Feng et al.¸2004).  A slightly later 
study highlighted the same phosphorylation sites as interacting with 
AKT in cancer cell lines MCF-7, OSA and U2OS (Milne et al., 2004).  
This link between AKT phosphorylation at serine 473 and MDM2 
serine 188 is something which has been confirmed within this study.  
PSMA has also previously been linked to AKT, with knockdown of 
PSMA in prostate cancer cell line LNCaP, resulting in a decrease in 
the phosphorylation of AKT at serine 473, implicating these proteins 
in a signalling pathway concerning the tumourigenicity of cells, with a 
decrease in proliferation, migration and cell survival being seen by 
the group (Guo et al.¸2014).  Another later study showed the same 
results (Perico et al., 2016).  Again, this link of PSMA knockdown and 
phosphorylation at AKT serine 473 was exhibited in my own work.  
In terms of my own results, in both breast cancer cell lines studied, I 
found that PSMA knockdown leads to a decrease in phosphorylation 
of AKT at serine 473.  In addition MDA-MB-231 cells also showed a 
decrease in phosphorylation of this site following MDM2 siRNA 
treatment, whereas ZR-75.1 cells showed no difference.    
 In line with previously undertaken studies reported in the literature, 
MDM2 serine 186/188 phosphorylation was assessed, as well as just 
serine 186 (MDM2 serine 166 had already been studied in earlier 
work) and it was seen that PSMA knockdown also led to a decrease 
in the phosphorylation of serine 186/188, but showed no change 
when cell lysates were probed with an antibody specific for serine 
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186, implicating PSMA in the phosphorylation of MDM2 serine 188. 
This directly links PSMA knockdown to phosphorylation of MDM2 at 
serine 188, possibly through phosphorylation of AKT at serine 473, 
and a schematic was drawn up to illustrate the potential link between 
the proteins, as shown in the literature and my own work (Figure 6.8).   
Interestingly, when total AKT levels were assessed through western 
blotting, MDA-MB-231 cell showed an increase in protein levels in 
both MDM2 and PSMA siRNA treated cells.  However, ZR-75.1 
showed an increase in total AKT levels following just PSMA 
knockdown.  This increase in total AKT falls in line with the decrease 
in phosphorylated AKT in each cell line.  This increase in total protein 
could be an attempt by the cell to restabilise AKT levels when activity 
of the molecule through phosphorylation of serine 473 is decreased.   
To further link AKT to MDM2, PSMA and MMPs, an inhibitor of PI3K 
was used in order to indirectly inhibit the phosphorylation of AKT at 
serine 473 (Scheid et al., 2002).  Gene expression was assessed 
following treatment of MDA-MB-231 and ZR-75.1 cell with either this 
inhibitor of PI3K or its control.  Interestingly, it was seen that both 
MDM2 and PSMA levels were decreased following inhibitor 
treatment.  This, again, links the gene expression levels of MDM2 
and PSMA, showing that when one is knocked down, so is the other.  
This could go some way towards explaining why PSMA siRNA 
decreased MDM2 transcript levels, when our own data are taken into 
consideration.  However, it does not explain why both cell lines 
tested would show a decrease in PSMA following MDM2 siRNA  
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Figure 6.8. Schematic diagram showing the possible interplay 
between PSMA, phosphorylated AKT (serine 473) and 
phosphorylated MDM2 (serine 188).  Illustrates the potential 
interplay between the molecules, as indicates by my own data and 
that in the literature.  It may be that PSMA knockdown leads to a 
decrease in the phosphorylation of AKT at serine 473 (Guo et 
al.¸2014) and decreased phosphorylation of this residue on AKT 
leads to a decrease in phosphorylation of serine 188 on MDM2 
(Feng et al.¸2004; Milne et al., 2004).   
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treatment, since only MDA-MB-231 cells show a decrease in serine 
473 phosphorylation following MDM2 knockdown.   
In addition, assessment of MMP2 and MMP8 gene expression levels 
following this inhibitor treatment showed the same as was seen from 
both knockdowns at transcript level, with MMP2 showing a significant 
decrease compared to the control, but MMP8 levels showing no 
difference.  This similar gene pattern could link AKT to the 
differences seen in MMP protein levels following MDM2 and PSMA 
siRNA treatment.  
It is important to remember that the inhibitor used was not specific to 
the phosphorylation site serine 473, it inhibited the activity of PI3K, 
and so results are showing the effects on gene level from inhibiting 
this kinase, not solely the inhibition of phosphorylation at serine 473.  
As a start point, however, it is an interesting study and linked 
phosphorylation inhibition of AKT to a decrease in MDM2, PSMA and 
MMP2 gene expression.  
Therefore, this chapter shows that PSMA knockdown leads to a 
decrease in serine 473 phosphorylation on AKT and with this a 
decrease in MDM2 serine 188 phosphorylation. In addition, c-JUN 
phosphorylation at serine 63 was shown to increase following MDM2 
knockdown in both cell lines and following PSMA knockdown in ZR-
75.1cells.  
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PSMA overexpression is observed in the neovasculature of solid 
tumours but not in that of normal tissues (Kasperzyk et al.¸2013).  In 
addition, increased PSMA expression is positively associated with 
tumour stage and grade, although its function in cancer remains 
unclear (Chang et al.¸2004).  MDM2 is a negative regulator of tumour 
suppressor p53 (Lahav, 2008) but also plays p53-independent roles 
in the cell (Ganguli and Wasylyk, 2003, Thomasova et al., 2012).  
Both proteins have been considered as biomarkers and therapeutic 
targets for advanced solid tumours.   Additionally, MDM2 and PSMA 
have been shown to play an important role in the progression of 
breast cancer (Turbin et al., 2005; Jiang et al., 1997; Ross et 
al.¸2003; Perner et al., 2007).  
A recent study showed that knockdown of PSMA led to a decrease in 
MDM2 gene expression levels, as well as changes to MMP2, MMP3 
and MMP13 transcript levels (Xu et al.¸2013).  Both MDM2 and 
PSMA have also been linked to the regulation of MMPs (Conway et 
al., 2013; Zhao et al.¸2012; Yang et al., 2006; Rajabi et al., 2012; 
Chen et al., 2013; Cheng et al., 2014). In addition, the PI3K-AKT 
pathway has been linked to the MDM2, PSMA and the MMPs (Parks 
et al.¸2001; Thant et al.¸2001; Zhang et al.¸2003; Kim et al., 2001; 
Liotta & Kohn, 2000; Suzuki et al., 2004).   Notably, it has been 
shown that PSMA knockdown in prostate cancer cell lines leads to a 
decrease of phosphorylation at serine 473 on AKT (Guo et al.¸2014), 
whilst the phosphorylation state of MDM2 is known to be regulated 
by AKT phosphorylation, although the site on MDM2 which is 
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phosphorylated by AKT is still unclear, as different reports suggest 
varying sites (Ogawara et al.¸2002; Feng et al.¸2004; Ashcroft et 
al.¸2002; Mayo & Donner, 2001; Zhou et al., 2001).  Therefore, we 
hypothesised that MDM2, PSMA and AKT form a pathway which 
results in regulation of the MMPs in breast cancer cell lines.   
Following the choice of MDA-MB-231 and ZR-75.1 cell lines, MDM2 
and PSMA were effectively knocked down in both cell lines. In these 
breast cancer cell lines, transcript levels of MDM2 were seen to 
decrease following PSMA siRNA treatment, which echoes what Xu et 
al., (2013) observed in the prostate cancer cell line, LNCaP.  
Interestingly, we also found that the PSMA transcript level was 
decreased following MDM2 siRNA treatment, which has not before 
been reported.  However, this decrease was not replicated at protein 
level.  Interestingly, transcript levels of MDM2 were seen to decrease 
following PSMA siRNA and PSMA transcript levels were decreased 
following MDM2 siRNA treatment.  This falls in line with what Xu et 
al.(2013) saw in the prostate cancer cell line, LNCaP.  However, this 
decrease was not replicated at protein level.   
A decrease was seen in proliferative, adhesive, migratory and 
invasive capacity, following each knockdown in both cell lines.  In 
addition, a decrease in serine 473 phosphorylation of AKT was seen 
when PSMA was knocked down, shown through both western 
blotting and flow cytometric analysis. This is similar to what has 
already been seen in prostate cancer cells by two groups, with each 
claiming that PSMA is able to activate AKT through phosphorylation 
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at serine 473 (Perico et al.¸2016; Guo et al.¸2014).    Interestingly, 
the decrease in phosphorylation at this site was linked to an increase 
in the total levels of AKT in the cells.  To gain a better understanding 
of this and why it occurs, further work would need to be undertaken.  
Following this, assessment of MDM2 phosphorylation sites following 
knockdown of both MDM2 and PSMA showed a decrease in 
phosphorylation at serine 188 after both knockdowns, but no change 
at serine 166 or 186.  A decrease in phosphorylation at this site 
following PSMA knockdown was very interesting and implicated the 
two proteins in a pathway, with AKT phosphorylation being a possible 
link between them.  Phosphorylation of MDM2 at serine 188 by AKT 
has already been shown in mouse embryonic fibroblasts (MEFs) 
(Feng et al., 2004) and a range of cancer cell lines (Milne et al., 
2004).  Now our work has highlighted this link in two metastatic 
breast cancer cell lines, whilst also showing that PSMA knockdown 
can cause a decrease in phosphorylation at serine 473 on AKT.   
As already mentioned, AKT has been linked to the regulation and 
production of MMP2, MMP9 and MT1-MMP (Parks et al.¸2001; Thant 
et al.¸2001; Zhang et al.¸2003; Kim et al., 2001; Liotta & Kohn, 2000; 
Suzuki et al., 2004).   Assessment of MMP secretion from breast 
cancer cells with MDM2 or PSMA knockdown showed a decrease in 
MMP2 and MMP8, with ZR-75.1 also showing a decrease in MMP9.  
This could implicate this pathway in the regulation, production and 
secretion of MMPs by MDM2, PSMA and AKT seen in previous 
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literature (Chen et al., 2013; Zhang et al.¸2014; Rajabi et al., 2012; 
Zhao et al.¸2012; Conway et al.¸2013).   
This change in MMP levels, especially MMP2, explains why a 
decrease in migration, invasion and adhesion was seen in cells with 
knockdown of MDM2 and PSMA (Bauvois, 2012, Jezierska and 
Motyl, 2009).  
Additionally, c-JUN may link MDM2 and PSMA activity as predicted 
by the search tool GeneMANIA.  Interestingly, knockdown of MDM2 
led to an increase in c-JUN phosphorylation at serine 63, but 
conveyed no effect on total protein levels.   PSMA knockdown also 
showed an increase in c-JUN phosphorylation at serine 63, but only 
in one of the cell lines tested.  This is against what would be 
expected from cells with knockdown of known pro-angiogenic 
proteins since c-JUN phosphorylation at serine 63 activates the 
molecule (Li et al., 2004).  This leads to a cellular ability to promote 
proliferation and decrease angiogenesis (Vleugel et al.¸2006).   
AKT is also implicated in cell proliferation and survival (Lawlor and 
Alessi, 2001), with the protein driving cell proliferation and inhibiting 
apoptosis.   
Proliferation of cells was seen to decrease following a knockdown of 
both MDM2 and PSMA proteins, which is what we would expect from 
AKT serine 473 phosphorylation decrease, but not from c-JUN serine 
63 increase.  Apoptosis data showed a significant increase in only 
the early stages of apoptosis following MDM2 knockdown.  However, 
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late stage apoptosis may also be expected to increase and live cells 
decrease.  The increase in c-JUN phosphorylation may account for 
this, leading to less of a dramatic change than would be expected.  In 
addition, the results gained from the cell cycle assay are varied 
between cell lines after PSMA knockdown and this may be due to the 
difference in an increase in serine 63 phosphorylation of c-JUN 
between the two cell lines.  It may be important to also assess the 
phosphorylation levels of serine 73, which is also implicated in the 
activation of c-JUN (Li et al., 2004).   
Clinically, since both MDM2 and PSMA are implicated as therapeutic 
targets, this signalling data could be highly important and may 
highlight why clinical trials involving these proteins have so far not 
been hugely successful.   
A link between these two proteins is an important step forward in this 
area of research, as a more exact understanding of the interplay 
between them, AKT and MMPs, which are all therapeutic targets, 
could lead to a dual targeting with drugs which hadn’t before been 
considered.   
In conclusion, the main and novel finding of this study was that, in 
metastatic breast cancer cell lines, PSMA knockdown leads to a 
decrease in AKT phosphorylation at serine 473, and also a decrease 
in MDM2 phosphorylation at serine 188.  Knockdown of both MDM2 
and PSMA leads to similar phenotypes in terms of growth, migration, 
invasion and adhesion which may be due to this pathway.  In 
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addition, each of the knockdowns leads to a decrease of MMP2 and 
MMP8 in both cell lines tested, which could also be due to both of the 
protein’s involvement in this pathway.  This work could also implicate 
MDM2 serine 188 as an important phosphorylation site on the protein 
and this must be further investigated.  
Future work 
Since it seems that PSMA knockdown leads to a decrease in AKT 
serine 473 phosphorylation, it is important that future work addresses 
how this occurs.  It is not known currently if PSMA holds kinase 
activity and so it may act through a kinase which is known to work 
upstream of AKT.   
It would also be important to assess the levels of MDM2 serine 188 
following a decrease in serine 473 phosphorylation of AKT, perhaps 
through use of an inhibitor, allowing us to assess if there is a true link 
between phosphorylation statuses of each of the proteins.  
In addition, since this work has suggested that MDM2 serine 188 
may play a role in a pathway downstream of AKT and the importance 
of phosphorylation of MDM2 at serine 188 in terms of functionality of 
cells could be investigated using cells harbouring MDM2 with a 
mutation at this site, leading to no phosphorylation of serine 188 
being able to occur.  This would allow us to investigate how important 
phosphorylation of this site is to the functionality of cells and 
secretion of MMPs.   
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It may also be interesting to investigate how MDM2 and PSMA may 
further interplay in folate metabolism, via their interactions with DHFR 
(Samplaski et al., 2011, Pinto et al., 1996) (Figure 7.1) and how they 
may fit into the schematic including VEGF and HIF1 (Figure 7.2).  
In terms of a wider clinical implication, the potential use of PSMA-
targeting drugs in breast cancer could be a highly useful as these 
drugs have already been developed and undergone clinical trials for 
prostate cancer. Additionally, the functional implications of PSMA in 
breast cancer cell shows that it is an important molecule in the 
malignancy of breast cancer, and further investigation of this may 
lead to the use of PSMA as a biomarker or a therapy in breast 
cancer.  
Thus far, the targeting of MDM2 and AKT in cancer cells has not 
yielded as significant results as we may have expected and the 
discovery of this pathway and the subsequent targeting of one or 
more of the molecules within it, may lead to more encouraging 
results.  
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Figure 7.2. Proposed interplay roles of MDM2 and PSMA in tumour 
invasion and metastasis through multiple signalling pathways. 
MDM2 and PSMA have both been linked to MMP2 and MMP9.  HIF-1α 
is known to regulate the MMP inhibitor, TIMP-1.  Since MDM2 activates 
HIF-1α, both PSMA and MDM2 may play a role in MMP regulation in 
hypoxia.  MDM2 inactivates p53 which is known to suppression 
transcription of VEGF.  The PI3K and PAK pathways in endothelial cells 
can be activated directly by VEGF and indirectly by PSMA through 
binding with integrin.  Therefore, MDM2 and PSMA may mediate 
angiogenesis which could permit the exertion of a synergetic pro-
angiogenic effect between the proteins. (Taken from Bradbury et al., 
2015).   
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